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Abstract 
The misconception that all bacterial infections could be cured with existing antibiotics resulted in a 
gap in antibiotics production, effectively ending the golden era of antibiotics. The subsequent loss of 
interest of big pharma-companies in developing new antibiotics as well as issues in the drug 
regulation, led to an increased number of multidrug resistant bacterial strains and a rapid rise of 
neglected diseases, over the last 25 years. Today, the identification of novel antibacterial scaffolds 
and their development into drugs has again become vital to human health and for that natural 
products have come into focus. Two very important sources to find biologically active natural 
products are the actinobacteria and myxobacteria. To find new strains as well as new secondary 
metabolites, this study deals with the isolation of these organisms especially from marine habitats.  
This thesis is divided into 5 parts. The first part is dedicated to the isolation of marine myxobacteria 
from the “Marine Myxobacteria Cluster” (MMC). Therefore surface sediment was sampled from the 
Wadden Sea from northern Germany, the specific sequence for marine myxobacteria (MMC) was 
detected via specific PCR and diverse isolation approaches were started. Finally, 12 halotolerant 
Myxococcus strains were isolated which were closely related to terrestrial strains and do not harbour 
the MMC sequence. From these strains no new bioactive secondary metabolites could be detected. 
Two parts focus on the taxonomical analysis as well as the screening for novel bioactive secondary 
metabolites from marine actinobacteria. These were isolated from living marine sponges or sediment 
from Guam and the rhizosphere sediment from mangrove plants from India. Taxonomically, strains 
ICN19 and 21 seemed to present a new species, however some further studies have to be done. For 
the screening of novel secondary metabolites a new multi resistant test panel could be established, 
consisting of Gram - positive and -negative bacteria as well as fungi including same multi resistant 
clinical relevant strains like methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus faecium (VREF) and different antibiotic resistant E .coli strains. Rakicidins A, B and E as 
well as the anthraqiunones aloesaponarin II and 5-hydroxyaloesaponarin II were isolated. All five 
compounds exhibited bioactivity against Gram-positive bacteria, including the MRSA and VREF 
strains, which was never described before. Furthermore, 5-hydroxyaloesaponarin II was described to 
be produced by a bacterial wild type strain for the first time. Moreover the bioactive compound 
staurosporine was isolated from the marine Streptomyces strain ICN21. 
Out of deep sea samples from the North Atlantic Ocean 4 marine Streptomyces strains were isolated. 
Using 16S rRNA PCR, MALDI-TOF, RiboPrinter® and DNA-DNA analyses as well as physiological and 
morphological approaches, the strain ASO4 wet was described as a new species.  
Abstract 
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In the last part of this thesis strain Streptomyces davawensis (roseoflavin producer) and the 
cinnabaramid producer JS360 were characterized by polyphasic taxonomy and identified as novel 
species of the genus Streptomyces                                             
Abstract 
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1. Introduction 
Microorganisms are known to produce a plethora of secondary metabolites with a high structural 
variety and a wide spectrum of biological activity (Newman et al. 2003). Actinobacteria, especially 
Streptomyces strains, are one of the most importat sources for bioactive natural products with about 
two-thirds of the antibiotics from natural origin being produced by members out of this genus (Baltz 
1998; Weber et al. 2003). However, during the last decades it became increasingly difficult to isolate 
new actinobacterial strains, producing novel structurally uncommon bioactive substances (Mohr 
2016). Additionately, the number of antibiotic resistant strains increased (Cooper and Shlaes 2011), 
because basing on Davies (2006) “resistance develops within two or three years after the 
introduction of a new antibiotic treatment” (Mohr 2016). Hence, other microorganisms such as 
myxobacteria came into focus as producers of bioactive natural products (Clardy et al. 2006; Behal et 
al. 2003). Actino- as well as myxobacteria are known to live in soil (Dawid 2000; Madigan et al. 2009). 
This leads to the assumption that they release secondary metabolites to protect themselves as well 
as their food source against other bacteria and fungi. Unfortunately, it became harder to find new 
strains using big screening approaches (Balz 2006). Consequently, modern screening approaches 
have to focus on selected sources from special habitats for the isolation of new bacteria. Hence, this 
study is dedicated to the isolation of myxobacteria and actinobacteria from marine habitats, where 
both are known to be present (Dawid 2000; Lam 2006; Brinkhoff et al. 2011).  
 
1.1. Natural products 
1.1.1. Bioactive compounds /antibiotics 
“Natural products” are products of natural origins. They include for example an entire organism 
(plant, animal or microorganism), a part of an organism (leaves or flowers of a plant or an isolated 
organ of an animal) parts or exudates of organisms or even secondary metabolites like alkaloids, 
glycosides sugars, steroids, etc. (Samuelsson 1999). Secondary metabolites are small molecules 
which are not essential for growth or development of the producing organisms but are by-products 
of their metabolism (Cannell 1998). However, most of the secondary metabolites are “end products 
of complex biosynthetic processes” (Habeck 2002) which were built by highly organized enzyme 
systems, called nonribosomal peptide synthases (NRPSs) and polyketide synthases (PKSs), out of 
simple building blocks (Cane 1997; Staunton & Weissmann 2001; Rawlings 2001; Schwarzer et al. 
2003; Schwarzer & Marahiel 2001). Microorganisms are producers of many different secondary 
 2 
 
metabolites with a high structural variety and a wide spectrum of biological activity (Newman et al. 
2003). The best-investigated microorganisms for the production of secondary metabolites are the 
actinobacteria (Challis et al. 2003). But also bacilli and pseudomonads are well known sources for 
secondary metabolites. However, the increasing resistance of pathogenic bacteria against known 
antibiotics (Walsh, 2003) and the rising recovery rate of already known antibiotics resulted in the 
discovery of new sources for antibiotic research (Fenical et al. 1999; Lam 2006; Donadio et al. 2010). 
Therefore, myxobacteria as well as cyanobacteria came more and more into the focus as bacterial 
producers (Clardy et al. 2006; Behal 2003). With more than 9000 strains, including all validly 
described type strains, the working group “Microbial Strain Collection” of the Helmholtz Centre for 
Infection Research (HZI, Braunschweig, Germany) harbour the largest collection of myxobacteria 
worldwide (Landwehr et al. 2016). Scientists of the HZI were able to isolate more than 500 new 
natural products from about 6000 different myxobacterial strains with at least 100 novel scaffolds 
(Gerth et al. 2003; Reichenbach 2001) exhibiting antifungal, antibiotic and cytotoxic biological 
activities (e.g. Irschik et al. 1983; Irschik et al. 1985a; Surup et al. 2014; Gerth et al. 1994; Geth et al. 
1996). To screen for novel actinobacteria and actinobacterial secondary metabolites, the in-house 
strain collection of the HZI features more than 3000 actinobacterial strains and several collaborations 
with working groups all over the world. However, to detect the potential of the production of 
different secondary metabolites of a strain, a phenotypic analysis is not sufficient (Wenzel & Müller 
2009). The biosynthetic potential cannot be fully utilised using standard fermentation conditions 
(Bode & Müller 2005) but with the help of variable cultivation conditions like changing media 
compositions, modifying the aeration (Bode et al. 2002) the transcription, translation and the 
enzyme activity profiles can be influenced (Wenzel & Müller 2009). The variation of the culture 
conditions and the resulting increase of the produced secondary metabolites was also shown in the 
“OSMAC (One Strain – Many Compounds) approach by Bode et al. (2002) who isolated more than 
100 compounds which belong to 25 different structural classes from only six different 
microorganisms. 
 
1.1.2. Need of new antibiotics 
In contrast to the often described assumption that Alexander Fleming was the first scientist who 
discovered penicillin, misleadingly described as the first antibiotic compound from microbial origin in 
1928, the antibiotic activity of mold has been described several times before (Mohr 2016). 
Particularly the scientific results of Ernest Duchesne which has been published in 1897 as 
“Contribution to the study of vital competition between microorganisms: antagonism between 
moulds and microbes” (Duchesne 1897) gave an interesting insight into the inhibitory growth of 
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bacteria effected by moulds. However, after the publication of Alexander Fleming in 1928, Florey and 
Chain worked on the structure elucidation of penicillin and with the help of Heatley the large scale 
production was possible so that finally in 1941 penicillin was introduced in therapy (Fleming 1929; 
Chain et al 1940; Mohr 2016). Nonetheless, Fleming revolutionized the screening method for 
bioactive compounds. He spread soil dilutions on diverse agar plates which were incubated with 
pathogens before and focused on the microorganisms causing a growth inhibition of the test strains 
(Mohr 2016). Finally, with the discovery of penicillin and the development of the new time and 
money reducing screening method by Fleming, the “golden age” of antibiotics (1950-1960) was 
initiated. This not only led to the discovery of new antibiotics but also created a new industry 
(Demain 2006). During this period of time, one half of the antibiotics which are in clinical use today, 
were generated. Unfortunately, with the intense use of antibiotics for human therapy and 
therapeutic as well as nontherapeutic use e.g. for animal farming, the number of resistant bacteria 
increased immensely (Davies 2006) and the need for new antibiotics never stopped. In the beginning 
of the 1990th antibiotic research changed into a combination of high throughput screening as well as 
chemistry- and computer-assisted design of small molecule ligands (Koehn et al. 2005). However, the 
commercial natural product research came back into focus because “the pipeline for new antibiotics 
was running dangerously low” (Walsh 2003). While the rate of newly discovered antibiotics 
decreased, the rate of re-isolations increased (Fenical et al. 1999; Lam 2006). Hence, the last few 
years have shown a significant increase in drug discovery costs leading to those screening 
approaches to be put down as scientific failures and even financial disasters. The time period of ten 
years was too long within costs and resistance development and newly discovered antibiotics were 
used as last-resort drugs which resulted in low sales for the new product. Moreover, “quality-of-life 
drugs” are more marketable and profitable (Davies 2006). As a result, more and more 
pharmaceutical companies stopped working on antibiotic research while the number of resistant 
bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), the vancomycin-resistant 
Enterococcus faecium (VREF) or the fluoroquinolone-resistant Pseudomonas aeruginosa (FQRP) 
increased (Cooper and Shlaes 2011). 
Therefore, to discover new drugs, the focus has to be on new chemical classes or chemical classes 
which are known in research but new in the clinic. Strategies for this approach are the screening of 
microorganisms from unexplored environments and new taxa, the mining of the microbial genome, 
like the manipulation of the biosynthetic pathway, and the usage of new innovative assays (Donadio 
et al. 2010). This study is dedicated on the screening of actino- and myxobacteria, isolated with new 
isolation techniques from the marine environment (e.g. Wadden Sea, deep sea, sponges and 
mangroves). Furthermore, a new multi-resistant test panel was established for the screening of 
secondary metabolites. 
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1.1.3. Myxobacteria: Uncommon bacteria with a high potential as producers of natural 
….products 
Myxobacteria are gram-negative, rod shaped soil bacteria which live obligate aerobe and 
chemotroph. The first myxobacterium was described 1809 from the German botanist H.F. Link. 
However, because of its uncommon fungi-like life cycle, it was characterized as a fungus, 
“Polyangium vitellinum (Link 1809). More than 80 years later the American botanist R. Thaxter 
identified the myxobacteria as bacteria (Thaxter 1892). Today, myxobacteria belong to the δ-
Proteobacteria and build the order Myxococcales. To date, this order consists of 55 species including 
28 genera (Figure 1).   
 
 
Figure 1: Current taxonomy of the order Myxococcales (Landwehr et al. 2016). 
 
 
Myxobacteria differ to other bacteria in their uncommon behaviour during their lifecycle. Because of 
their ability to move in a defined direction on a thin slime film on hard substrate (Hodgkin et al. 
1979), they are able to develop “social behaviour”. At a lack of nutrients, they have the ability to 
move together to build fruiting bodies (Reichenbach 1986, Shimkets 1990) with up to 105 cells which 
differentiate into myxospores which are able to survive in a vegetative resting state till the 
environmental conditions changed. The shape of the fruiting bodies differs between the species from 
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tall and tree-like (Stigmatella aurantica, Chondromyces crocatus) to globular formations in 
Angiococcus and Sorangium species. Even the colour differs between yellow, orange or red until 
brown or even black (Reichenbach 1983, Garcia & Müller 2014a-e). To date, fruiting bodies as well as 
the different swarming formations (Figure 2) are highly important for the classification of the 
different species of myxobacteria (Reichenbach 2001) and remind sometimes more of eukaryotic 
myxomycetes or fungi than prokaryotic bacteria (Gerth et al. 2003).  
 
 
Figure 2: Fruiting bodies and swarming formations of different myxobacterial type strains. A: fruiting bodies of 
Stigmatella aurantiaca (Sga M15, DSM17044T); fruiting bodies and swarming formation of B: Corallococcus coralloides 
(SBCo036, DSM2259T); C: Polyangium sorediatum (Pls12, DSM14670T); D: Sorangium cellulosum (Soce1871, DSM14627T) 
(Microbial strain collection, HZI Braunschweig, Germany). 
 
Moreover, because of their different nutrition requirements, myxobacteria are divided into two 
ecological groups, the predators and the cellulose decomposers. By excreting lytic exoenzymes, they 
are able to lyse other bacteria, yeasts or organic material like wood to take up proteins and nucleic 
acids (Reichenbach et al. 1988; Reichenbach et al. 2006).  
Myxobacteria are also well known for their large genome with a very high amount of G-C interactions 
(Mandel et al. 1965). The model strain Sorangium cellulosum Soce56 has with a genome size of 13.04 
Mbp and more than 10000 genes the largest known bacterial genome (Pradella et al. 2002). The 
large genome size was linked to the extraordinary and complex life cycle of the myxobacteria. For 
their special social behaviour, like swarming and the formation of fruiting bodies, they need a more 
complex genetic constitution than other bacteria (Wenzel & Müller 2009; Landwehr et al. 2016).  
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Myxobacteria are well known for the production of structurally diverse secondary metabolites, many 
of which show biological activity. For example, within the genome of Soce 56, 17 gen clusters were 
found which were involved in secondary metabolism (Schneiker et al. 2007). However, using the 
traditional screening methods only three metabolite families could be identified, yet (Weissman & 
Müller 2009; Irschik et al. 2007; Ambrosi et al. 1998; Kunze 1989, Jansen et al. 1997; Irschik et al. 
1995). The great potential of secondary metabolite production has also been observed via genome 
screening of strain Myxococcus xanthus where 8.5% of the genome was identified to be involved in 
natural product biosynthesis (Goldmann et al. 2006; Weissmann & Müller 2009). In their natural 
habitat, most strains were isolated from soil, which is a highly competitive environment, 
myxobacteria have to defend their ecological niche. Cellulose degrading strains combat with cellulose 
degraders, e. g. fungi, and predatory strains lyse other bacteria decaying organic material (Gerth et 
al. 2003). Therefore it is not surprising that 29% of the myxobacterial compounds exhibit 
antibacterial and 54% antifungal properties (Weissman & Müller 2009). However to date, next to 
antibacterial and fungicidal effects, myxobacterial compounds act as antitumor drugs and show e.g. 
antiviral, insulin-sensitizing and immunoregulatory characteristics (Gerth et al. 1996; Reichenbach & 
Höfle 2008; Schreurs et al. 2009; Koutsoudakis et al. 2015; Berod et al. 2014; Corominas-Faja et al. 
2014). The most important myxobacterial compounds with the highest pharmaceutical interest are 
epothilones A and B (Figure 3). They were isolated from a Sorangium cellulosum strain in 1996 and 
described as antifungal and cytotoxic agents (Gerth et al 1996). To date, modified versions of these 
compounds are in clinical trials against different types of cancer. As Ixempra® (ixabepilone) (Figure 
3), developed in October 2007, a semi-synthetic epothilone B derivative is used for monotherapy of 
different stages of breast cancer (Reichenbach & Höfle 2008). However, during the last few years 
some very promissing compounds were described isolated from different types of myxobacteria 
showing diverse bioactivities. The antibiotics disciformycin A and B (Figure 3), isolated from 
Pyxidicoccus fallax, are biologically active against Gram-positive bacteria including MRSA strains 
(Surup et al. 2014). Corallopyronin A (Figure 3), isolated from Corallococcus coralloides (Irschik et al 
1985b), was described to be a promising compound against filarial nematodes which cause lymphatic 
filariasis and onchocerciasis (Schäberle et al. 2014). Nannocystin A (Figure 3) was isolated from 
Nannocystis sp. (Hoffmann et al. 2015) and was described as inhibitor of the eukaryotic translation 
elongation factor 1α. This compound has an overlapping binding site with the anticancer compound 
didemnin B, whose derivates reached phase II in clinical trials, and therefore nannocystins “may 
serve as alternative starting point to develop new medicine” (Krastel et al. 2015). The macrolide 
chlorotonil A (Figure 3) which was isolated from a Soranguim cellulosum strain, was found to exhibit 
promising antimalarial activity and is proposed as a “lead structure for further development as an 
antimalarial chemotherapeutic” (Held et al. 2014). And finally, cystobactamides (Figure 3) which 
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show potent inhibitory effects against various E. coli strains and pathogenic Gram-negative strains 
like A. baumannii and P. aeruginosa. These compounds were isolated from the strain Cystobacter 
velatus (Baumann et al. 2016). In sum, myxobacteria are a promising source of new bioactive 
compounds.  
 
 
Figure 3: Chemical structures of interesting bioactive substances produced by terrestrial myxobacteria: epothilone A and 
B (and the semi-synthetic epothilone B derivative ixabepilone), disciformycin A and B, nannocystin A, corallopyronin A, 
chlorotonil A and the cystobactamides  
 
1.1.4. Actinobacteria as producers of natural products 
In contrast to the myxobacteria and Pseudomonas species, which are known as good producers for 
secondary metabolites, actinobacteria do not belong to the Proteobacteria. However, besides the 
Cyanobacteria which built a separate group in the domain bacteria, actinobacteria and the Bacillus 
species (Firmicutes) belong to the Gram-positive bacteria (Madigan et al. 2009). As mentioned above, 
these five bacterial groups are described to be the best producers of secondary metabolites. 
However, actinobacterial species, especially the filamentous Streptomyces strains, produce about 
three times more bioactive substances than the other producer strains in sum (Berdy 2005).  
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The phylum actinobacteria is „one of the major phyla in the domain Bacteria” (Goodfellow 2001a); 
Garrity & Holt 2001; Ludwig & Klenk 2005). Basing on Goodfellow (2001a), this phylum included five 
classes, 19 orders, 50 families and 221 genera. Thus, because of the rising discovery rate of members 
belonging to the phylum actinobacteria, these data are incomplete to date. The five classes are 
Acidimicrobiia, Actinobacteria (Stakebrandt et al. 1997), Coriobacteriia, Rubrobacteria and 
Thermoleophilia. However, because of the high amount of differences in morphology, physiology and 
G-C content, which differs between 50% and 70% within the diverse genera, this study focuses on the 
class Actinobacteria for further description. This class is divided into 15 orders, 43 families and 203 
genera. They are Gram-positive bacteria which diverse morphological appearance differing between 
cocci, short rods, irregular rods, rods and cocci, mycelia which fragments into coccoid and rod like 
elements as well as the development of branched substrate hyphae which bears spores or spore 
vesicle or the formation of stable branched mycelium with aerial hyphes that differentiate into short 
or long spore chains or spore vesicles, respectively (Goodfellow et al. 2001b). Actinobacteria are 
described to be common soil inhabitants (Berdy 2005), however they are also widely distributed in 
the marine environments and extreme habitats like deep sea sediments (Pathom-aree et al. 2006), 
and in soil of hyper arid deserts (Okoro et al. 2009). In soils they are amongst others responsible for 
the turnover of organic material and recalcitrant of molecules (Goodfellow and Simpson 1983; 
Goodfellow and Williams 1983). But some of them are also found as animal or plant pathogens, plant 
commensals, and nitrogen- forming symbionts or as inhabitants of the gastrointestinal tract 
(Goodfellow et al. 2001b). 
Moreover, the class Actinobacteria is considered as the richest source for bioactive natural products 
(Goodfellow et al. 2001b; Berdy 2005; Newman and Cragg 2007; Olano et al. 2009), because 45% of 
the bioactive substances in clinical use today were produced by filamentous bacteria of which 80% 
are products of members of the genus Streptomyces (Berdy 2005; Newman and Cragg 2007; Olano et 
al. 2009). The discovery of penicillin and the World War II led to the “intensive search for new 
synthetic and natural antibiotics around the 1940th” and the focus of this search lay on the screening 
of “microorganisms from the environment for antimicrobial activity” (Mohr 2016). The biochemist 
Waksman and his students screened soil bacteria basing on the new screening method described by 
Fleming and detected bacteria from the genus Streptomyces as “highly promissing candidates for the 
production of new antibiotics” (Mohr 2016). The first antibiotic compound described from an 
actinobacterium was the substance actinomycin in 1940. It was isolated from Streptomyces 
antibioticus subsp. antibioticus and showed biological activity against a broad range of bacteria and 
even against the tuberculosis strain Mycobacterium tuberculosis. However, it was too toxic against 
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human cells for the usage as a therapeutic agent (Waksman & Woodruff 1940; Waksman & Woodruff 
1941). But actinomycin D was found to have a significant anticancer activity and therefore it is still in 
use in antitumor therapy (Mohr 2016). Only four years later the first aminoglycoside antibiotic had 
been discovered. The potent broad-spectrum antibiotic streptomycin was isolated from 
Streptomyces anulatus subsp. griseus in 1944 by Schatz et al. and co-discovered by Waksman and 
colleagues who were awarded the Nobel Prize in 1952 (Mohr 2016). Streptomycin was the first 
described antibiotic with an activity against tuberculosis which was used in therapy (1946) but also 
showed biological effects against meningitis (Hamdy 2006; Mohr 2016). Also the other 
aminoglycosides like kanamycin and gentamycin were described as “milestones” because of their 
activity against infectious diseases caused by Gram-negative bacteria (Mingeot-Leclercq et al 1999; 
Shaw et al. 1993; Mohr 2016). This was the beginning of the golden age of antibiotics largely evoked 
by actinobacterial research. However, most of the antibiotics discovered in this time, are still in 
clinical use today (Mahajan 2012). The most famous antibiotics from the “golden age” are the before 
mentioned aminoglycoside streptomycin (Schatz et al. 1944) as well as the broad-spectrum 
aminoglycoside neomycin  (Waksman & Lechevalier 1949) which was isolated from Streptomyces 
fradiae and is active against streptomycin-resistant bacteria, kanamycin, produced by Streptomyces 
kanamyceticus (Takeuchi et al. 1957) and mainly used as therapeutic agent for eye infections and as 
reserve antibiotic (Mohr 2016) and gentamicin which was isolated from Micromonospora purpurea 
(laboratories of the Schering Corporation, Bloomington, New Jersy 1967 ; no authors listed) and 
showed a high antibiotic activity against almost all Enterobacteria, especially against the Gram-
positive Staphylococci. Unfortunately, because of its strong side effects it is only used as an 
emergency antibiotic (Mohr 2016). Further examples for interesting antibiotics produced by 
actinobacteria are the broad-spectrum antibiotic chloramphenicol, produced by Streptomyces 
venezuelae (Ehrlich et al. 1947; Ehrlich et al. 1948; Smith et al. 1947; Gottlieb et al. 1948), the broad-
spectrum antibiotics tetracyclines aureomycin (chlortetracycine) (Duggar 1948), terramycin (Finlay et 
al. 1950) and the structurally atypical chelocardin (Oliver et al. 1962; Mitscher et al. 1970; Oliva et al. 
1992), the broad-spectrum macrolide antibiotic erythromycin (McGuire et al. 1952) which is to date 
the standard antibiotic against infections of the respiratory tract (Mohr 2016) and glycopeptides 
vancomycin (McCormick 1955) and teicoplanin (Parenti et al. 1978) which are exclusively active 
against Gram-positive bacteria and serve as reserve antibiotics because of their activity against 
bacteria showing a resistance to other antibiotics (Kahne et al. 2005; Mohr 2016), to name just a few. 
Furthermore, there are also some “old” antibiotics which came back into the focus because of their 
interesting bioactivity. A good example is the bioactive substance griselimycin (Terlain & Thomas 
1971) whose activity was first described in 1973 in a patent of Mancy, Ninet and Preud, but the name 
was never validated and the describtion was incomplete. However, because of its specific activity 
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against mycolic acid-containing Gram-positive bacteria it came back into the focus in the 21st 
century. During the last years, the biosynthesis gene cluster was identified and characterized 
(Broenstrup et al. 2012) and a taxonomic analysis of the producer strain Streptomyces caelicus was 
published (Wink et al. 2016). Today some new optimized derivates of griselimycin are known which 
are active against tuberculosis, both in vivo and in vitro (Kling et al. 2015). However, the difficulties to 
isolate new actinobacteria during the last years with the common isolation methods (Fenical 1999) 
and the connected challenge to find new carbon skeletons and with this new bioactive compounds in 
Streptomyces, led to the isolation of new actinobacteria from unexplored habitats (Lam 2006). The 
biggest almost unexplored habitat is the ocean, which is described to be a promising new source for 
the discovery of new bioactive compounds (Fenical & Jensen 2006). 
 
1.2. Marine environment 
70% of the world’s surface is covered with water and “with a microbial abundance of 106 per mL in 
sea water and 109 per mL in ocean bottom, oceans are the world’s biggest environment” (Fenical & 
Jensen 2006; Landwehr et al. 2016) 
 
1.2.1. Marine myxobacteria 
1.2.1.1. Are there “real” marine myxobacteria? 
Like mentioned before, myxobacteria have been described for a long time as soil bacteria which are 
common in many terrestrial environments (Dawid 2000; Reichenbach 1999). However, during the 
last years, more and more myxobacteria were isolated from limnic or even marine habitats. Because 
of their close relationship to their terrestrial relatives, Reichenbach (1999) suggested the limnic as 
well as the marine isolates to be no indigenous organisms but washed in from the terrestrial 
surroundings. Furthermore, most of the strains isolated from marine habitat were able to grow on 
rather low salinities (Li et al. 2002). Contrary to these findings, in 1998 Iizuka et al. isolated the first 
myxobacteria from marine samples from the coast of Japan which were adapted to marine habitats. 
Those strains need sodium chloride for growth and form fruiting bodies on media containing NaCl in 
concentrations from 2 to 3%, which are comparable to sea water. These bacteria were classified as 
new myxobacterial genera and described as Haliangium sp. (H. ochroceum and H. tepidum) and 
Plesiocystis sp. (P. parcifica), a few years later (Fodou et al. 2002: Iizuka et al. 2003a). Furthermore, 
Iizaka et al. (2003b) also described the new genus Enhygromyxa (E. salina), which was also well 
adapted to live in the marine environment. However, despite the new genera of the isolated marine 
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myxobacteria all of them belong to the genus Nannocystis. Basing on Zhang et al. (2005) the 
myxobacteria described to date could be divided into nonhalotolerant, halotolerant and halophile 
strains. Due to their ability to grow with and without NaCl as well as the phylogenetic relationship to 
the terrestrial isolates, members from the three myxobacterial genera Haliangium, Plesiocystis and 
Enhygromyxa were classified as halotolerant myxobacteria “which might form a different 
evolutionary group that is indigenous in the ocean” (Zhang et al. 2005). However, during molecular 
analysis of different marine sediment samples Jiang et al. (2010) established myxobacteria-enriched 
libraries of 16S rRNA gene sequences and found similar sequences which were closely related to 
terrestrial myxobacteria strains but simultaneously they were phylogenetically separate with a 
distance of about 10%. In the phylogenetic tree, clones harbouring this sequence clustered together 
and were named as the “Marine Myxobacteria Cluster (MMC)“ (Brinkhoff et al. 2012). This cluster 
included, besides the generated clone sequences from the Wadden Sea samples, various clone 
sequences and sequences from uncultured bacteria, isolated from divers marine habitats from all 
over the world.  
 
1.2.1.2. Bioactive substances produced by marine myxobacteria 
To date only members of the halophile genera Haliangium, Plesiocystis and Enhygromyxa are 
described as marine myxobacteria. Therefore, the antifungal compound haliangicin (Figure 4) was 
the first bioactive compound isolated from a myxobacterium from marine origin. Haliangicin was 
isolated from Haliangium luteum and showed high activities against filamentous fungi but no 
antibacterial activity. Furthermore, it belongs to the class of compounds with a ß-methoxyacrylate 
moiety and is a respiratory inhibitor. It inhibits the electron transport within complex III of the 
respiratory chain (Fudou et al. 2001a, b). Moreover, twelve years after the discovery of haliangicin a 
second metabolite was isolated from an obligate marine myxobacterium. Salimabromide (Figure 4) 
was isolated from an Enhygromyxa salina strain and showed moderate antibiotic activity against the 
Gram-negative bacterium Anthrobacter cristallopoedes (Felder et al. 2013). With its unusual 
structure, salimabromide emphasized the phylogenetical distance of the producer strain with its 
terrestrial relatives. Further bioactive metabolites like the miuraenamides were only described from 
slightly halophilic myxobacteria like “Paraliomyxa miuraensis”. The compounds miuraenamide A-F 
(Figure 4) were more or less active against the phytopathogen Phytophthora capsici (Ojika et al. 
2008) However, the derivates miuraenamides A and B were described to have inhibitory effects 
against the NADH oxidase (Iizaka et al. 2006). 
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Figure 4: Chemical structures of bioactive natural secondary metabolites produced by marine / halophilic myxobacteria: 
haliangicin, salimabromide and miuraenamides A-F. 
 
1.2.2. Marine actinobacteria 
1.2.2.1. Are there “real” marine actinobacteria? 
Actinobacteria are like myxobacteria common soil bacteria. Because of this it was a long time not 
clear, whether “real” marine actinobacteria did exist. Most people suggested that because of the 
high amount of re-isolation of known terrestrial strains from marine samples, “marine” 
actinobacteria are the result of wash-in of terrestrial spores into the marine habitat (Goodfellow & 
Haynes 1984). Another reason for this assumption could be that, because of the difficulty of sampling 
within the marine habitat, most of the samples have been taken close to the coast (Fenical & Jensen 
2006). However, the strain Rhodococcus marinonascence was the first isolate which was described as 
marine actinobacterium (Helmke & Weyland 1984). A few years later, the first actinobacteria 
described as strains with “specific marine adaptations” (Jensen et al. 1991) or strains which were 
“metabolically active in marine sediments” (Moran et al. 1995) were published. The real 
breakthrough of marine actinobacteria came with the discovery of the first obligate marine genus 
Salinispora spp. in 1991 (Jensen et al. 1991). Members from this genus require sea water for growth. 
However, even about 10 years later, Mincer et al. described in 2005 the genus “Salinospora” 
(grammatically incorrect; corrected to Salinispora) by analysing the relationship of this genus with its 
terrestrial relatives and detected the widespread population of this genus in ocean sediments via 
DNA sequence-based methods (Mincer at al. 2002, 2005). Furthermore, based on the active growth 
in some sediment samples, Mincer demonstrated the ability of Salinispora strains to be metabolically 
active in their marine habitat (Mincer et al. 2005). Some Salinispora strains were also isolated from 
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the marine sponge Pseudoceratina clavata (Kim et al. 2005) collected from the Great Barrier Reef. 
For the formal description of this genus, the type strains Salinispora tropica and Salinispora arenicola 
were published in 2005 (Maldonado et al. 2005) and in 2014, the third type strain Salinispora 
parcifica was described (Ahmed et al. 2014). These findings encouraged many scientists to further 
work on marine actinobacteria. Starch and Bull (2005) found 1300 different actinobacterial 
operational taxonomical units in deep sea sediments which indicate the presence and great 
opportunity to isolate novel species and genera. According to this finding, Fenical and Jensen (2006) 
were able to isolate some marine strains which belong to six different actinobacterial families and 
seemed to represent new taxa like Mariniphilus and the above described Salinispora. To date, it is 
known, that actinobacteria are present in diverse marine habitats: from the sea surface layer over 
the water column down to the sea surface with its micro- and macro-fauna and –flora to the sea 
subfloor and the deep biosphere (Ward and Bora 2006).  
 
1.2.2.2. Bioactive substances produced by marine actinobacteria 
In addition to the taxonomic findings of the marine actinobacteria, it turned out that these strains 
are also “excellent producers of secondary metabolites” (Fenical and Jensen 2006). They produce a 
great spectrum of metabolites which can be used for diverse biotechnological applications like the 
production of melanins, single cell proteins and probiotics in aquaculture as well as enzymes and 
enzyme inhibitors. However, this study focuses on the production of bioactive metabolites like 
antibiotics, cytotoxic agents and fungicides (Manivasagan et al. 2013).  
Most of the bioactive compounds described from marine actinobacteria are produced by strains 
from the genus Streptomyces. For example the antibacterial frigocyclinone from Streptomyces 
griseus (Brutner et al. 2005), the daryamides from Streptomyces sp., which have antifungal and 
anticancer activities and the antitumor agents chromomycins B, A2 and A3 produced by 
Streptomyces coelicolor (Lu et al. 2012). However, there are a few interesting compounds described, 
which were produced by members from the only obligate marine actinobacteria genera Salinispora 
and Marinospora (Manivasagan et al. 2013). Salinosporamide A (Figure 5) is the most promising 
bioactive compound. Becides salinosporamide B (Figure 5), it is produced by Salinispora tropica and 
is an orally active proteasome inhibitor which induces apoptosis in multiple myeloma cells. Its mode 
of action differs from the mechanism of the commercial proteasome inhibitor anticancer drug 
bortezomib (Chauhan et al. 2005; Manivagasan et al. 2013). As the first compound isolated from an 
obligate marine actinobacterium, salinosporamide A (also known as NPI-0052) entered the clinical 
studies in multiple phase I trials for solid tumours, lymphoma and multiple myeloma 
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(http://www.nereuspharm.com/NPI-0052.shtml). The structure of salinosporamide B differs only by 
the lack of a chlorine atom, which decreases the activity by a factor of 500 (Manivasagan et al. 2013). 
Both compounds are unusual bicyclic γ-lactams. However, the cinnabaramides, which are produced 
by the terrestrial Streptomyces strain JS360 are chemically closely related to the salinosporamide A. 
These compounds also act as selective proteasome inhibitors but show weaker cytotoxic bioactivities 
(Stadler et al. 2004; Stadler et al. 2007; Rachid et al. 2011). Except salinosporamide A and B, 
Salinispora tropica was also described as producer strain for sporolide A, arenicolide A, 
cyanosporaside A and salinipyrone A (Figure 5) (Jensen et al. 2007; Manivasagan et al. 2013). The 
bioactive compounds salinipyrones A and B (Figure 5), first described to be produced by Salinispora 
parcifica (Oh et al. 2008), cause a moderate inhibition of the interleukin-5 production without cell 
cytotoxicity on human cells. However, they did not show any antibiotic effect on human pathogens 
(Manivasagan et al. 2013). Marinomycin A (Figure 5) is the only compound described to be produced 
by a strain from the obligate marine genus Marinophilus. The polyene macrolide displayed a high 
toxicity on tumour cells and had in addition an antibiotic effect on vancomycin-resistant 
Enterococcus faecium and methicillin–resistant Staphylococcus aureus strains (MIC values of 0.1-
0.6µM) (Kwon et al. 2006). 
 
 
Figure 5: Examples of new bioactive compounds and their corresponding structures produced by novel genera of marine 
actinobacteria: salinosporamide A and B, sporolide A, arenicolide A, cyanosporaside A, salinipyrone A and B, marinomycin 
A.  
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1.3. Working projects and previous work 
1.3.1. Part 1: Isolation of marine myxobacteria from the sediment of the Wadden Sea: search 
for the MMC sequence and screening for new bioactive compounds 
In 2010, Jiang et al. detected myxobacterial 16S rRNA sequences in marine sediment samples which 
were closely related to terrestrial myxobacteria strains on the one hand but simultaneously clustered 
phylogenetically in separate clades with a distance of more than 10% on the other hand. Based on 
this study, Brinkhoff et al. (2012) developed specific primer (MMC655f and MMC841r) to detect 
members of this clade which was named the “Marine Myxobacteria Cluster” or MMC. In their study 
they showed the worldwide distribution of the MMC sequence in marine sediment samples almost 
all over the world to a water depth of 4300 m. It was detected in sediments from various climate 
regions like the Mediterranean Sea, the Atlantic, the Pacific, the Indian Ocean and from the North 
Sea where the MMC was found to make up 13% of the total bacteria 16S rRNA genes in the surface 
sediments. In addition to the molecular approaches like the construction of fosmid libraries und the 
phylogenetic analysis of the MMC sequences, they also tried to isolate marine myxobacteria 
harbouring the MMC sequence from marine sediments from the coast of Neuharlingersiel (North 
Sea, Germany). Different enrichment approaches were used but at last two Myxococcus sp. strains 
which did not belong to the MMC were almost cultivated (Brinkhoff et al. 2012). 
 
1.3.2. Part 2: Actinobacteria isolated from marine sponges and sediments from Guam: 
Taxonomic characterization and screening for new bioactive compounds  
The working group of Prof Dr. Peter Schupp from the University of Oldenburg works with marine 
sponges and the microorganisms living within these sponges. Commonly used methods for the 
isolation of microorganisms living within sponges are stamping techniques or even plating of 
different dilutions of crushed sponges (e.g. Mantalvo et al. 2005; Abdelmohsen et al. 2010; Selvin et 
al. 2004; Jiang et al. 2007). For all of this approaches the living sponge had to be harvested. However, 
Steinert et al. (2014) constructed a so called “Diffusion Growth Chamber” (DGC). This chamber is 
made out of two combined centrifuge micro filter and includes inoculation media. The filter 
membranes of both sides allow the diffusion of nutrients and waste products in and out of the 
chamber. This DGC can be inserted into the sponge and retaken after a certain incubation time 
(Figure 6). This isolation method keeps the sponges alive.  
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Figure 6: Diffusion growth chamber (DGC) for in vivo cultivation of sponge-associated bacteria. Build-up of DGC out of two 
combined centrifuge micro filter sections with diffusible membranes (DM), inoculated with different types of media within 
the chamber (AC) and the plastic holder (H) for fixing within the sponge.   
 
With the help of the DGC, members of the working group of Prof. Dr. Schupp isolated diverse 
bacterial strains from the sponge Rhabdastrella globostellata at the coast of Guam as well as from 
marine sediments from the Blue Hole in Guam. For taxonomic characterization as well as for the 
screening for new bioactive compounds, 10 actinobacterial strains were analyzed during this study. 
 
1.3.3. Part 3: Actinobacteria isolated from marine and rhizosphere sediment from mangroves 
in India: Taxonomic characterization and screening for new bioactive compounds  
The working group of Dr. S. G. Prakash Vincent from the International Centre for Nanobiotechnology 
(ICN) of the Manonmaniam Sundaranar (MS) University in India isolated actinobacteria from 
rhizosphere sediment of mangrove plants Avicinnia officinalis, Acrostichum aureum and Rhizophora 
mucronata as well as from marine sediment. The samples were taken at a fish farm by the side of the 
Centre for Marine Science and Technology from the MS University (Figure 7A) and the Manakkudy 
Mangrove environment at the southwest coast of Tamil Nadu (India) (Figure 7B). 
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Figure 7: Sampling sites and isolated ICN strains of the Manonmaniam Sundaranar (MS) University in India. A: fish farm 
by the side of the Centre for Marine Science and Technology from the MS University; B: Manakkudy Mangrove environment 
at the southwest coast of Tamil Nadu (India); C: Agar-shakes of isolated ICN strains.  
 
For the taxonomic classification and the screening for secondary metabolites, 10 strains which 
belong to the actinobacteria were analyzed in this study. 
  
1.3.4. Part 4: Actinobacteria from deep sea samples from the North Atlantic Ocean: Isolation, 
taxonomic characterization and screening for new bioactive compounds  
In December 2014 the research vessel “Sonne” cruised through the North Sea and parts of the North 
Atlantic Ocean. Prof. Dr. Peter Schupp from the University of Oldenburg sampled two sponges and 
one soft-coral with the help of a ROV as well as sediment from 1092 m depth. Some previously 
prepared plates were directly inoculated and send to our working group to the HZI in Braunschweig 
for the isolation of new marine actinobacteria.   
 
1.3.5. Part 5: Polyphasic description of Streptomyces strains JS360 and S. davawensis  
During a screening program for new antibiotics, strain Streptomyces davawensis (DSM 101723T) was 
isolated and detected to produce a red compound which showed biological activity against Gram-
positive bacteria (Otani et al. 1974; Shinobu 1974). Because of its structural similarity to riboflavin 
(vitamin B2) and the red colour of the compound it was named roseoflavin. This compound is the 
only known natural riboflavin analogue with antibiotic function and therefore presents a new class of 
antibiotics with new target structures. It is taken up by many bacteria via riboflavin transporters 
(Pedrolli et al. 2013; Grill et al. 2008; Hemberger et al. 2011; Vogl et al. 2007). During the search of 
related bacteria producing roseoflavin, Jankowitsch et al. (2011) detected strain S. cinnabarinus as 
close relative via 16S rRNA sequence which also used the same pathway as S. davawensis for the 
roseoflavin biosynthesis. In parallel we worked with the cinnabaramide producer JS360 which was 
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also described to be a member of S. cinnabarinus. However, instead of roseoflavin, this strain 
produced the cinnabaramides A-G, wich were described as proteasome inhibitors and are interesting 
substances for the treatment of allergies, asthma and cancer. The cinnabaramides are structurally 
close related to the marine compound salinosporamide A (Stadler et al. 2004; Stadler et al. 2007, 
Kyle et al. 2004).  
In this study S. davawensis, S. cinnabarinus and strain JS360 were analyzed using a polyphasic strain 
description approach to clarify the phylogenetic relationship between all three strains.  
 
1.5 Aim of the study 
The aim of this study is divided into five different parts.  
• Isolation of new marine myxobacteria from sediment from the Wadden Sea and screening 
for new bioactive metabolites (collaboration with the working group of Prof. Dr. Simon, ICBM 
(University of Oldenburg)) 
• Characterization of new actinobacteria isolated from marine sponges and sediments from 
Guam and screening for new bioactive compounds (collaboration with the working group of 
Prof. Dr. Schupp, ICBM (University of Oldenburg)) 
• Characterization of new actinobacterial strains isolated from marine and rhizosphere 
sediments from mangroves from India and screening for new bioactive compounds 
(collaboration with the working group of Dr. Vincent, Centre for Marine Science and 
Technology Mananmanian Sundarana University of Rajakamangalam, India) 
• Isolation and characterization of new marine actinobacteria from deep sea samples from the 
North Atlantic Ocean and screening for new bioactive compounds (collaboration with the 
working group of Prof. Dr. Schupp, ICBM (University of Oldenburg)) 
• Characterization and phylogenic arrangement of S. davawensis and the cinnabaramide 
producer JS360 (S. cinnabaragriseus) (collaboration with the working group of Prof. Dr. Mack, 
University of Mannheim)  
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2. Material and Methods 
2.1. Material  
2.1.1. Media 
All media used in this study are listed in table 1. They were freshly prepared after the recipies 
described below with destilled water and the pH was adjusted with 1 M NaOH or rather HCl solution. 
Afterwards the media were sterilised for 20 min at 121 °C.   
Table 1: Media and ingredients used in this study. 
Media Ingredients/manufacturer 
Basal medium  1% casein peptone 
(pH 7.0) 0.5% yeast extract 
 
2% Bacto Agar 
 
(1.5% Bacto Agar) 
 
dest. water  
  
 
CY-medium 0.3% casiston 
(pH 7.2) 0.1% yeast extract 
 
0.1% CaCl2 
 
50 mM HEPES (11.8 g/L) 
 
dest. water 
  
 
CY / H-medium 50% CY- / 50% H-medium 
  
 
DULBCCO´s modified EAGLE´s medium DMEM, Bio Whittaker, Walkersville, MD 
  
 
E-medium 0.4% skimmed milk 
(pH 7.4) 0.4% soy flour 
 
1.0% starch 
 
0.1% MgSO4 
 
50 mM HEPES (11.9 g/L) 
 
8 mg/L Fe-EDTA 
 
0.5% glycerine 
 
dest. water  
  
 
Eluent A2 50mL acetonotrile 
 
385mg ammonium acetate 
 
40 µL acetic acid 
 
950 mL H2O 
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Eluent B2 950 mL acetonitrile 
 
385 mg ammonium acetate 
 
40 µL acetic acid 
 
50 mL H2O 
  
 
GYM-medium 0.4% glucose 
(pH 7.2) 0.4% yeast extract 
 
1% malt extract 
 
0.2% CaCO3 
 
dest. water 
  
 
GYM-ASW 0.4% glucose 
(pH 7.2) 0.4% yeast extract 
 
1% malt extract 
 
0.2% CaCO3 
 
artificial sea water “Coral Ocean”, ATI 
  
 
H-medium 0.2% soy flour 
(pH 7.4) 0.2% glucose 
 
0.8% starch 
 
0.2% yeast extract 
 
0.1% CaCl2 
 
0.1% MgSO4 
 
50 mM HEPES (11.8 g/L) 
 
8 mg/L Fe-EDTA 
 
dest. water  
  
 
ISP 2 1% malt extract  
(pH 7.0) 0.4% yeast extract 
 
0.4% glucose  
 
1.5% Bacto Agar  
 
dest. water 
  
 
ISP 3 2% oatmeal (Quaker white oats) 
(pH 7.2) 1.8% Bacto Agar 
 
dest. water 
 
1 mL/L Trace salt solution ISP3 
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ISP 4 1% soluble starch  
(pH 7.3) 0.2% (NH4)2SO4 
 
0.1% K2HPO4 
 
0.1% MgSO4 x 7 H2O 
 
0.1% NaCl 
 
0.2% CaCO3 
 
2% Bacto Agar 
 
dest. water 
  
 
ISP 5 0.1% L-Asparagine 
(pH 7.2) 1% glycerol 
 
0.1% K2HPO4 
 
1 mL/L Trace salt solution ISP 5 
 
2% Bacto Agar 
 
dest. water 
  
 
ISP 6 1.5% peptone 
(pH 7.2) 0.5% proteose Peptone 
 
0.05% C6H8FeNO 
 
0.1% sodium glycerophosphate 
 
0.0126% sodium thiosulfate-5-hydrate 
 
0.1% yeast extract 
 
2% Bacto Agar 
 
dest. water 
  
 
ISP 7 1.5% glycerol 
(pH 7.3) 0.05% L-Tyrosine 
 
0.1% L-Asparagine 
 
0.05% K2HPO4 
 
0.05% NaCl 
 
0.001% FeSO4 x 7 H2O 
 
1 mL/L trace salt solution ISP 7 
 
2% Bacto Agar 
 
dest. water 
  
 
Marine Broth medium Becton, Dickinson and Company, France 
  
 
Middelbrock Broth medium Becton, Dickinson and Company, France 
  
 
Müller-Hinton Bouillon (MHB) Carl Roth GmbH + Co.KG, Germany 
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Myc-medium 1% phytone peptone 
(pH 7.0) 1% glucose 
 
50 mM HEPES (11.8 g/L) 
 
dest. water 
  
 
Myxovirescin-medium 1% soy peptone 
(pH 7.0) 0.005% CaCl2 
 
0.025% MgSO4 
 
1 mg/L CoCl2 
 
100 mM HEPES (23.8 g/L) 
 
dest. water 
  
 
Sea water agar 0.8% sampled sea water (NHS) 
 
0.8% Bacto Agar 
  
 
Sea water agar 1.5% sampled sea water (NHS) 
 
1.5% Bacto Agar 
  
 
Solvent A (Maxis) 1 mL formic acid 
 1 L water 
  
 
Solvent B (Maxis) 1mL formic acid 
  1 L acetonitrile 
  
Stan 21 
 
solution A 3.2 g K2HPO4 
 
6.4 mL yeast extract solution (1%) (from 
yeast extract micro granulate) 
 
57.6 g Bacto Agar 
 
Addition of dest H2O to 2.4 L  
solution B 3.2 g KNO3 
 
3.2 g MgSO4 x 7 H2O 
 
0.32 g MnSO4 
 
1.08 g FeCl x 6 H2O 
 
3.2 mL trace element solution after 
Drewes 
 
3.2 g CaCl2 x 2 H2O 
 
Addition of dest. H2O to 0.8L 
Combination of solution A and B 
after autoclaving combination of 
solutions A and B 
 
at about 40 °C 
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Suter medium with and without  tyrosine 1.5% glycerol 
(pH 7.2) (0.1% tyrosine) 
 
0.5% L-arginine 
 
0.5% L-glutamic acid 
 
0.03% L-methionine 
 
0.03% L-isoleucine 
 
0.05% K2HPO4 
 
MgSO4 x 7 H2O  
 
1 mL/L trace element solution (5341) 
 
2% Bacto Agar 
 
dest. water 
  
 
Trace element solution 5314  0.3% CaCl2 x H2O 
 
0.1% iron(III)citrate 
 
00.2% MnSO4 
 
0.01% ZnCl2 
 
0.0025% CuSO4 x 5 H2O 
 
0.02% Na2B4O7 
 
0.0004% CoCl2 x 6 H2O 
 
0.001% Na2MoO4 
 
dest. water 
  
 
Trace element solution 5341 1% CuSO4 x 5 H2O  
 
0.1% CaCl2 x 2 H2O 
 
0.1% FeSO4 x 7 H2O 
 
0.1% ZnSO4 x 7 H2O 
 
0.4% MnSO4 x 7 H2O 
 
dest. water 
  
 
Trace salt solution ISP3 0.1 g/100 mL FeSO4 x 7 H2O  
 
0.1 g/100 mL MnCl2 x 4 H2O  
 
0.1 g/100 mL ZnSO4 x 7 H2O  
 
dest. water 
  
 
Trace salt solution ISP 5 1 g/100 mL FeSO4 x 7 H2O 
 
1 g/100 mL MnCl2 x 4 H2O 
 
1 g/100 mL ZnSO4 x 7 H2O  
 
dest. water 
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Trypticase soy broth (TSB) Becton, Dickinson and Company, France 
(Soybean-Casein Digest Broth)  
 
  
 
  
VY/2 - ASW 0.5% yeast (fresh) 
(pH 7.0) 0.1% CaCl2 
 
50 mM HEPES (11.8 g/L) 
 
1.8% Bacto Agar 
 
artificial sea water “Coral Ocean”, ATI 
  
 
Wadden Sea medium 
10% supernatant of cooked Wadden Sea 
sediment 
 
0.01% yeast extract 
 
dest. water  
  
 
Wadden Sea sediment medium 50% Wadden Sea sediment 
 
50% sampled sea water (NHS) 
 
1.5% Bacto Agar 
  
 
Water agar dest. water 
 
1.5% Bacto Agar 
  
 
5010-medium 3% sucrose 
(pH 6.8) 0.2% NaNO3 
 
0.1% KH2PO4 
 
0.05% MgSO4 x 7 H2O 
 
0.05% KCl 
 
0.001% FeSO4 
 
dest. water 
  
 
5038-medium 0.0857% KH2PO4 
(pH 7.2) 0.0125% K2HPO4 
 
0.05% MgSO4 x 7 H2O 
 
0.01% NaCl  
 
0.01% CaCl2 x 6 H2O 
 
0.2% glucose 
 
0.2% L-methionine 
 
1 mL trace element solution 5314  
 
dest. water 
  
 
5080-medium 2% soy flour 
(pH 7.2) 2% mannit 
 
dest. water 
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5254-(ASW) medium 1.5% glucose 
(pH 7.2) 1.5% soy flour 
 
0.5% corn steep liquor 
 
0.2% CaCO3 
 
0.5% NaCl 
 
(artificial sea water “Coral Ocean”, ATI) 
  
 
5294-(ASW) medium 1% soluble starch 
(pH 7.2) 0.2% yeast extract 
 
1% glucose 
 
1% glycerol 
 
0.25% corn steep liquor 
 
0.2% peptone 
 
0.1% NaCl 
 
0.3% CaCO3 
 
(artificial sea water “Coral Ocean”, ATI) 
  
 
5304-medium 0.1% glucose 
(pH 7.0) 2.4% starch 
 
0.5% tryptone 
 
0.3% meat extract 
 
0.4% CaCO3 
 
dest. water 
  
 
5305-medium 3% potato starch 
(pH 7.0) 1.5% soy flour 
 
0.5% corn steep liquor 
 
0.2% yeast extract 
 
1 mL trace element solution 5314 
 
dest. water 
  
 
5319-medium 0.3% glycerol 
(pH 7.0) 0.2% casein peptone 
 
0.1% K2HPO4 
 
0.1% NaCl 
 
0.05% MgSO4 x 7 H2O 
 
5 mL trace element solution 5314 
 
dest. water 
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5321-medium 1% peptone 
(pH 7.5) 2% glucose 
 
0.2% CaCO3 
 
0.0001% CoCl2 x 6 H2O 
 
dest. water 
  
5330-medium 1% glucose 
(pH 6.5) 1% dextrin 
 
0.5% yeast extract 
 
0.5% casein peptone 
 
0.1% CaCO3 
 
0.5% celit 
 
dest. water 
  
 
5333-medium 0.4% yeast extract 
(pH 7.0) 1.5% starch 
 
0.1% K2HPO4 
 
00.5% MgSO4 x 7 H2O 
 
dest. water 
  
 
5334-medium 2% glucose 
(pH 6.9) 1% soy flour 
 
0.02% CaCO3 
 
0.0001% CoCl2 x 6 H2O 
 
dest. water 
  
 
5336-ASW 1% soluble starch 
(pH 7.3) 0.1% casein 
 
0.05% K2HPO4 
 
0.5% MgSO4 x 7 H2O 
 
2% Bacto Agar 
 
artificial sea water “Coral Ocean”, ATI 
  
 
5388-medium 1.5% glycerol 
(pH 6.8) 1% soy flour 
 
0.5% NaCl 
 
0.1% CaCO3 
 
0.0001% CoCl2 
 
dest. water 
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2.1.2. Chemicals 
Table 2: Chemicals used in this study. 
Chemicals Manufacturer 
1 kb DNA ladder BioLabs 
Acetone J.T. Baker 
Acetonitrile J.T. Baker 
Acetic acid Roth 
Ammonium acetate Roth 
Ammonium iron(III) citrate ((NH4)5Fe(C6H4O7)2) Roth 
Algea Bamboo Garden Japan Nori-Blätter 
Artificial sea water “Coral Ocean” ATI, Hamm 
Agarose Gibco BRL 
Arabinose  Merck 
Bacto Agar® BD 
Chitin Merck 
Calcium chloride (CaCl2 x 2H2O) Merck 
Calcium carbonate (CaCO3) Appli Chem Panreac 
Casein peptone Marcor 
Cobalt(II) chloride (CoCl2) Merck 
Bacto Casitone BD 
Celit 503 Roth 
Cellulose Serva, Heidelberg 
Corn steep liquor Schering 
Copper(II) sulfate (CuSO4 x 5 H2O) Merck 
Dimethylsulfoxid (DMSO) Roth 
DULBCCO´s modified EAGLE´s medium DMEM, Bio Whittaker, Walkersville, MD 
Ethylenediaminetetraacetic acid (EDTA) Riedel-de Haën 
Ethanol J.T. Baker 
Ethyl acetate J.T. Baker 
Iron(III) ethylenediaminetetraacetic acid (Fe EDTA) Fluka 
Fetal bovine serum (FBS) FBS, JRH Bioscience, Lenexa, KS 
Iron(III) chloride (FeCl3 x 6H2O) Merck 
Iron(II) sulfate (FeSO4 x 7 H2O) Riedel-de Haën 
Formic acid Sigma 
Fructose Roth 
Glucose Roth 
Glycerol Roth 
Hydrochloric acid (HCL) Roth 
HEPES ((4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
Roth 
Inositol (Ino) Merck 
Iron(III) citrate (FeC6H6O7 X H2O)  Merck 
Jump Start Taq Ready Mix Stigma- Aldrich 
Potassium chloride (KCl) Stigma- Aldrich 
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Potassium dihydrogen phosphate (KH2PO4) Merck 
Potassium hydrogen phosphate (K2HPO4) Merck 
Potassium nitrate (KNO3) Riedel-de Haën 
L-asparagine Merck 
L-isoleucine Fluka 
L-glutamic acid Merck 
L-methionine Merck 
L-Tyrosine Sigma 
Mannitol Merck 
Marine Broth medium Becton, Dickinson and Company, France 
Meat extract Roth 
Malt extract Roth 
Methanol J.T.Baker 
Middelbrock Broth medium Becton, Dickinson and Company, France 
Magnesium sulfate (MgSO4x7H2O) Roth 
Manganes (II) chloride (MnCl2)  Merck 
Manganese sulfate (MnSO4) Merck 
Müller-Hinton Bouillon (MHB) Carl Roth GmbH + Co.KG, Germany 
Disodium tetraborade (Na2B4O7 x 10 H2O) Merck 
Sodium chloride (NaCl) Merck 
Sodium bromide (NaBr) Merck 
Sodium hydroxide (NaOH) Riedel-de Haën 
Ammonium sulfate ((NH4)2SO4) Merck 
Sodium molybdate (Na2MoO4 x 10 H2O) Merck 
Sodium nitrate (NaNO3) Merck 
Oatmeal (Quaker white oats)  Herrnmühle 
Peptone Marcor S Marcor 
Phytone peptone Marcor 
Potato starch  Denkavit Emsland  
Proteose Peptone BD 
Rhamnose Merck 
Raffinose Sigma 
Skim milk powder Merck 
Soy flour Cargill 
Soy peptone Merck 
Sucrose Merck 
Starch Roth 
Soluble starch  Roth 
Sodium glycerophosphate  Serva  
Sodium thiosulfate-5-hydrate   Merck 
SYBR-Green Quiagen 
Trypsin solution Gibco 
Trifluoro acetic acid Riedel-de Haën 
Trypticase soy broth (TSB) (Soybean-Casein Digest 
Broth) 
Becton, Dickinson and Company, France 
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Tryptone BD 
Tyrosine Sigma 
XAD Amberlight 16N adsorber resin Rohm and Hass  
Xylose (Xyl) Merck 
Yeast extract  Ohly 
Yeast extract micro granulate (yeast extract 
solution) 
Carl Roth GmbH & Co. KG  
Zinc chloride (ZnCl2) Merck 
Zinc sulfate (ZnSO4 x 7H2O) Merck 
 
 
2.1.3. Bacterial strains 
All strains used in this study are listed below. Tables 3, 4, 5, 6 and 9 include the working strains such 
as the isolated myxobacteria from the Wadden Sea sediment and the marine actinobacteria isolated 
from sponges, marine sediment and mangroves from Guam and India as well as from deep sea 
sediments. Additionately, the different test panels used in this study are listed in tables 7 and 8. 
Furthermore, the strains used as reference strains for the characterization of the working strains 
were combined in table 9. Table 10 include the prey test organisms for the isolation of marine 
myxobacteria.  
  
Table 3: Working strains: isolated myxobacteria from Wadden Sea sediment from the coast of Neuharlingersiel, 
Germany.  
Name  Genus Source Method 
WS 1.1 Myxococcus Wadden Sea sediment NHS Wadden Sea agar + E.coli  (20°C) 
WS 15.1 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (20°C) 
WS 21.3 Myxococcus Wadden Sea sediment NHS Wadden Sea + E.coli (20°C) 
WS 28.1 Myxococcus Wadden Sea sediment NHS Stan21 agar + filter paper (20°C) 
WS 28.3 Myxococcus Wadden Sea sediment NHS Stan21 agar + filter paper (20°C) 
WS 2.1 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (30°C) 
WS 2.3 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (30°C) 
WS 3.3 Myxococcus Wadden Sea sediment NHS Wadden Sea + E.coli (30°C) 
WS 3.4 Myxococcus Wadden Sea sediment NHS Wadden Sea + E.coli (30°C) 
WS 4.1 Myxococcus Wadden Sea sediment NHS Water agar + T4 (30°C) 
WS 5.1 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (30°C) 
WS 9.1 Myxococcus Wadden Sea sediment NHS Wadden Sea agar + V. fischeri (30°C) 
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Table 4: Working strains: actinobacteria isolated from sponges and sediment samples in Guam with and without 
Diffusion Growth Chamber (DGC).  
Name  Genus Source Method 
Guam 928 Micromonospora Sponge (Rhabdastrella globostellata) non-DGC 
Guam 1509 Micromonospora Sediment sample (Guam Blue Hole, 110m depth)  non-DGC 
Guam 1510 Micromonospora Sediment sample (Guam Blue Hole, 110m depth) non-DGC 
Guam 1582 Micromonospora Sponge (Rhabdastrella globostellata) DGC 
Guam 1583 Micromonospora Sediment sample (Guam Blue Hole, 110m depth) non-DGC 
Guam 1566 Rhodococcus Sponge (Rhabdastrella globostellata) DGC 
Guam 1257 Microbacterium Sponge (Rhabdastrella globostellata) DGC 
Guam 1322 Streptomyces Sponge (Rhabdastrella globostellata) DGC 
Guam 1285 Streptomyces Sponge (Rhabdastrella globostellata) DGC 
 
 
Table 5: Working strains: actinobacteria isolated from a marine sponge and sediment from a depth of 1092 m of the 
North Atlantic Ocean.  
Name  Genus Source Method 
ASO4 wet Streptomyces Sponge (sampled with ROV) Stamping (wet) 
A-Sed H10-3 Streptomyces Sediment (1092m depth) Dilution series 
B-Sed H10-3 Streptomyces Sediment (1092m depth) Dilution series 
C-Sed H10-3 Streptomyces Sediment (1092m depth) Dilution series 
 
 
Table 6: Working strains: Actinobacteria isolated from marine sediment and rhizosphere sediment samples from 
different mangrove plants from the coast of Tamil Nadu, India.  
Name  Genus Source 
 ICN4 Streptomyces Rhizosphere sediment of mangrove plant (Avicinnia officinalis)  
ICN16 Streptomyces Rhizosphere sediment of mangrove plant (Rhizophora mucronata)  
ICN18 Streptomyces Rhizosphere sediment of mangrove plant (Rhizophora mucronata)  
ICN19 Streptomyces Marine sediment 
ICN21 Streptomyces Rhizosphere sediment of mangrove plant (Rhizophora mucronata)  
ICN26 Streptomyces Rhizosphere sediment of mangrove plant (Rhizophora mucronata)  
ICN27 Streptomyces Rhizosphere sediment of mangrove plant (Rhizophora mucronata)  
ICN28 Streptomyces Rhizosphere sediment of mangrove plant (Acrostichum aureum)  
ICN32  Streptomyces Rhizosphere sediment of mangrove plant (Rhizophora mucronata)  
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Table 7: Standard test panel for the detection of the bioactivity of the secondary metabolites produced by the working 
strains.  
Test strain  Strain no. / Comment 
 Staphylococcus aureus  Newman* 
Bacillus subtilis  (DSM 10) 
Micrococcus luteus  (DSM 1790) 
Mycobacterium smegmatis  (ATCC700084) 
Escherichia coli  (DSM 1116) 
Escherichia coli  TolC 
Pseudomonas aeruginosa  PA14 (DSM 19882) 
Chromobacterium violaceum  (DSM 30191) 
Candida albicans  (DSM 1665) 
Mucor hiemalis  (DSM 2656) 
Pichia anomaler  (DSM 6766) 
* Staphylococcus aureus strain Newman was obtained from PD Dr. Markus Bischoff,  
Saarland University Hospital, Homburg (Duthie 1952). 
 
 
Table 8: Multi resistant test panel for the detection of the bioactivity of secondary metabolites produced by the working 
strains. 
Test strain / strain no. Comment 
Staphylococcus aureus Newman* standard panel 
Staphylococcus aureus N315 (DSM 11822) MRSA; from Prof. Herrmann (Uniklinik Homburg)  
Enterococcus faecium (DSM 20477) Type strain microaerophilic 
Enterococcus faecium (DSM 17050) VREF (vanA) microaerophilic 
Escherichia coli (DSM 1116) standard panel 
Escherichia coli WT-3  quinolone resistance, (#644; gyrA[S83L,D87G]) 
Escherichia coli XL-1 blue tetracycline resistance, Tn10 (TetR) on F plasmid 
Escherichia coli ESBL (DSM 22664) produces CTX-M15 beta-lactamase 
Pseudomonas aeruginosa PA14 (DSM 19882) standard panel, from Prof. Häußler (Twincore) 
Candida albicans (DSM 1665) standard panel 
* Staphylococcus aureus strain Newman was obtained from PD Dr. Markus Bischoff,  
Saarland University Hospital, Homburg (Duthie 1952). 
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Table 9: Test panel for the detection of the bioactivity of isolated pure compounds produced by the working strains. 
Test strain / strain no. Comment 
Staphylococcus aureus Newman* standard panel 
Staphylococcus aureus N315 (DSM 11822) MRSA; from Prof. Herrmann (Uniklinik Homburg)  
Enterococcus faecium (DSM 20477) Type strain microaerophilic 
Enterococcus faecium (DSM 17050)  VREF (vanA) microaerophilic 
Bacillus subtilis (DSM 10) standard panel 
Micrococcus luteus (DSM 1790) standard panel 
Mycobacterium sp. (DSM 43270) standard panel 
Escherichia coli (DSM 1116) standard panel 
Escherichia coli WT-3   quinolone resistance, (#644; gyrA[S83L,D87G]) 
Escherichia coli XL-1 blue tetracycline resistance, Tn10 (Tet
R) on F plasmid 
Escherichia coli ESBL  (DSM 22664) produces CTX-M15 beta-lactamase 
Pseudomonas aeruginosa PA14 (DSM 19882) standard panel, from Prof. Häußler (Twincore) 
Chromobacterium violaceum (DSM 30191) standard panel 
Candida albicans (DSM 1665) standard panel 
Mucor hiemalis (DSM 2656) standard panel 
Pichia anomala (DSM 6766) standard panel 
Schizosaccharomyces pombe (DSM 70572) standard panel 
Rhodotorula glutinis (DSM 10134) standard panel 
* Staphylococcus aureus strain Newman was obtained from PD Dr. Markus Bischoff, Saarland University Hospital, Homburg (Duthie 1952). 
 
 
Table 10: Reference strains for the phylogenetic characterization of the working strains (inclusive working strains S. 
davawensis, S. cinnabarinus and JS360 (S. cinnabaragriseus)). 
Strain name Strain no. 
Streptomyces davawensis JCM 4913 = DSM 101723T 
Streptomyces cinnabarinus DSM 40467T 
Streptomyces cinnabaragriseus JS360 = DSM 101724T 
Streptomyces avermitilis DSM 46492T 
Streptomyces flavovariabilis DSM 41479T 
Streptomyces novaecaesareae DSM 40358T  
Streptomyces alboniger DSM 40043T 
Streptomyces cellostaticus DSM 40189T 
Streptomyces bobili DSM 40056T 
Streptomyces galilaeus DSM 40481T 
Streptomyces griseochromogenes  DSM 40499T 
Streptomyces pseudovenezuelae DSM 40212T 
Streptomyces phaeoluteigriseus DSM 41896T 
Streptomyces atriruber DSM 41860T 
Streptomyces resistomycificus DSM 40133T 
Streptomyces yokosukanensis DSM 40224T 
Streptomyces olivochromogenes DSM 40451T 
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Streptomyces corchorusii DSM 40340T 
Streptomyces longwoodensis DSM 41677T 
Streptomyces curacoi DSM 40107T 
Streptomyces antibioticus DSM 40234T 
Streptomyces canus DSM 40017T 
Streptomyces ciscaucasicus DSM 40275T 
Streptomyces griseorubiginosus DSM 40469T 
Streptomyces phaeopurpureus DSM 40125T 
Streptomyces griseruber DSM 40281T  
Streptomyces karpasiensis DSM 42068T 
Streptomyces glycovorans DSM 42021T 
Streptomyces abyssalis DSM 42024T 
Streptomyces wuyuanensis DSM 42132T 
Streptomyces indianensis DSM 43803T 
Micromonospora chalcea DSM 43026T 
 
Table 11: Prey organisms for the isolation of marine myxobacteria. All strains were isolated from Dr. Thorsten Brinkhoff 
(University of Oldenburg) from the marine environment. 
 Species 
TK Rhizobiales sp. 
T9 Vibrio sp. 
T8 Alteromonas sp. 
T17 Oceanospirillum sp. 
BIA Flavobacter sp. 
TV Cytophagales sp. 
Marinum T2 Actinobacteria sp. 
T4 Pseudonocardia sp. 
DR Dino roseobacter 
 
 
2.1.4. Kits 
The listed Kits were used for the DNA isolation from myxobacteria and actinobacteria and the 
purification of the PCR products after 16S rRNA- PCR. 
• PowerSoil®DNA isolation kit (MO Bio Laboratories Inc., USA)  
• Invisorb Spin Plant Mini Kit (250) (stratec molecular, Germany) 
• MasterPureTM Yeast DNA Purification Kit (epicentre, Wisconsin, USA) 
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2.1.5. Primer 
Used primer for the detection of the 16S rRNA (F27/R518/R1525) and the “Marine Myxobacteria 
Cluster” (MMC) sequence (MMC655f and MMC841r), respectively.  
Table 12: Primer used in this study. Primer sets and the corresponding sequences: F27/R1525 (R518) for the detection of 
the 16S rRNA sequence and MMC655f/MMC841r to detect the MMC (F/f: forward primer; R/r: reverse primer). 
Primer Sequence Reference 
F27 AGAGTTTGATCMTGGCTCG Czarnetzki & Tebbe 2004 
R518 CGTATTACCGCGGCTGCTGG Gafan et al. 2005 
R1525 AAGGAGGTGATCCAGCCGCA Czarnetzki & Tebbe 2004 
MMC655f AGTAATGGAGAGGGTGGC Brinkhoff et al. 2012 
MMC841r GGCACAGCAGAGGTCAAT Brinkhoff et al. 2012 
 
2.1.6. Equipment 
Table 13: Used equipment and manufacturers. 
Equipment Manufacturer 
Centrifuge Eppendorf Centrifuge 5804 R  
Centrifuge  Eppendorf Centrifuge 5427 R  
Clean Bench Thermo Scientific Type MS 2020 1.2 
CO2 incubator Thermo Scientific Heracell 150i CO2 Incubator 
HPLC (RP-HPLC system) Agilent 1260 Series; Aligent technology, USA 
HPLC Aligent 1100 series; Aligent technology, USA 
Incubator Hereus Instruments Function Line 
Light microscope Zeiss Axio Sc pie. A1 microscope 
MS (HRESIMS) MaXis ESI-TOF-MS spectrometer (Bruker) equipped with an 
Agilent 1260 series RP-HPLC system 
Multichannel pipette  RAININ 8-Kanal-Pipette ED P3 Plus 100-1200 µL 
N2 dryer (plates) MiniVap (porvair science) 
Photometer IMPLEN Nano Photometer UV / VIS Spektralphotometer 
Pipettes Eppendorf Research plus 
Rotary evaporator Heidolph Laborata 4003 
Shaker  Pilot-Shake System Kühner RC-6-U 
Shaker (plates) Heidolph Titramax 1000 
Thermocycler Eppendorf Thermocycler Mastercycler gradient 
UV detector Herolab RH-5.1 darkroom hood + B-1393-3K7N camera 
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2.2. Methods myxobacteria 
2.2.1. Sampling 
To isolate marine myxobacteria from marine sediment, Wadden Sea sediment was sampled at 
the North Sea (Germany). For a high distribution of the samples, we sampled at the coast of 
Neuharlingersiel, the island Juist and the sandbank Janssand (Figure 8).  
Figure 8: Sampling sites of marine sediment for isolation of marine myxobacteria: the island Juist, the sandbank Janssand 
and the coast of Neuharlingersiel.  
(Map: Maximilian Dörrbecker (https://en.wikipedia.org/wiki/East_Frisian_Islands)) 
 
2.2.1.1. Neuharlingersiel 
At the coast of Neuharlingersiel the first samples were collected at low tide next to the coast. 
Sediment samples from the upper two centimetres as well as snail shells were collected. 
Furthermore, for the isolation of anaerobe and facultative anaerobe marine myxobacteria, sediment 
cores from the Wadden Sea down to the depth of about 15 cm from different locations (mud, close 
to the beach and close to the water) were taken (Figure 9). 
Figure 9: Wadden Sea sediment cores from the coast of Neuharlingersiel (northern Germany) from different locations: 
mud, close to the beach and close to the water 
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2.2.1.2. Juist 
Because of the high similarity of the isolated “marine” Myxococcus sp. strains to terrestrial ones 
(Brinkhoff et al. 2012) samples were also taken from islands to minimise the probability to isolate 
terrestrial strains which were distributed by humans walking around the beach. Five different 
samples from the island Juist were collected by Thorsten Brinkhoff from the University of Oldenburg: 
dry sand from the beach, wet sand from the beach saturated with sea water, wet algae (green): Ulva 
sp., wet algae (brown): Fucus sp. and a dried algae (brown) Fucus sp. (Figure 10). 
 
Figure 10: Samples for the isolation of myxobacteria from the island Juist, Germany:  1: dry sand from the beach; 2: wet 
sand from the beach saturated with sea water; 3: algae (green): Ulva sp., algae (brown): Fucus sp.; 4: dried algae (brown) 
Fucus sp.. 
 
2.2.1.3. Janssand 
To further minimize the ability for wash-in or drag-in of terrestrial bacteria by humans into the 
marine sediment samples, the sandbank “Janssand” near Spiekerook (Figure 11) was sampled. This 
sandbank is well known in the field of marine research. The upper two centimetres of the sediment 
on different locations as well as rock worm excretions were taken at low tide for the following 
isolation of aerobic bacteria. 
 
 
 
 
 
Figure 11: Sampling site Janssand. A: Sandbank Janssand and B: example of rock worm excretions sampled for the isolation 
of new myxobacteria. 
 
A B 
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2.2.2. Isolation of marine myxobacteria 
To isolate myxobacteria from marine sediments four different media were used. Like Reichenbach 
described in the Prokaryotes (Shimkets et al. 2006) water agar treated with dead E. coli dots as well 
as Stan 21 agar, picked with filter paper, were utilized to isolate the predatory as well as the cellulose 
degrading myxobacteria, respectively. To enrich especially the marine myxobacteria, the isolation 
media were modified. Collected seawater from the cost of the North Sea was used for seawater agar 
plates. Subsequently, Wadden Sea media was established which was made up out of the supernatant 
from cooked marine sediment. Another approach was to prepare Wadden Sea sediment plates which 
were made up out of 50% sampled sediment from the Wadden Sea from Neuharlingersiel and 50% 
collected sea water. All approaches were treated with E. coli dots to isolate the predatory 
myxobacteria. Furthermore, Wadden Sea sediment Agar plates were picked with filter paper to 
isolate cellulose degraders. Afterwards, the different samples, were placed on every prey dot or filter 
paper and incubated at room temperature, at 30°C as wells as at 30 °C with 5% CO2, respectively. The 
sediment cores were split up and separated into 1 cm sections. For the isolation centimetres 1, 4, 8 
and 12 were used. 
Furthermore, coated agar plates were prepared. Therefore, some inoculated sea water agar plates 
were coated with 0.8% of sea water agar to mimic the semi anoxic conditions close underneath the 
sediment surface. To create a more natural environment for the isolation of the predatory marine 
myxobacteria different prey organisms from the natural habitat were used. The Wadden sea and 
water agar media were treated with E. coli dots and crosses as well as some marine prey organisms 
(TK (Rhizobiales sp.), T9 (Vibrio sp.), T8 (Alteromonas sp.), T17 (Oceanospirillum sp.), BIA (Flavobacter 
sp.), TV (Cytophagales sp.), marinum T2 (Actinobacteria sp.), T4 (Pseudonocardiacea sp.) and Dino 
Roseobacter strain (DR)). Afterwards, the plates were incubated at room temperature and at 30 °C. 
Moreover, a mesocosm was constructed inside an aquarium which was filled with sediment from the 
Wadden Sea as well as sampled sea water. To enrich the myxobacteria, some coated agar slides (2% 
agar, 5% peptone) were placed close to the sediment. After an incubation time of five days, the agar 
was transferred to different enrichment plates described before (Brinkhoff et al. 2012). 
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2.2.3. DNA isolation  
2.2.3.1. DNA isolation from sediment samples and algae 
The DNA was isolated from the sediment samples from the Wadden Sea from Neuharlingersiel, Juist 
and Janssand as well as from the different algae samples. An old sediment sample from Bensersiel 
was used as positive control. For the isolation the PowerSoil®DNA isolation kit (MO Bio Laboratories 
Inc., USA) was used. About 0.25 g of the sediment or a small piece of algae was applied and the 
procedure was done like manufacturers description.  
 
2.2.3.2. DNA isolation from cells for 16S rRNA analysis and detection of the MMC  
…………. sequence 
The DNA was isolated via Invisorb Spin Plant Mini Kit (250) (stratec molecular, Germany). For 
preparation either, 1.5 mL of al well grown cell suspension was centrifuged or some cells were taken 
from an agar plate. The cell pellet was mixed with 100 µL of lysation buffer and incubated at 95 °C for 
5 min. Afterwards, 300 µL lysation buffer and 20 µL protein kinase K were added, mixed up and 
incubated for 30 min at 65 °C. Further DNA isolation steps were done like manufactures description. 
 
2.2.4. Molecular approaches  
2.2.4.1. Specific PCR for the detection of the MMC 
The isolated DNA from the sediment samples and algae was diluted 1:10 for the MMC PCR. The 
specific primer MMC655f and MMC841r (Brinkhoff et al. 2012) were used. The PCR mixture had a 
final volume of 25 mL and consisted of the fallowing components: water, “Jump Start Ready Mix” 
(JSRM), the primer pair MMC655f/MMC8415r as well as the DNA template. The JSRM is a mixture 
including Jump Start Taq DNA polymerase, 99% pure desoxynucleotides and buffer in an optimized 
reaction concentration. The PCR mixture had a final volume of 25 µL and consisted of the fallowing 
components: 12.5 µL JSRM, 10 µL water, 1 µL forward and reverse primer dilution as well as 0.5 µL of 
the template DNA. The conditions for the PCR were based on a publication by Brinkhoff et al. (2012). 
To find the best conditions it was modified to the following protocol for a touch down PCR. The PCR 
within the thermocycler started with an activation temperature of 95 °C for 5 min. The first cycle of 
the touch down PCR started with a denaturation step of 94 °C for 1 min and a primer annealing at 
70 °C for 1 min, followed by two minutes of elongation at 72 °C. During the next nine cycles the 
annealing temperature was decreased for 1 °C per cycle to 60 °C. Finally, for the replication of the 
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template, 28 cycles of denaturation at 95 °C for 1 min, annealing at 60 °C for 1 min and elongation at 
72 °C for 2 min were performed.  
Afterwards, the samples were mixed with loading buffer charged with DNA-dye SYBR-Green and 
were loaded on a 0.8% agarose gel. After 60 min at 70 V the bands were visible under UV light. 
 
2.2.4.2. 16S rRNA PCR for phylogenetic analysis 
To analyze the 16S rRNA sequence, two primers were used matching most of the known eubacterial 
orders on the positions 27 (forward) and 518 (reverse). For the conduction of the 16S rRNA PCR a 
special mastermix was created, containing water, primers and “Jump Start Ready Mix” (JSRM). The 
PCR mixture had a final volume of 50 µL and consisted of the fallowing components: 25 µL JSRM, 
22 µL water, 1 µL forward and reverse primer dilution as well as 1 µL of the template DNA. The PCR 
within the Thermocycler started with an activation temperature of 95 °C for 5 min. Followed by 34 
cycles of denaturation (94 °C, 30 sec.), a primer annealing at 52 °C for 30 sec. and 2 min of elongation 
at 72 °C. The final elongation was done at 72°C for 10 minutes. Afterwards, the samples were mixed 
with loading buffer charged with the DNA-dye SYBR-Green and were loaded on a 0.8% agarose gel. 
After 90 min at 70 V the bands were detectible under UV light. Finally, all samples were sequenced 
und compared to bacterial type strain sequences using the NCBI “BLAST” tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch). 
 
2.2.4.3. Calculation of phylogenetic trees using ARB 
The 16S rRNA sequences of the isolated myxobacterial or actinobacterial strains, respectively, as well 
as the 16S rRNA sequences of the closest related type strains detected via NCBI “Blast” 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) were imported into the ARB 
database (Ludwig et al. 2004; version 14.02.2005 database; http://www.arbhome.de). After the 
alignment, a distance matrix tree was constructed using the Neighbour-Joining method (Saitou & Nei 
1987) and Jukes Cantor correction (Jukes & Cantor 1969). The topology of the phylogenetic tree was 
built by bootstrap analysis of 1000 operons without using a filter.  
The ARB tree for the myxobacterial part was constructed by Dr. Kathrin Mohr (working group 
Microbial Drugs, HZI Braunschweig). 
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2.2.5. Sodium chloride tolerance 
Because of the marine habitat of the isolated myxobacteria from the Wadden Sea, their resistance 
towards sodium chloride was tested. The tolerance was analyzed by the growth of the strains on 
basal medium with the addition of 0, 2.5, 5, 7.5 and 10 % of sodium chloride. After five to ten days of 
incubation the highest salt concentration still allowing growth was detected. 
 
2.2.6. Screening for secondary metabolites 
Figure 12: Flow chart of the screening procedure used in this study. 
 
Figure 12 gives an overview about the different steps of the screening process. All methods are 
described in detail in the following chapters. To screen for secondary metabolites, the strains were 
cultivated in production media and afterwards the secondary metabolites were isolated. With the 
Upscaling and strain 
optimization 
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help of a bioactivity assay to detect the MIC (Minimal Inhibition Concentration) via serial dilution 
assay on a standard and a multi resistant test panel, antifungal and antibiotic activities of the crude 
extracts (mixture of compounds produced by the organism) were detected. Crude extracts which 
show a high or interesting biological activity, e. g. activities against Candida albicans, Pseudomonas 
aeruginosa or multi resistant bacteria, were chosen for further analysis. To identify the bioactive 
compound in the mixture of different compounds, the crude extract was fractionated via semi-
preparative HPLC into a 96-well plate which was dried and inoculated with the positive tested 
pathogens. Simultaneously the crude extract was analyzed via LC-MS to detect the masses of all 
compounds within the mixture. Correlating the LC-MS data with the results of the HPLC fractionation, 
the wells which show growth inhibitions can be assigned to the corresponding peak in the LC-MS 
chromatogram revealing the mass of the biologically active compound. Due to a search in the in-
house database Myxobase (Krug & Müller 2014) and the dictionary of natural products (DNP) most of 
the hits were correlated to known compounds. If a compound could not be identified, its production 
was enhanced by optimization of the culture conditions. Using the optimized culture conditions the 
culture is scaled up and the biologically active compound was isolated. Structure elucidation was 
done via HRESIMS spectrometry and NMR spectroscopy. A structure search was conducted, using the 
Myxobase, the DNP as well as SciFinder and other open access chemical databases, ensuring the 
novelty of the isolated compounds. The antibiotic activity and the cytotoxicity of the pure 
compounds were tested to determine their respective activity spectra. 
 
2.2.6.1. Extraction of secondary metabolites 
The 15 isolated myxobacteria (20 °C: WS 1.1, WS 15.1, WS 21.3, WS 28.1 WS 28,3; 30 °C: WS 2.2, WS 
2.3, WS 3.3, WS 4.1, WS 5.1, WS 9.1) were cultured in 100 mL E-medium, CY/H-medium and 
Myxovirescin-medium, treated with 2% of the absorber resin Amberlight XAD-16. After 14 days of 
incubation at 20 °C and 30 °C, respectively, the XAD was reaped. The XAD and the cells were filtered 
through a metal mesh and flushed with dest. H2O. Subsequently, the resin was dried and removed to 
a flask, 70 µL of acetone were added and the resulting mixture was incubated for one hour. 
Afterwards, the acetone extract was filtrated into a 250 mL round bottom flask and the solvent was 
evaporated in a rotary evaporator at 40 °C. The resulting residue was resolved in 1 mL methanol. 
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2.2.6.2. Bioactivity test via serial dilution assay with standard panel   
Table 14: Test strains and the corresponding medium and incubation temperatures of the standard test panel used for 
the bioactivity tests of crude extracts. 
Test strain  Medium Temp. 
Staphylococcus aureus Newman* MHB 30°C 
Bacillus subtilis (DSM 10) MHB 30°C 
Micrococcus luteus (DSM 1790) MHB 30°C 
Mycobacterium smegmatis (ATCC700084) Middlebrock 37°C 
Escherichia coli (DSM 1116) MHB 37°C 
Escherichia coli TolC  MHB 37°C 
Pseudomonas aeruginosa PA14 (DSM 19882) MHB 37°C 
Chromobacterium violaceum (DSM 30191) MHB 30°C 
Candida albicans (DSM 1665) Myc 30°C 
Mucor hiemalis (DSM 2656) Myc 30°C 
Pichia anomala (DSM 6766) Myc 30°C 
* Staphylococcus aureus strain Newman was obtained from PD Dr. Markus Bischoff,  
Saarland University Hospital, Homburg (Duthie 1952). 
 
To test the bioactivity of the crude extracts, a panel of Gram-positive and -negative bacteria as well 
as fungi and yeasts were used (Table 14). The assays were conducted according to standard 
procedures using 96-well plates. Initially, an OD600 of 0.01 (for yeast and fungi 0.05) of the test strains 
was adjusted in 20 mL of the suitable media listed in table 14. Subsequently, 150µl of the test strain 
culture was pipetted in every well, merely the first row was inoculated with 130µl. Afterwards, 20µl 
of each extract was adjoined to the wells of the first row. The last well (A12) was used as negative 
control by adding 20µl of methanol. The extract was diluted in 1:2 steps down to row H and the last 
150µl were discarded. Finally, the plates were incubated for 1-2 days at 30°C and 37°C, respectively 
(Table 14).  
 
2.2.6.3. Compound analysis: HPLC fractionation and mass spectrometry (MS) 
Fractionations were carried out using an analytical HPLC (High performance liquid chromatography) 
(Aligent 1100 series; Agilent technology, USA) system equipped with a fraction collector. Using HPLC, 
different chemical compounds could be detected in a liquid mixture. Diverse agents can be 
distinguish by means of the time they need to elute from the column. This time is called “retention 
time” and is individual for every substance. The fractionation of the extracts helps to identify the 
substance which inhibits a certain test organism. While the HPLC measurement, the detached 
substances from the column were collected in a 96-well plate. Every 30 seconds the injector switched 
to another well and thereby the retention time of the different substances can be correlated with the 
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specific wells and afterwards with the inhibition of the test organisms. The fractionations were 
carried out with an Agilent 1100 HPLC system equipped with a diode-array UV detector (DAD) and a 
fraction collector. HPLC conditions: XBridge C18 column 100×2.1 mm (Waters), 3.5 μm, eluent A2: 
H2O-acetonitrile (95/5), 5 mmol NH4Ac, 0.04 mL/L CH3COOH; eluent B2: H2O-acetonitrile (5/95), 
5 mmol NH4Ac, 0.04 mL/L CH3COOH; gradient system: 10% B increasing to 100% B in 30 min; flow 
rate 0.3 mL/min; 40 °C; UV-detection at 210-450 nm. 
The samples in the 96-well plates were dried for 45-60 min at 40°C with heated nitrogen in a MiniVap 
(porvair science). Afterwards, 150 µL of the specific test organism were added to each well and the 
inoculated plates were incubated at 30/37 °C for 24 h. For the inoculation mixture 20 mL of a suitable 
medium were inoculated with the test organism to a final OD600 of 0.01 (for yeast and fungi 0.05). 
Specific media and incubation temperatures can be taken out of tables 14 and 15.  
The MS analysis in this study was carried out via HPLC-MS (High Pressure Liquid Chromatography – 
Mass Spectrometry) or in detail via HPLC-HRESIMS (High Pressure Liquid Chromatography – high 
resolution electron spray ionization mass spectrometry). Thus, the HPLC which separate the different 
chemical compounds is coupled to a mass spectrometer to identify and quantify the substances via 
mass to charge ratio m/z. Within this combination, every substance was correlated to the 
corresponding peak in the HPLC run. Therefore, the HRESIMS data were recorded on a MaXis ESI-
TOF-MS spectrometer (Bruker) equipped with an Agilent 1260 series RP-HPLC system. HPLC system: 
Acquity UPLC BEH C18 column 50x2.1 mm (Waters); solvent A: 0.1% formic acid in H2O, B: 0.1% formic 
acid in acetonitrile; gradient system: 5% B for 0.5 min, in 19.5 min to 100% B and holding 5 min at 
100% B; flow rate 0.6 mL/min; 40 °C; UV-detection at 200-600 nm. Alternatively with buffer gradient 
system: XBridge C18 column 100×2.1 mm (Waters), 3.5 μm, solvent A: H2O-acetonitrile (95/5), 5 mmol 
NH4Ac, 0.04 mL/L CH3COOH; solvent B: H2O-acetonitrile (5/95), 5 mmol NH4Ac, 0.04 mL/L CH3COOH; 
gradient system: 10% B increasing to 100% B in 30 min; flow rate 0.3 mL/min; 40 °C; UV detection at 
200-600 nm. Molecular formulae were calculated using the SmartFormula algorithm including the 
isotopic pattern (Bruker). 
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2.3. Methods actinobacteria 
2.3.1. Isolation of actinobacteria from marine deep sea sediment from the North Atlantic…… .   
Ocean  
2.3.1.1. Sampling 
The samples were taken by the Team of Prof. Dr. Peter Schupp (University of Oldenburg) in 
December 2014 from the North Atlantic Ocean during an expedition of the new marine research 
vessel “Sonne”. They sampled two sponges and one soft-coral via ROV as well as marine sediment 
from 1092 m depth.  
 
Figure 13: Sampling of the marine samples taken by the research vessel “Sonne”. A: Sampling site; B: sampling of the 
sponge and C: sampling of the sediment sample via ROV. 
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2.3.1.2. Isolation 
For the isolation of marine actinobacteria from deep sea sediment different isolation media were 
prepared as agar plates: VY/2–ASW, water agar treated with dead E.coli, GYM-ASW and 5336-ASW. 
To inoculate the plates the team of Prof. Dr. Schupp used various isolation techniques: dilution series 
of sediment samples with autoclaved sampled sea water; heat treatment of homogenated sampled 
organisms up to 60 °C before plating them in different dilution series; as well as wet and dry 
stamping of sampled organisms. Therefore, the organism was stamped with a previously raised area 
several times on the agar plate to cause a dilution. Afterwards the plates were incubated for 8-10 
weeks at about 18 °C. Colonies, which seemed to be actinobacteria were picked with a sterile 
inoculating loop and streaked on a fresh GYM-ASW plate.  
 
2.3.2. Cultivation 
2.3.2.1. Cultivation of actinobacterial strains 
For the cultivation of the nine strains from Guam, two different media were used. Guam 928, 1509, 
1582 and 1583 were cultured in GYM medium. The remaining strains, Guam 1285, 1510, 1566, 1257 
and 1322 showed better growth in Marine Broth medium. The nine strains from India, ICN4, ICN16, 
ICN18, ICN19, ICN21, ICN26, ICN27, ICN28, ICN32 as well as strains  ASO4 wet, A-, B- and C-Sed H10-3 
from the deep sea sediment from the North Atlantic Ocean were cultured in GYM medium. 
Additionally, strains JS360, S. cinnabarinus, S. davawensis and all further Streptomyces strains used in 
this study were cultured in GYM medium.  
All strains were cultured in 250 mL flasks filled with a volume of 100 mL at 30 °C and 160 rpm for 5 to 
8 days. 
 
2.3.2.2. Cultivation for the extraction of secondary metabolites 
For the extraction of secondary metabolites, the isolated actinobacteria were cultured in the 
production media 5254 and 5294 with and without sampled sea water or artificial sea water. All 
strains were cultured in 250 mL flasks filled with a volume of 100 mL at 30 °C and 160 rpm. 
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2.3.3. Characterization 
To characterize the Streptomyces strains, the morphology, physiology, phylogeny and 
chemotaxonomy as well as the production of secondary metabolites has been analyzed. In this study 
we concentrated on the parts listed in figure 14. The chemotaxonomic analyses were done by the 
working group of Karin Martin of the HKI in Jena and for the DNA-DNA hybridization the isolated DNA 
was sent to the working group of Prof. Dr. Peter Kämpfer, University of Gießen (Germany).    
 
 
Figure 14: Flow chart of the aspects mentioned for the isolation of a new strain: morphology, physiology, phylogeny and 
the production of secondary metabolites. 
 
2.3.3.1. Morphology 
2.3.3.1.1. Growth on agar plates 
For the analysis of the morphology and colony description, the strains were plated on different 
media described by Shirling and Gottlieb (1966). Therefore, about 500 µL of a well grown liquid 
culture was plated on different agar plates: The Streptomyces medium GYM, yeast extract-malt 
extract agar (ISP 2), oatmeal agar (ISP 3), inorganic salt starch agar (ISP 4), glycerol-asparagine agar 
(ISP 5), peptone-yeast extract iron agar (ISP 6) and tyrosine agar (ISP 7). Furthermore, the last two ISP 
media as well as Suter medium (Suter 1978) with and without tyrosine were used for the detection of 
melanin production which is visible as a dark brown to black pigment in the agar (Kutzner 1981). 
After the incubation time of 10-14 days at 30 °C (or any other temperature which is required by the 
strain) the morphological differences like growth, colony colour (detected via RAL-code colour cards), 
areal mycelium and soluble pigments were observed and correlated to the closest related type 
strains. 
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2.3.3.1.2. Light and electron microscopy (SEM) 
For the light microscopic images one drop of a 5-day old liquid culture was taken with an inoculation 
loop and the slide was regarded under a 400-fold amplification with a Zeiss Axio Sc pie. A1 
microscope. 
To detect the structure of mycelium and spores, electron microscopy was used. Therefore, the 
cultures were grown on agar plates of complex media like GYM or the ISP 3 oatmeal medium. 
According to the description of Wink (2003), a well-covered piece was cut out and fixed in 
glutaraldehyde. After critical-point-dehydration and gold-palladium-sputtering, a Zeiss Merlin field 
emission scanning electron microscope (SEM) was used to observe diverse spores and spore chains. 
The SEM harbour an Everhart-Thornley SE-detector and Inlens-SEM detector in a 25 : 75 % ratio 
applying the SEMSmart software version 5.05. 
The electron microscopic analyses were done by Prof. Dr. Manfred Rhode, HZI Braunschweig.  
 
2.3.3.2. Physiology 
2.3.3.2.1. Utilization of carbohydrates 
The ability to utilize different carbon sources is a marker for the differentiation of bacteria. To get an 
overview of the utilization of carbon sources of the different actinobacteria, their growth was 
detected on minimal medium with the addition of different carbohydrates used as source. The 
experiment was performed in 12 well plates filled with basal medium including 1% of the fallowing 
carbon sources: glucose (Glu), arabinose (Ara), sucrose (Suc), xylose (Xyl), inositol (Ino), mannitol 
(Man), fructose (Fra), rhamnose (Rha), raffinose (Raf) and cellulose (Cel). Additionately, water was 
taken as negative and glucose as positive control (Shirling & Gottlieb (1966)). After the inoculation of 
about 100 µL of a well grown liquid culture of the test strain, the plates were incubated 10-14 days at 
30 °C (or any other temperature which is required by the strain).  
 
2.3.3.2.2. Sodium chloride tolerance 
The resistance towards sodium chloride is a helpful tool for the differentiation between all species of 
actinobacteria not only between those of the marine or halophilic representatives. Therefore, basal 
medium agar was prepared with addition of 0, 2.5, 5, 7.5 and 10% of sodium chloride and filled in 6 
well plates. The different media were inoculated with about 100 µL of a well grown liquid culture of 
the test strain and incubated 10-14 days at 30 °C (or any other temperature which is required by the 
strain). The highest salt concentration still allowing growth was recorded (Kutzner, 1981).    
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2.3.3.2.3. Enzymatic activity via api® stripes 
ApiZym® stripes were developed by BioMérieu for the identification of microorganisms by 
determining a specific fingerprint of enzymatic activities (Humble et al. 1977). In 1978 Kilian 
demonstrated the successfully identification of Actinomycetales and related bacteria after using this 
method. The method was performed as described by the manufacturer. To detect an enzymatic 
reaction a homogenized suspension of a well grown liquid culture is transferred into the test stripes 
which contain different substrates. In case of an enzymatic reaction, a visible colour can be detected.  
Using the ApiZym® stripes the reaction of the following enzymes and substrates can be detected: 
phosphatase alkaline: 2-naphthyl phosphate , esterase (C 4): 2-naphthyl butyrate, esterase lipase (C 
8): 2-naphthyl caprylate, lipase (C 14): 2-naphthyl myristate, leucine arylamidase: L-leucyl-2-
naphthylamide, valine arylamidase: L-valyl-2-naphthylamide, cystine arylamidase: L-cystyl-2-
naphthylamide, trypsin: N-benzoyl-DL-arginine-2-naphthylamide, chymotrypsin: N-glutaryl-
phenylalanine-2-naphthylamide, phosphatase acid: 2-naphthyl phosphate, naphthol-AS-BI-
phosphohydrolase: Naphthol-AS-BI-phosphate, galactosidase: 6-Br-2-naphthyl-D-galactopyranoside, 
galactosidase: 2-naphthyl-D-galactopyranoside,  glucuronidase: Naphthol-AS-BI-D-glucuronide, 
glucosidase: 2-naphthyl-D-glucopyranoside, glucosidase: 6-Br-2-naphthyl-D-glucopyranoside, N-
acetyl-glucoseamidase: 1-naphthyl-N-acetyl-D-glucoseaminide, mannosidase: 6-Br-2-naphthyl-D-
mannopyranoside and fucosidase: 2-naphthyl-L-fucopyranoside. 
 
 
2.3.3.3. Phylogeny 
2.3.3.3.1. DNA isolation and 16S rRNA PCR for the taxonomic description 
The genomic DNA for the phylogenetic analysis was isolated with the MasterPureTM Yeast DNA 
Purification Kit (epicentre, Wisconsin, USA). The isolation was done as described by the 
manufacturer. 
The 16S rRNA analyses were done as described in chapter 2.2.4.2 for the myxobacteria. For the 
actinobacterial strains the primer set F27 and R1525 was used. 
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2.3.3.3.2. Calculation of phylogenetic trees using the Genome-to-Genome Distance 
………..Calculator (GGDC) of the DSMZ 
Pairwise sequence similarities were calculated using the method recommended by Meier-Kolthoff et 
al. (2013b) for the 16S rRNA gene available via the GGDC web server (Meier-Kolthoff et al. 2013a) 
available at http://ggdc.dsmz.de/.Phylogenies were inferred by the GGDC web server (Meier-Kolthoff 
et al. 2013a) available at http://ggdc.dsmz.de/ using the DSMZ phylogenomics pipeline (Meier-
Kolthoff et al. 2014) adapted to single genes. A multiple sequence alignment was created with 
MUSCLE (Edgar 2004). Maximum likelihood (ML) and maximum parsimony (MP) trees were inferred 
from it with RAxML (Stamatakis 2014) and TNT (Goloboff et al. 2008), respectively. For ML, rapid 
bootstrapping in conjunction with the autoMRE bootstopping criterion (Pattengale et al. 2010) and 
subsequent search for the best tree was used; for MP, 1000 bootstrapping replicates were used in 
conjunction with tree-bisection-and-reconnection branch swapping and ten random sequence 
addition replicates. The sequences were checked for a compositional bias using the Χ² test as 
implemented in PAUP* (Swofford 2002). 
All data was unrooted and used for an overview about the relationship between the isolated strains 
and their closest relatives. 
 
2.3.3.3.3. MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight) analysis 
The sample preparation was done according to the ethanol/formic acid extraction protocol described 
by Schumann & Maier (2014): about 10 mg of biomass from a liquid culture (cultivated in GYM 
medium for 6-8 days at 30 °C or the optional temperature of the individual strain) was suspended in 
300 µL H2O and homogenised carefully. 900 µL ethanol was added to the suspension. Further 
preparation steps as well as the MALDI-TOF measurements and following analyses were done at the 
DSMZ in Braunschweig at the working group of Dr. Peter Schumann. 
MALDI-TOF mass spectra were recorded using a Microflex L20 mass spectrometer (Bruker Daltonics) 
with a N2 laser unit. The spectra were measured in linear positive mode and the acceleration voltage 
was 20 kV. The spectra were collected from 250 shots across a spot. To analyze the data, a mass 
range of m/z 2000-20,000 Da was observed. For internal calibration the Bacterial Test Standard 
#255343 (Bruker Daltonics) was used. Using the Flexanalysis software (version 3.3, Bruker Daltonics), 
the MALDI-TOF MS spectra were smoothed, baseline corrected and re-calibrated. A score-orientated 
dendrogram was calculated by using the BioTyper software (version 3.1, Bruker Daltonics).  
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2.3.3.3.4. RiboPrinter® analysis 
RiboPrinter® analysis was used to distinguish strains of the same species. Based on ribosomal 
sequences on the DNA this method generates a significant fingerprint for every analyzed strain after 
fragmentation of the DNA using specific enzymes. The experimental part was carried out as 
described by Schumann & Pukall (2013). 
The sample preparation and the following workflow inside the fully automated Characterization Unit 
of the RiboPrinter® system is divided into 5 parts: sample preparation (outside of the Charaterization 
Unit), DNA preparation, separation and transfer, membrane processing and pattern detection. For 
the sample preparation, a small amount of cells from a well grown GYM medium agar was used. The 
RiboPrinter® analysis was conducted by the working group of Dr. Peter Schumann, DSMZ (Germany).   
 
2.3.4. Production of secondary metabolites 
2.3.4.1. Screening of secondary metabolites  
The screening procedure (2.2.6.1), the bioactivity test (serial dilution assay for the detection of the 
MIC) with the standard panel (2.2.6.2) as well as the compound analysis via HPLC fractionation and 
mass spectrometry (MS) (2.2.6.1.3) were done as described in the myxobacterial chapters.  
 
2.3.4.1.1. Extraction of secondary metabolites 
20 mL of a 5-day old culture was mixed with 20 mL of ethyl acetate in a 50 mL reaction tube. After a 
2 min shaking step the tubes were mixed for 10 min in a rotary shaker. Afterwards the samples were 
centrifuged at 9000 rpm for 10 min and the upper phase was transferred into a 50 mL round bottom 
flask. At about 40 °C the ethyl acetate is evaporated in a rotary evaporator. Finally, the extract was 
solved in 1 mL of ethyl acetate: acetone: methanol (1:1:1). 
 
2.3.4.1.2. Bioactivity tests of crude extracts via serial dilution assay with multi resistant.   .           
test panel 
To confine the strains for further analysis, a new serial dilution assay test panel with mainly multi 
resistant bacteria was created. For this panel bacteria with common antibiotic resistances and their 
corresponding type strains (Table 15) were used. The procedure of the serial dilution assay was done 
as described above for the standard test panel. Aside from Candida albicans (OD600: 0.05, 30 °C) all 
test strains were inoculated at an OD600 of 0.01 and were cultured at 37 °C. 
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Table 15: Test strains and the corresponding medium and incubation temperatures multi resistant test panel used for the 
bioactivity tests of crude extracts. 
Test strain Comment Medium Temp. 
Staphylococcus aureus Newman* standard panel MHB 37 °C 
Staphylococcus aureus N315 (DSM 11822) MRSA; from Prof. Herrmann (Uniklinik Homburg)  MHB 37 °C 
Enterococcus faecium (DSM 20477) Type strain microaerophilic TSB 37 °C 
Enterococcus faecium (DSM 17050) VREF (vanA) microaerophilic TSB 37 °C 
Escherichia coli (DSM 1116) standard panel MHB 37 °C 
Escherichia coli WT-3  quinolone resistance, (#644; gyrA[S83L,D87G]) MHB 37 °C 
Escherichia coli XL-1 blue tetracycline resistance, Tn10 (TetR) on F plasmid MHB 37 °C 
Escherichia coli ESBL (DSM 22664) produces CTX-M15 beta-lactamase MHB 37 °C 
Pseudomonas aeruginosa PA14 
 (DSM 19882) 
standard panel, from Prof. Häußler (Twincore) 
MHB 37 °C 
Candida albicans (DSM 1665) standard panel MYC 30 °C 
* Staphylococcus aureus strain Newman was obtained from PD Dr. Markus Bischoff, Saarland University Hospital, Homburg (Duthie 1952). 
 
2.3.4.2. Optimization of culture conditions: Media variation, kinetics and “upscaling” 
For the extraction of secondary metabolites, the strains were cultured in the production media 5254 
and 5294 with and without artificial sea water (“Coral Ocean”, ATI). To enhance the production of 
interesting compounds the culture conditions were optimized.  
Strain Guam 1582 was cultured in 5294 medium with dest. water, artificial sea water (“Coral Ocean”, 
ATI) and sampled sea water form Neuharlingersiel. The peptone was varied between Bacto Peptone 
(BP) and Marcor Soy Peptone (PSM). For comparison, a fresh activated strain as well as a strain which 
was inoculated several times was used. 
Additionally to the media 5254 and 5294, strain Guam 928 was cultivated in the following media: 
5010, 5038, 5080, 5288, 5304, 5305, 5319, 5321, 5330, 5333 and 5334. 
A second media variation for the strain Guam 928 was done using the screening medium 5294 with 
the addition of some compounds of the marine habitat such as shells, algae, chitin, NaBr as well as 
cobalt chloride. Eight variations of medium 5294 without artificial sea water were also used, each 
omitting one component of the original medium.  
Every experiment was done in 250 mL flasks filled with 100 mL of the respective medium. The 
cultures were inoculated 1:10 with a 5 day old well grown preculture and incubated at 30 °C and 
160 rpm for 7 days.   
 
For the strains Guam 1582 and 928 a kinetic experiment was conducted to find the optimal growth 
period for the best production of the compound. Six 250 mL flasks filled with 100 mL of 5294-ASW 
medium, each, were inoculated 1:10 with a 5 day old well grown preculture and were incubated at 
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30 °C and 160 rpm. From day 3 to 8 every day one flask was harvested and crude extract was 
produced. For strain Guam 928 only two flasks were inoculated and harvested at days 5 and 7. 
For the isolation of interesting compounds 50 250 mL flasks, filled with 100 mL of the medium 
showing the best metabolite production, were inoculated 1:10 with a 5 day old preculture of a well 
grown strain. Afterward the cultures were incubated at 30 °C and 160 rpm for 7 days.  
 
2.3.4.3. Isolation, purification and structure elucidation of pure compounds 
These experiments were conducted by Sabrina Karwehl, PhD student in the working group “Microbial 
drugs” of the HZI, Braunschweig (Germany). 
 
2.3.4.4. Bioactivity tests of pure compounds: serial dilution assay and cytotoxicity test 
The biological activity was tested using a serial dilution assay to detect the minimal inhibition 
concentration (MIC) of the pure compounds. The procedure was done as described in Kuhnert et al. 
2015. The assay was done in a 96-well plate. The isolated bioactive compounds were solved in DMSO 
(Dimethylsulfoxid) in a 1 mg/mL concentrated stock solution. This solution was mixed with the test 
strain (OD600: 0.01 (bacteria) / 0.05 (yeast) / OD548: 0.1 (Schizosaccharomyces pombe; Rhodotorula 
glutinis)) to a final concentration of 66.6 µg/mL in the first lane and was diluted in 1:2 steps with the 
inoculated test strain medium. In addition to the standard panel consisting of yeasts, fungi, Gram-
positive and -negative bacteria, a test panel consisting of multi resistant strains, e. g. MRSA und VREF 
(Table 16) was used. The strains were cultivated in the corresponding medium and after inoculation 
the plates were incubated at 30/37 °C and 160 rpm for one day. 
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Table 16: Description, media and incubation temperature of the strains of the test panel for the analysis of pure 
compounds.  
Test strain Comment Medium Temp. 
Staphylococcus aureus Newman* standard panel MHB 37 °C 
Staphylococcus aureus N315 (DSM 11822) MRSA; from Prof. Herrmann (Uniklinik Homburg)  MHB 37 °C 
Enterococcus faecium (DSM 20477) Type strain microaerophilic TSB 37 °C 
Enterococcus faecium (DSM 17050)  VREF (vanA) microaerophilic TSB 37 °C 
Bacillus subtilis (DSM 10) standard panel MHB 37 °C 
Micrococcus luteus (DSM 1790) standard panel MHB 30 °C 
Mycobacterium sp. (DSM 43270) standard panel MHB 30 °C 
Escherichia coli (DSM 1116) standard panel MHB 37 °C 
Escherichia coli WT-3   quinolone resistance, (#644; gyrA[S83L,D87G]) MHB 37 °C 
Escherichia coli XL-1 blue tetracycline resistance, Tn10 (TetR) on F plasmid MHB 37 °C 
Escherichia coli ESBL  (DSM 22664) produces CTX-M15 beta-lactamase MHB 37 °C 
Pseudomonas aeruginosa PA14  
(DSM 19882) 
standard panel, from Prof. Häußler (Twincore) 
MHB 37 °C 
Chromobacterium violaceum (DSM 30191) standard panel MHB 30 °C 
Candida albicans (DSM 1665) standard panel MYC 30 °C 
Mucor hiemalis (DSM 2656) standard panel MYC 30 °C 
Pichia anomala (DSM 6766) standard panel MYC 30 °C 
Schizosaccharomyces pombe (DSM 70572) standard panel MYC 30 °C 
Rhodotorula glutinis (DSM 10134) standard panel MYC 30 °C 
* Staphylococcus aureus strain Newman was obtained from PD Dr. Markus Bischoff, Saarland University Hospital, Homburg (Duthie 1952). 
 
To determine the cytotoxicity of the substances the murine fibroblast cell line L929 was used as 
target in a serial dilution assay in 96 well plates to detect the minimal inhibition concentration (MIC). 
The cells were cultured in tissue culture flasks in culture medium consisting of DULBCCO’s modified 
EAGLE’s medium (DMEM, Bio Whittaker, Walkersville, MD) supplemented with 10% fetal bovine 
serum (FBS, JRH Bioscience, Lenexa, KS). For the cytotoxicity assay the cells were removed from the 
flask using 0.25% of a trypsin solution (Gibco). After removing the trypsin, the cells were incubated 
for 5 min at 37 °C and 5% CO2. The detached cells were resuspended in 10 mL of the culture medium 
DMEM + 10% FBS and the concentration of 50,000 cells/mL were adjusted. 87 µL of culture medium 
was inserted in the first wells of the 96 well plate. After the addition of 3 µL of the compounds, the 
substances were diluted in 1:6 steps with the medium stock solution. Subsequently, 120 µL of the 
previously prepared L292 cell line stock solution (50,000 cells/mL) was appended to every well. The 
cells were incubated for 5 days at 37 °C at 5% CO2. For the analysis the cells were examined under a 
light microscope. 
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3. Results 
3.1. Part 1: Isolation of marine myxobacteria from the sediment of the Wadden Sea: 
search for the MMC sequence and screening for new bioactive compounds 
All samples were tested for the presence of the MMC sequence. Simultaneously, myxobacteria were 
isolated and afterwards also screened for the MMC sequence. Furthermore, the samples were 
phylogenetically analyzed, the sodium chloride tolerance of the isolates was tested and they were 
screened for the production of new bioactive secondary metabolites.  
 
3.1.1. Isolation of new myxobacteria from marine samples 
 
 
Figure 15: Isolates of the marine sediment samples from the Wadden Sea. A and B: sediment samples on E. coli dot and 
visible fruiting bodies and swarming of myxobacteria. C and D: Isolated myxobacterium Myxococcus sp. WS 3.4:  C shows 
the lysis of an E.coli dot by the Myxococcus strain WS 3.4 and D the fruiting bodies in detail. 
 
After 10 days of incubation the first myxobacterial fruiting bodies and swarming were visible. The 
first colonies were detected at the wet sediment samples on the Wadden Sea agar plates and water 
agar plates with E. coli as prey organisms which were incubated at 30 °C (Figure 15 A, B). At the end 
of this study 12 Myxococcus strains were isolated from Wadden Sea and water agar plates treated 
with E. coli dots as well as the Wadden Sea isolates T4 (Pseudonocardiaceae sp.) and Vibrio fischeri 
and from Stan 21 plates. 5 of these Myxococcus strains were isolated and afterwards incubated at 
20 °C (WS 1.1, 15.1, 21.3, 28.1, 28.3) and the remaining 7 strains (WS 2.1, 2.3, 3.3, 3.4, 4.1, 5.1, 9.1) 
at 30 °C (Table 17). All strains were visible in different shades of orange (example Figure 15 C, D). 
Some strains form some kind of inhibition zone around their swarming area to protect themselves 
from the fungi on the enrichment plates.  
C 
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Table 17: Name, genus, source and isolation method from the new isolated strains from Wadden Sea sediment: WS 1.1, 
15.1, 21.3, 28.1, 28.3, 2.1, 2.3, 3.3, 3.4, 4.1, 5.1 and 9.1. 
 
Name  Genus Source Method 
WS 1.1 Myxococcus Wadden Sea sediment NHS Wadden Sea agar + E.coli (20 °C) 
WS 15.1 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (20 °C) 
WS 21.3 Myxococcus Wadden Sea sediment NHS Wadden Sea + E.coli (20 °C) 
WS 28.1 Myxococcus Wadden Sea sediment NHS Stan21 agar + filter paper (20 °C) 
WS 28.3 Myxococcus Wadden Sea sediment NHS Stan21 agar + filter paper (20 °C) 
WS 2.1 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (30 °C) 
WS 2.3 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (30 °C) 
WS 3.3 Myxococcus Wadden Sea sediment NHS Wadden Sea + E.coli (30 °C) 
WS 3.4 Myxococcus Wadden Sea sediment NHS Wadden Sea + E.coli (30 °C) 
WS 4.1 Myxococcus Wadden Sea sediment NHS Water agar + T4 (30 °C) 
WS 5.1 Myxococcus Wadden Sea sediment NHS Water agar + E.coli (30 °C) 
WS 9.1 Myxococcus Wadden Sea sediment NHS Wadden Sea agar + V.fischeri (30 °C) 
 
 
The strain Juist 2.2 was isolated from the wet sand from the beach saturated with sea water from the 
island Juist. With its yellow colour, swarming growth and rod shape this bacterium looked like a 
myxobacterium (Figure 16). However, the sequencing results showed that the isolated bacterium 
was a Cellulophaga lytica which belongs to the family Flavobacteriaceae within the phylum 
Bacteroidetes. This bacterium was previously isolated from an alga (Fucus) from a marine habitat 
(Johansen et al. 1999). This fact supports the assumption that the yellow isolates which were isolated 
from algae samples from Juist belong to the same family.  
 
Figure 16: Isolate Juist 2.2: Cellulophaga lytica. A: Strain growing on a Marine Broth medium plate; B: Microscopic image of 
a well grown culture in Marine Broth medium 
 
 
 
 
 
 
A B 
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During the work of the bachelor thesis of Stephanie Akgün, no differences between the used marine 
prey organisms and the standard E. coli were detected. During the enrichment processes swarming 
bacteria were picked but to date there is no pure culture available. The analysis of the whole 
genomic DNA from the sediment samples showed the MMC sequence detection in the coastal 
sediment samples of Neuharlingersiel as well as in the samples taken from the sandbank Janssand. 
From all of the other samples no myxobacterial pure culture was isolated.  
 
3.1.2. Detection of the MMC sequence in the different samples and the isolated 
….myxobacteria from the Wadden Sea 
 
  
Figure 17: Image of the agarose gel of the specific MMC PCR 1. 1: positive control sediment Bensersiel; 2, 3: sediment 
sample Neuharlingersiel 
 
On the PCR gel a clear band was observed in the positive control as well as in the two sediment 
samples from Neuharlingersiel (Figure 17). Furthermore, the MMC sequence was detected in all 
depths of the Wadden Sea sediment cores from Neuharlingersiel (appendix), in the different 
sediment and rock worm excrution samples from Janssand (appendix), in the wet sediment samples 
from Juist (Figure 18, sample 2) and Neuharlingersiel (Figure 18, sample 6-9) as well as in the snail 
shells (Figure 18, sample 5). However it was not found in one sediment core sample from a depth of 
12 cm (appendix) as well as the dry sand from Neuharlingersiel, in all of the algae samples (Figure 18, 
sample 3b, 3g, 4, 10, 11) and the dry sand from Neuharlingersiel (Figure 18, sample 1). 
A positive signal confirms the existence of living or dead organisms in the sediment samples which 
harbour the MMC sequence. 
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Figure 18: Image of the agarose gel of the specific MMC PCR 2. 1: dry sand from the beach (Juist), 2:wet sand from the 
beach saturated with sea water (Juist), 3b: algae brown: Fucus (Juist), 3g: algae green: Ulva (Juist), 4: dried algae (Fucus) 
(Juist), 5: snail shells (NHS), 6: light Wadden Sea sediment (NHS), 7: dark /green Wadden Sea sediment (NHS), 8: dark 
/brown-black Wadden Sea sediment (NHS), 9: Wadden Sea sediment near the coast (NHS), 10: light green algae wet, 11: 
dark green algae wet. 
 
All 12 isolated Myxococcus strains, listed in table 17 were tested due to the existence of the marine 
myxobacteria sequence in their genome. Unfortunately, the MMC sequence was not detected in any 
of the new isolated strains, resulting none of them belong to the “Marine Myxobacteria Cluster”. 
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3.1.3. Phylogeny of isolated myxobacteria 
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The 16S rRNA sequences of the 12 Myxococcus isolates were clustered against the marine 
myxobacterial clones (1: red cluster) and uncultured myxobacteria from extreme habitats (2: green) 
as well as the cultured myxobacterial type strains (3: blue) (modified after Brinkhoff et al. 2012). The 
isolates clustered very close to the cultured Myxococcus type strains but also to the two Myxococcus 
isolates MX1 and MX2 which were isolated before from Brinkhoff et al. (2012) from the University of 
Oldenburg (Figure 19).  
 
3.1.4. Sodium chloride tolerance of the isolated myxobacteria 
The growth of the different strains was detected by the phenotypic colour of the fruiting bodies and 
the swarm. All strains grew well at 0% NaCl. Swarming behavior and formation of orange fruiting 
bodies were detected. At higher salt concentrations, the fruiting bodies were colourless und the cells 
did not seem to be very fit (Table 18, Figure 20). The strain WS 5.1 showed a good growth and orange 
fruiting bodies at salt concentrations up to 10% (Table 18). 
 
Table 18: Sodium chloride tolerance of the isolated Myxococcus sp. strains from the Wadden Sea: o fb: orange fruiting 
body; c fb: colourless fruiting bodies. 
Strain 0% NaCl 2.5% NaCl 5% NaCl 7.5% NaCl 10% NaCl 
WS 1.1 o fb, swarm cl fb cl fb cl fb cl fb 
WS 2.1 o fb, swarm cl fb cl fb cl fb cl fb 
WS 2.3 o fb, swarm cl fb cl fb cl fb cl fb 
WS 3.3 o fb, swarm cl fb cl fb cl fb cl fb 
WS 3.4 o fb, swarm o fb, swarm cl fb cl fb cl fb 
WS 4.1 o fb, swarm o fb, swarm cl fb cl fb cl fb 
WS 5.1 o fb, swarm o fb, swarm o fb o fb o fb 
WS 9.1 o fb, swarm cl fb cl fb cl fb cl fb 
WS 15.1 o fb, swarm cl fb cl fb cl fb cl fb 
WS 21.1 o fb, swarm cl fb cl fb cl fb cl fb 
WS 23.1 o fb, swarm cl fb cl fb cl fb cl fb 
WS 28.1 o fb, swarm cl fb cl fb cl fb cl fb 
WS 28.3 o fb, swarm cl fb cl fb cl fb cl fb 
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Figure 20: Sodium chloride tolerance test plate of the isolated Myxococcus sp. strain WS 4.1. 1: 0% NaCl, 2: 2.5% NaCl, 3: 
5% NaCl, 4: 7.5% NaCl, 5: 10% NaCl. 
 
3.1.5. Secondary metabolites produced by the isolated myxobacteria  
The 12 isolated myxobacteria from Wadden Sea sediment were cultivated in the three production 
media Myxovirescin, CY/H and E medium. These media are used especially for members of the genus 
Myxococcus. After cultivation and isolation of the secondary metabolites, the bioactivity was tested 
via serial dilution assay to detect the MIC. Interesting compounds were detected by analytical scale 
fractionation experiments and identified using LC-MS analysis.   
 
3.1.5.1. Bioactivity tests: serial dilution assay with standard test panel  
After cultivation and harvesting of the secondary metabolites the bioactivity of the crude extract was 
tested on the standard test panel.  
Table 19: MIC of the crude extracts from the Myxococcus strains, isolated from the Wadden Sea sediment, in different 
media: 1 Myxovirescin; 2 CY/H medium; 3 E medium.  
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WS 1.11 - - A  - E C B  - - - A 
WS 1.12 - - A  - G E D  - - - B 
WS 1.13 - - -  - D D A  - - - A 
WS 2.11 C A A  A C C A  - - - A 
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WS 2.12 - - A  D F E E  - - - C 
WS 2.13 - - A  A C C A  - - - A 
WS 2.31 C A B  A C D A  - - - B 
WS 2.32 - - A  B E D D  - - - B 
WS 2.33 - - A  A C C A  - - - A 
WS 3.31 C A B  A C C -  - - - A 
WS 3.32 - - A  B F D D  - - - B 
WS 3.33 - - A  A C C A  - - - A 
WS 3.41 - - -  - - B D  - - - - 
WS 3.42 - - A  A E D -  - - - B 
WS 3.43 - - A  - A B -  - - - - 
WS 4.11 C A -  A B C F  A - - G 
WS 4.12 - - -  A F E D  - - - G 
WS 4.13 - - A  A C B -  - - - E 
WS 5.11 C B F  H H H A  H - E H 
WS 5.12 - - -  E G G -  D - - G 
WS 5.13 - - -  E F G D  D - - F 
WS 9.11 C A A  A B C A  A - - A 
WS 9.12 - - -  A E D -  - - - B 
WS 9.13 - - -  - A B -  - - - - 
WS 15.11 - - A  - E C B  - - - - 
WS 15.12 - - A  - F E C  - - - B 
WS 15.13 - - -  - D C A  - - - - 
WS 21.31 - - A  - H C B  - - - A 
WS 21.32 - - A  - H E C  - - - A 
WS 21.33 - - -  - E C B  - - - - 
WS 28.11 - - A  F G G D  D - A E 
WS 28.12 - - A  H H H C  G - B G 
WS 28.13 - - -  H H G -  D - A E 
WS 28.31 - - A  - G E D  - - - B 
WS 28.32 - - -  - E C B  - - - A 
WS 28.32 - - -  - D C -  - - - - 
              
 
 62 
 
Most of the extracts showed moderate biological activities (Table 19). Concentrating on strains 
showing growth inhibitions higher than a dilution step of 1:8 (row C) for further fractionation 
experiments, mostly compounds that were already known could be found. 
 
3.1.5.2. Known compounds produced by the isolated myxobacteria 
Most of the produced compounds of the isolated marine myxobacteria showed a high bioactivity 
against Gram-positive bacteria (Table 19). This growth inhibition is caused by the production of fatty 
acids like octadecadienoic acids (e. g. linoleic acid) or hexadecenoic acids (e. g. palmitoleic acid). The 
production of fatty acids is well known for myxobacteria especially for Myxococcus sp. species. The 
correlation between the bioactivity of the fatty acids to the growth inhibition on the test plate is 
demonstrated with the example of strain WS 1.1 in CY/H medium (Figure 21).  
Figure 21: Correlation between the bioactivity of the extract of WS 1.1 in CY/H medium against the test organism E.coli 
and the corresponding peak in the HPLC chromatogram. 
 
In addition to the bioactivity against Gram-positive bacteria, fatty acids as well as other media 
compositions and cell components could also cause a weak growth inhibition of the Gram–negative 
bacterium E. coli Tol C.  
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3.1.5.3. HPLC fractionation and MS analysis of the crude extract of strain 
…………..Myxococcus sp. WS 5.1  
The MIC from the crude extract of strain WS 5.1 in Myxovirescin medium, revealed a strong activity 
against E.coli. To identify the responsible compound for the inhibition, the extract was fractionated 
and afterwards inoculated with E.coli. The growth inhibition of the E.coli strain was correlated to a 
peak in the HPLC chromatogram with the retention time of 10.9 min (Figure 22). After LC-MS 
analysis, this peak (m/z 567.2444 [M+H]+) was identified as the known compound saframycin 
(saframycin Mx1 BCH) (Trowitzsch-Kienast et al. 1988) (Figure 23). Saframycin Mx1 BCH is described 
as to show a strong activity against E.coli. Additionally a saframycin derivative with a saframycin-
chromophore and a specific chlorine isotopic pattern was detected (Figure 24). Unfortunately, this 
saframycin derivative could not be reproduced.  
 
Figure 22: Correlation between the bioactivity of the extract of WS 5.1 in Myxovirescin medium against the test organism 
E.coli and the corresponding peak in the HPLC chromatogram. 
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Figure 23: Chemical structure of saframycin Mx1 BCH. 
 
 
Figure 24: LC-MS chromatogram (UV and mass spectra) of the crude extract of WS 5.1 in Myxovirescin medium.                
1: saframycin MX1 BCH; 2: saframycin derivative with typical chlorine isotopic pattern. 
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3.2. Part 2: Actinobacteria isolated from marine sponges and sediment in Guam: 
Taxonomic characterization and screening for new bioactive compounds  
The marine actinobacterial strains Guam 928, 1257, 1285, 1322, 1509, 1510, 1566, 1582 and 1583 
were isolated from marine sponges and sediments in Guam. The strains were screened for the 
production of secondary metabolites and were taxonomically analyzed.  
 
3.2.1. Phylogenetic analysis 
16S rRNA analyses were done for all nine Guam strains (Guam 928, 1257, 1285, 1322, 1509, 1510, 
1566, 1582 and 1583). Using the “Blast” tool on the homepage of the ”National Centre for 
Biotechnology Information” (NCBI) (www.ncbi.com) the closest relatives of these strains were 
detected. The strains were identified as members of the genera Micromonospora, Rhodococcus, 
Microbacterium as well as Streptomyces. 
 
3.2.1.1. Micromonospora 
The strains Guam 928, 1509, 1510, 1582 and 1583 were identified as Micromonospora sp. strains 
after 16S rRNA analysis. Because most of these strains had the same relatives (Micromonospora type 
strains with 99% homology in the 16S rRNA sequence) (appendix) all of them were prepared for one 
phylogenetic tree based on the 16S rRNA sequences as well as for MALDI-TOF analysis as additional 
tool for the taxonomic differentiation of the strains.   
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Figure 25: Neighbourhood joining tree of the isolated strains Guam 928, 1509, 1510, 1582 and 1583 and their closest 
relatives. All Micromonospora type strains were detected via “Blast” tool on NCBI and the tree was calculated using GGDC.     
 
Figure 25 shows the phylogenetic tree generated with the GGDC of the DSMZ based on the 16S rRNA 
sequences. The Guam isolates 1583, 1510, 1509 and 1582 were very closely related and formed a 
separate cluster, whereas strain Guam 928 clustered together with M. schwarzwaldiensis 
(DSM45708T), M. chalcea (DSM43026T), M. halophytica (DSM43171T) and M. aurantiaca 
(DSM43813T). 
Figure 26: MALDI-TOF dendrogram of the Micromonospora strains Guam 928, 1509, 1510, 1582 and 1583 after and their 
closest relatives. 
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Similar clustering was observed in the dendrogram of the MALDI-TOF analysis. The strains Guam 
1510, 1583, 1582 and 1509 clustered together, however strains Guam 928 and the type strain of     
M. schwarzwaldiensis formed a separate cluster within the Guam cluster. Whereas the other three 
strains M. chalcea (DSM43026T), M. halophytica (DSM43171T) and M. aurantiaca (DSM43813T) 
clustered in separate clusters each (Figure 26).  
Because of the high amount of very closely related type strains within the 16s rRNA sequence of the 
isolated Guam strains this study was focused on Guam 928 and 1582 for closer analysis. These two 
strains showed an interesting secondary metabolite profile. The MALDI-TOF profile of strains Guam 
1509, 1510 and 1583 can be found in the appendix. 
For a better separation and the more distinct clustering with M. schwarzwaldiensis, Guam 928 was 
analyzed again using MALDI-TOF (Figure 27).  
Figure 27: MALDI-TOF dendrogram of the Micromonospora strain Guam 928 and its closest relatives. 
 
As detected before, the strain Guam 928 was revealed to be closely related to M. schwarzwaldiensis 
and formed a cluster with M. rosaria (Figure 27).  
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Figure 28: MALDI-TOF dendrogram of the Micromonospora strain Guam 1582 and its closest relatives. 
 
MALDI-TOF analysis suggested that the closest relative to strain Guam 1582 was the type strain       
M. chalcea (Figure 28). Because of the interesting and akin secondary metabolite profile of both 
strains, Guam 1582 was selected for further phylogenetic analysis.  
 
Figure 29: Phylogenetic tree based on the 16S rRNA sequence of Guam 1582 and its closest relatives. All Micromonospora 
type strains were detected via “Blast” tool on NCBI and the tree was calculated using GGDC.   
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The phylogenetic tree based on the 16S rRNA sequences showed Guam 1582 clustering together 
with M. aurantiaca but also with M. chalcea and M. halophytica (Figure 29) To be sure that Guam 
1582 is not a M. chalcea strain, RiboPrinter® analyses were done. These analyses showed that 
according to the different PvuII RiboPrinter patterns (Figure 30) strain Guam 1582 and M. chalcea are 
not identical at strains´ level. 
 
 
 
 
 
 
 
 
Figure 30: RiboPrinter® results of the Micromonospora strain Guam 1582 with its closest relative M. chalcea. 
 
3.2.1.2. Rhodococcus 
The strain Guam 1566 was at first an interesting strain for the taxonomic description because the 
closest relatives were the type strain Rhodococcus corynebacterioides with 99% and R. equi with 97% 
identity in the 16S rRNA sequence (Table 20). However, because of the high morphological similarity 
with the type strain R. corynebacterioides (data not shown), this strain was skipped for further 
taxonomic description.  
 
Table 20: Closest relatives (type strains) of the Rhodococcus strain Guam 1566 after using the “Blast” tool on NCBI. Based 
on the homology of the 16S rRNA sequence 
Guam 1566 
R. corynebacterioides (99%) DSM 20151T 
R. equi (97%) DSM 20307T 
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3.2.1.3. Microbacterium 
The strain Guam 1257 showed 97% identity in the 16S rRNA sequence (Table 21) with 8 strains, 
revealing it as a possibly new strain. However, no interesting metabolite profile was detected and 
therefore no further taxonomic analysis was done in this study. 
Table 21: Closest relatives (type strains) of the Microbacterium strain Guam 1257 after using the “Blast” tool on NCBI. . 
Based on the homology of the 16S rRNA sequence. 
Guam 1257 
M. testaceum (97%) DSM 20166T 
M. chocolatum (97%) DSM 12507T 
M. esteraromaticum (97%) DSM 8609T 
M. arabinogalactanolyticum (97%) DSM 8611T 
M. kitamiensis (97%) DSM 13237T 
M. trichothecenolyticum (97%) DSM 8608T 
M. thalassium (97%) DSM 12511T 
M. hominis (97%) DSM 12509T 
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3.2.1.4. Streptomyces 
Figure 31: Phylogenetic tree based on the 16S rRNA sequence of the isolated strains Guam 1285 and 1322 and their 
closest relatives. All Streptomyces type strains were detected via “Blast” tool on NCBI and the tree was calculated using 
GGDC.   
 
The genus Streptomyces is one of the largest bacterial groups with most members being 
plylogenetically very closely related. Hence, being 99% identical in the 16S rRNA sequence with 61 
other Streptomyces type strains was not surprising for the two isolated Streptomyces strains Guam 
1285 and Guam 1322 (Figure 31). Because of the high number of related type strains it was decided 
to stop working on the taxonomic description of the Streptomyces strains Guam 1322 and 1285. 
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3.2.2. Secondary metabolites produced by marine actinobacteria from Guam  
All nine Guam strains were screened in two standard media used for the screening for secondary 
metabolites (5254 and 5294 medium). Additionally, because of the marine origin of the isolates, the 
strains were screened on the same media prepared with artificial sea water. After cultivation and 
preparation of crude extracts, the bioactivity was tested for antimicrobial effects in the serial dilution 
assay. Interesting compounds were detected by fractionation experiments and identified using LS-MS 
analysis. The production rate of probably new compounds was increased by media optimization, 
kinetics and “upscaling” experiments to finally isolate and purify the substance for structure 
elucidation. 
 
3.2.2.1. Results of bioactivity tests: serial dilution assay of the standard and multi resistant test 
.panel  
After the cultivation of strains Guam 928, 1257, 1285, 1322, 1509, 1510, 1566, 1582 and 1583 in the 
different screening media crude extracts were prepared. Each extract was screened on the standard 
test panel. Extracts showing strong activities were tested on the multi resistant test panel. 
Most of the extracts produced by the Guam strains were detected to strongly inhibit the growth of 
Gram-positive bacteria from the standard test panel, however some of the strains also produced 
compounds which show higher bioactivity against Gram-negative bacteria, e. g. C. violaceum E. coli 
and E. coli TolC (appendix). Because of the high number of growth inhibitions the most interesting 
strains Guam 928, Guam 1257, Guam 1285, Guam 1509, Guam 1510, Guam 1566 and Guam 1582, 
were additionally tested on the multi resistant test panel (Table 22).  
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Table 22: MIC of the extracts from the isolated actinobacteria from sponges and marine sediment in Guam against the 
multi resistant test panel in different media: 4 5254 medium; 5 5254 sea water medium; 6 5294 medium; 7 5294 sea water 
medium.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of the extracts generated a high number of growth inhibitions in the standard as well as in the 
multi resistant test panel. Therefore, a few extracts were chosen for further fractionation 
experiments to correlate the biological activity to the corresponding peaks in the HPLC 
chromatogram. 
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Guam 9284 -  - - - A  - - - - A 
Guam 9285 -  D D C A  - - - - - 
Guam 12574 -  B - - A  - - - - - 
Guam 12575 -  B - - -  - - - - - 
Guam 12854 -  H H H -  - D E G - 
Guam 12855 -  H H H H  B C D E - 
Guam 13224 -  H H H -  - A D F E 
Guam13225 -  H H H H  - D D E - 
Guam 15094 -  B - - A  - - - F - 
Guam15104 -  - - - -  B - - - - 
Guam 15664 -  E D - -  - - - A - 
Guam15826 -  D A A C  - - - A - 
Guam 15827 -  D D E F  - - - B - 
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3.2.2.2. Interesting compounds produced by marine actinobacteria from Guam 
Most of the bioactivity, determined with the serial dilution assay could not be reproduced in the 
fractionation experiments. Furthermore, in some cases, the amount of produced bioactive 
compound was too low or the ionization was very poor. Therefore only strains Guam 1582 and 928 
were chosen for further metabolite analysis.    
 
3.2.2.2.1. Strain Guam 1582: producer of rakicidin A, B and E 
The raw extract of Guam 1582 showed a strong activity against the VREF and MRSA strains. Hence, 
the extract was fractionated to localise the retention time and detect the biologically active 
compound.  
 
Figure 32: Correlation between the bioactivity of the extract of Guam 1582 in 5294-SW medium against the test organism 
E. faecium DSM 17050 (VREF) and the corresponding area in the HPLC chromatogram. 
 
Due to the fractionation three peaks could be correlated to the biological activity, with retention 
times between 24 and 28.5 min (Figure 32). 
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Figure 33: LC-MS chromatogram (UV and mass spectra) of the extract of Guam 1582 in 5294-SW medium. The three peaks 
were correlated to the masses 1: m/z 607.4069 [M+H]+ (tR = 24.02 min); 2: m/z 621.4221 [M+H]+ (tR = 26.4 min); 3: m/z 
635.4378 [M+H]+ (tR = 27.0 min). 
 
Comparing the HPLC chromatogram from the fractionation with the LC-MS chromatogram the three 
peaks were identified using the characteristic UV chromophores, revealing the masses to be m/z 
607.4069 [M+H]+ (tR = 24.02 min), m/z 621.4221 [M+H]+ (tR = 26.4 min) and m/z 635.4378 [M+H]+ 
(tR = 27.0 min), respectively, indicating structurally related (Figure 33). 
To detect the best conditions for the production of the three bioactive compounds, the strain Guam 
1582 was cultured in medium 5294 prepared with dest. water or artificial sea water as well as 
different peptones. Furthermore, a fresh reactivated and a strain which was inoculated several times, 
were compared. 
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Figure 34: Media variation of Guam 1582. Production of the compounds with the masses 607.4069, 621.4221 and 
635.4378 [M+H]+ by the strain Guam 1582 in different media: SW PMS: 5294 medium with sampled sea water and soya 
peptone Macor; SW BP: 5294 medium with sampled sea water and Bacto peptone; PSM: 5294 medium with dest. water 
and soya peptone Marcor; BP: 5294 medium with dest. water and Bacto peptone; ASW PSM: 5294 medium with artificial 
sea water and soya peptone Marcor; ASW BP: 5294 medium with artificial sea water and Bacto peptone. 
 
All three compounds were produced in every medium combination. The best producer strain was the 
one which was inoculated several times before it was used as preculture. It could be clearly seen that 
the compound with the molecular cluster at m/z 621.4221 [M+H]+ was produced in the highest 
amounts followed by the compounds with the molecular clusters at m/z 607.4069 and 635.4378 
[M+H]+. However the medium resulting in the best production for all three compounds was the 5294 
medium with artificial sea water and Bacto peptone (ASW BP) (Figure 34).  
To find the best day to harvest the strain Guam 1582 to get the highest amount of the three wanted 
compounds, six 250 mL flasks filled with 100 mL were inoculated 1:10 with a 5 day old preculture of 
the strain Guam 1582. From day 3 to 8 after inoculation, every day one flask was harvested and 
analyzed. 
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Figure 35: Kinetics of Guam 1582 in 5294-ASW BP. Production of the compounds with the masses 607.4069, 621.4221 and 
635.4378 [M+H]+ by the strain Guam 1582 in 5294 medium with artificial sea water and bacto peptone (5294-ASW BP). The 
production of these compounds was detected by the harvest of one flask from day 3-8 (P3-P8) and following LCMS analysis. 
 
All three compounds were produced from day 5 to 8. Finally, day 7 showed the highest production of 
all three compounds und was therefore chosen as best day for harvesting (Figure 35). 
For the “upscaling” experiments 50 250 mL flasks filled with 100 mL 5294-ASW medium were 
inoculated 1:10 with a 5 day old preculture of a well grown strain. Afterward the cultures were 
incubated at 30 °C and 160 rpm for 7 days.  
The isolation, purification and structure elucidation was done by Sabrina Karwehl (PhD student 
MWIS, HZI Braunschweig).  
The compound with the molecular cluster [M+H]+ at m/z 607.4069 was identified as the known 
antibiotic Rakicidin A (C32H54N4O7), the compound with the molecular cluster [M+H]+ m/z 621.4221 as 
Rakicidin B (C33H56N4O7) and the compound with molecular cluster [M+H]+ m/z 635.4378 as Rakicidin 
E (C34H58N4O7) (Figure 36).  
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Figure 36: Chemical structures of the compounds rakicidin A, B and E. 
 
To test the bioactivity of the pure compounds of rakicidin A, B and E, a bioactivity test (serial dilution 
assay) was done against the MRSA strain Staphylococcus aureus N315 and VREF strain Enterococcus 
faecium DSM-17050 in different concentrations. 
 
Figure 37: Results of serial dilution assays of Rakicidin A, B and E. 5 µL of a 1 mg/mL in DSMO concentrated stock solution 
was inserted into the assay. The solvent DSMSO was used as negative control. A: serial dilution assay against 
Staphylococcus aureus N315 (MRSA strain); B: serial dilution assay against Enterococcus faecium DSM-17050 (VREF). 
 
Rakicidins A, B and E showed selective antibiotic activities against Gram-positive bacteria, including 
the methicillin resistant Staphylococcus aureus N315 (MRSA) and the vancomycin resistant 
Enterococcus faecium DSM-17050 (VREF) (Figure 37) as well as an inhibition of the murine fibroblast 
cell line L929. The biological activities against Micrococcus luteus (1.0 µg/mL), Bacillus subtilis 
(4.2 µg/mL) and the VREF strain (4.2 µg/mL) were detected for all tested rakicidins at a similar 
concentration. In contrast, against S. aureus rakicidin A showed the lowest MIC value of 2.1 µg/mL 
and rakicidins B and E higher values of 4.1 µg/mL and 8.3 µg/mL, respectively. All rakicidins had the 
same MIC values (4.1 µg/mL) against the MRSA strain but against the VREF strain rakicidin E showed 
considerably decreased activity with a MIC value of 16.5 µg/mL compared to 2.1 µg/mL for rakicidin 
A and B (Table 23). 
 
A B 
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Table 23: MIC [in µg/mL] values of rakicidins A, B and E Gram-positive and -negative bacteria (including multi resistant 
strains), fungi as well as the murine cell line L929. 
  Test organism Rakicidin A Rakicidin B Rakicidin E 
Fungi 
Schizosaccharomyces pombe (DSM70572) - - - 
Pichia anomala (DSM6766) - - - 
Candida albicans (DSM1665) - - - 
Mucor hiemalis (DSM2656) - - - 
Rhodosporidium toruloides (DSM10134) - - - 
Gram+ 
Micrococcus luteus (DSM1790) 1.04 1.04 1.04 
Bacillus subtilis (DSM10) 4.16 4.16 4.16 
Staphylococcus aureus Newman* 2.07 4.14 8.29 
Staphylococcus aureus N315 (DSM11822) (MRSA) 2.07 2.07 16.50 
Enterococcus faecium (DSM20477) 4.14 4.14 8.29 
Enterococcus faecium (DSM17050) (VREF) 4.14 4.14 4.14 
Mycobacterium sp. (DSM43270) - - - 
Gram- 
Chromobacterium violaceum (DSM30191) - - - 
Pseudomonas aeruginosa (DSM19882) - - - 
Escherichia coli (DSM1116) - - - 
Escherichia coli WT-3 (quinolone resistant) - - - 
Escherichia coli XL-1 blue (tetracycline resistant) - - - 
Escherichia coli ESBL (DSM-22664) - - - 
  
   
   Murine cell line L929 1.22 1.22 1.22  
 
3.2.2.2.2. Strain Guam 928: producer of aloesaponarin II and 5-hydroxyaloesaponarin II 
The crude extract of Guam 928 showed a strong growth inhibition against the MRSA strain 
Staphylococcus aureus N315 and also a slight inhibition against the VREF strain Enterococcus faecium 
DSM 17050. Thus, it was decided to further analyse this extract using semi-preparative HPLC 
fractionation as already described above for other strains. 
Both biological activities of the crude extract were correlated to compound 2 (K2) (see Figure 38 and 
39). Furthermore, a second area of inhibition was revealed on the fractionation plate inoculated with 
VREF. Unfortunately this area was too broad with no characteristic peaks (compound 3/K3), resulting 
in the dismissal of this area for further investigations during this study. Despite its biological 
inactivity, a third peak (compound 1/K1) was revealed due to its close proximity to compound 2, 
height and its UV chromophore being similar to that of compound 2. 
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Figure 38: Correlation of the biological activity of the extract of Guam 928 in 5294 medium against the test organism       
S. aureus N315 (MRSA) and the corresponding HPLC chromatogram. K1: compound 1, K2: compound 2.  
 
Figure 39: Correlation of the biological activity of the extract of Guam 928 in 5330 medium against the test organism       
E. faecium DSM 17050) and the corresponding HPLC chromatogram. K2: Compound 2, K3: Compound 3.  
 
The LC-MS analyses showed of the molecular cluster [M+H]+ at m/z 255.0647 (tR = 10.9 min) for 
compound 1 (K1) and the molecular cluster [M+H]+ at m/z 271.0596 (tR = 11.4 min) for compound 2 
(K2) (Figure 40).  
 81 
 
 
Figure 40: LC-MS run of the crude extract of Guam 928 in 5294 medium. UV absorption (1A und 2A) und mass spectra (1B 
und 2B) of compound 1 (K1) and compound 2 (K2).  
 
The media variation revealed medium 5294 as the best production medium for compounds 1 (K1) 
and 2 (K2) (Figure 41A). To enhance the yield of the compounds, the composition of medium 5294 
was varied using dest. water (dW), sampled sea water of the coast of Neuharlingersiel (SW) and 
artificial sea water (ASW) and was harvested at day 5 (T5) and 7 (T7) after inoculation. This variation 
and kinetic experiments revealed the best medium composition to be the one using artificial sea 
water (ASW) and the harvest point at day 7 (Figure 41B).  
 
 
 
Figure 41: Media variation and kinetics of Guam 928. To detect the production of the compounds 1 (K1) and 2 (K2) with 
the masses of 255.0647 and 271.0596 [M+H]+m/z, the peak area was determined. A: For amplified media variation of the 
strain Guam 928 was cultured in the media: 5010, 5038, 5080, 5254, 5288, 5294, 5304, 5305, 5329, 5321, 5330, 5333 and 
5334.B: The media variation and kinetics of the strain Guam 928 was done in the screening medium for actinobacteria 5294 
with dest. water (dW), sampled sea water of the coast of Neuharlingersiel (SW) and artificial sea water (ASW) and was 
harvested at day 5 (T5) and 7 (T7) after inoculation.  
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Unfortunately, the yield of the compounds was too low for compound isolation so further media 
composition variations of the medium 5294 were done. Therefore, a total variation of medium 5294 
was done. Each component of the medium was left out in one approach and additionally to the 
variation of the water (dest. and artificial sea water) and the variation of the age of the preculture 
(fresh or several times inoculated; in 5294 or GYM medium), different components out of the marine 
environment like shells and chitin (Table 24) were added.  
The variation of medium 5294 for the production of the compounds 1 (K1) and 2 (K2) showed high 
variation. The different precultures as well as diverse media compositions caused a very high 
discrepancy between the approaches. The medium 5294-ASW with the addition of chitin and the 
fresh inoculated preculture in GYM medium showed the highest production of the compounds K1 
and K2 (Figure 42).  
 
Table 24: Media compositions of 5294 medium for the production enhancement of the compounds 1 (K1) and 2 (K2) of 
the strain Guam 928.  
 
Media compositions of 5294 medium 
1 5294 medium ASW 
2 5294 medium ASW without starch 
3 5294 medium ASW without yeast extract 
4 5294 medium ASW without glucose 
5 5294 medium ASW without corn steep 
6 5294 medium ASW without peptone 
7 5294 medium 
8 5294 medium with seashells (10g/l) 
9 5294 medium with algea (1g/L) 
10 5294 medium with seashells (10g/l) and algae (1g/l) 
11 5294 medium with chitin (1g/l) 
12 5294 medium with sea sand (1g/l) 
13 5294 medium with NaBr (10g/l) 
14 5294 medium ASW without glycerol 
15 5294 medium with cobalt chloride (1g/l) 
16 5330 medium 
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Figure 42: Media variation of 
medium 5294 of Guam 928. To 
detect the production of the 
compounds 1 (K1) and 2 (K2) 
with the masses of 255.0647 and 
271.0596 [M+H]+m/z, the peak 
area was determined. The 
composition of the medium 5294 
was variated with marine 
ingredients. The media 
compositions 1-16 can be taken 
out of table 24. Every medium 
composition was inoculated with 
a preculture a fresh inoculated 
preculture or a preculture with 
was inoculated several times 
before. Furthermore, the 
precultures were cultured in 
GYM and 5294 Medium.  
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For the “upscaling” experiments 50 250 mL flasks filled with 100 mL 5294 medium with artificial sea 
water and chitin were inoculated 1:10 with a 5 day old preculture of a well grown strain in GYM 
medium. Afterward the cultures were incubated at 30 °C and 160 rpm for 7 days.  
The purification and structure elucidation were done by Sabrina Karwehl (HZI Braunschweig). After 
the NMR analysis, both masses were correlated to known compounds. With a molecular mass of 254 
Da the inactive compound was identified as Aloesaponarin II (C15H10O4) (Bartel et al. 1990) and the 
active compound, with a molecular mass of 270 Da, as its derivative: 5-hydroxyaloesaponarin 
(C15H10O5) (Bystrykh et al. 1997) (Figure 43). 
 
 
Figure 43: Chemical structures of aloesaponarin II and 5-hydroxyaloesaponarin II. 
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3.3. Part 3: Actinobacteria isolated from marine and rhizosphere sediment from 
mangroves in India: Taxonomic characterization and screening for new bioactive 
compounds  
The marine actinobacteria ICN4, 16, 18, 19, 21, 26, 27, 28 and 32 were isolated from marine and 
rhizosphere sediments from mangrove plants in Tamil Nadu, India. The strains were screened for the 
production of secondary metablites and were taxonomically analyzed.  
 
3.3.1. Characterization 
3.3.1.1. Phylogenetic analysis 
ICN16, 18, 19, 21, 26 and 27 were identified as members of the genus Streptomyces using the “Blast” 
tool on the homepage of the NCBI after sequencing the 16S rRNA. As explained above, this 
phylogenetic group is huge and its members are closely related to each other. For this reason it is not 
remarkable that the 16S rRNA sequence of ICN16 is 99% identical to 55, ICN18 to 58, ICN26 to 52 and 
ICN27 to 53 Streptomyces type strains. However, most of the closely related type strains are identical 
to each other and therefore one phylogenetic tree was calculated from all type strains which show 
99% identity to the 16S rRNA sequence of the 8 ICN strains (Figure 44). Moreover, strains ICN19 and 
21 were detected to be new species. However, both strains show a 100% identity on 16S rRNA to 
each other as well as 99% with the type strain of Streptomyces wuyanensis (DSM 42132T). Therefore, 
further studies focused on strains ICN19 and 21. 
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Figure 44: Phylogenetic tree based on the 16S rRNA sequence of strains ICN16, 18, 19, 21, 26 and 27 and their closest 
related type strains. All type strains were detected via “Blast” tool on the NCBI homepage and have more than 99% 
homology in the 16S rRNA sequence to the ICN strains. All Streptomyces type strains were detected via “Blast” tool on NCBI 
and the tree was calculated using GGDC.   
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The strain ICN32 was highly contaminated and the DNA of strain ICN28 could not be isolated in a high 
range. Therefore these two strains were not used for phylogenetic analysis.  
 
3.3.1.2. Morphology and physiology of strains ICN19 and ICN21 
Using 16S rRNA analysis, the two strains ICN19 and 21 were identified to be the same species, 
however, morphologically, these two strains show some differences. While ICN19 grew well on every 
ISP medium besides ISP7, ICN21 only grew well on ISP3. Furthermore, ICN21 merely produced areal 
mycelium on ISP3. In contrast, ICN19 as well as its closest relative, Streptomyces wuyuanensis formed 
grey/white areal mycelia on every ISP medium except ISP6 and 7. On ISP4, 5, 6 and 7 both strains had 
a beige/ivory colour but on ISP2 ICN19 had a reddish while ICN21 a yellow colony colour as well as on 
ISP3 on which ICN19 colonies were pink and ICN21 colonies blue. Soluble pigments were not 
produced by any of the three strains (Table 25).  
 
Table 25: Comparison of the morphology (growth, colony colour, aerial mycelium and soluble pigments on ISP plates) of 
the strains ICN19, 21 and the closest related type strain S. wuyuanensis (DSM 42132T). 
  ICN19 ICN21 
S. wuyuanensis 
DSM 42132 
ISP2 
  
 
Growth good sparse good 
colony colour beige red  sand yellow mouse grey 
aerial mycelium traffic white none light grey 
soluble pigment none none none 
ISP3 
   Growth good good good 
colony colour 
light pink/ antique 
pink 
azure blue dusty grey 
aerial mycelium cream light grey silk grey 
soluble pigment none none none 
ISP4 
   Growth good sparse good 
colony colour ivory ivory squirrel grey 
aerial mycelium pure white none light grey 
soluble pigment none none none 
ISP5 
   Growth good sparse good 
colony colour ivory ivory traffic grey  
aerial mycelium signal white none grey white 
soluble pigment none none none 
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ISP6 
   Growth good sparse good 
colony colour beige grey sand yellow brown beige 
aerial mycelium none none none 
soluble pigment terra brown none none 
ISP7 
   growth sparse sparse good 
colony colour grey beige ivory mouse grey 
aerial mycelium none none light grey 
soluble pigment none none none 
 
The three examined strains, ICN19, ICN21 and S. wuyuanensis (DSM 42132T), differed in their 
physiological characteristics. 
 
Table 26: Physiological properties of strains ICN19, ICN21 and the closest related type strain S. wuyuanensis                
(DSM 42132T). 
  ICN19 ICN21 
S. wuyuanensis 
DSM 42132 
Tests  
   
ApiZym: 
   
Phosphatases alcaline + + + 
Esterase (C4) + + + 
Esterase lipase (C8) + + + 
Lipase (C14)  +/- + - 
Leucine arylamidase + + + 
Valine arylamidase + + + 
Cystine arylamidase + + + 
Trypsin +/- + + 
Chymotrypsin +/- + + 
Phosphatase acid + + + 
Naphtol-AS-BI-
phosphohydrolase 
+ + + 
α galactosidase - - +/- 
β galactosidase - - - 
β glucuronidase - - - 
α glucosidase + +/- + 
β glucosidase - - +/- 
N-acetyl-β-
glucoseamidase 
- - + 
α mannosidase +/- +/- + 
α fucosidase - - - 
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Carbon utilization 
   
Glucose + + + 
Arabinose - - - 
Sucrose - - ++ 
Xylose (+) ++ ++ 
Inositol + - ++ 
Mannose - - - 
Fructose - ++ + 
Rhamnose - - - 
Raffinose - - - 
Cellulose - - - 
 
While ICN19 and 21 showed a positive reaction on lipase and a negative on β-glucosidase and N-
acetyl-β-glucoseamidase, S. wuyuanensis did not react on lipase but on the other two enzymes.  
The main differences between the strains were observed in the ability of the utilization of different 
carbon sources. In contrast to S. wuyuanensis, ICN19 and 21 could both utilize sucrose. ICN19 and S. 
wuyuanensis were able to use inositol as carbon source and fructose was only utilized by ICN21 and 
S. wuyuanensis (Table 26). 
 
3.3.2. Secondary metabolites produced by marine actinobacteria from India 
ICN4, 16, 18, 19, 21, 26 and 28 were screened for bioactive secondary metabolites. Like all 
actinobacteria in this study, the strains were cultivated in the production media 5254 and 5294 
prepared with and without artificial sea water. After cultivation and preparation of a raw extract, the 
bioactivity was tested using serial dilution assay. Interesting compounds were detected by 
fractionation experiments and identified by LS-MS analysis. The production rate of possibly new 
compounds was increased by media optimization, kinetics and “upscaling” experiments to finally 
isolate and purify the substance for the structure elucidation. 
 
3.3.2.1. Results of bioactivity tests: serial dilution assays with standard and…………………     
…………. multi resistant test panel 
After cultivation and harvesting of the secondary metabolites, the crude extracts of the different 
strain and media approaches were tested primarily on the standard test panel. The interesting 
extracts were afterwards also screened on a multi resistant test panel (Table 27). 
Most of the extracts showed inhibitory effects against Gram-positive bacteria and fungal strains from 
the standard test panel. However, some of the strains also produced compounds showing bioactivity 
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against Gram-negative bacteria (appendix). The interesting extracts were additionally screened in the 
multi resistant test panel. 
Table 27: MIC of the extracts from the isolated actinobacteria from marine and rhizosphere sediment from mangroves in 
India against the multi resistant test panel in different media: 4 5254 medium; 5 5254 sea water medium; 6 5294 medium; 7 
5294 sea water medium. 
 Fungi Gram + Gram - 
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Most of the extracts showed a high number of inhibitions in the standard as well as in the multi 
resistant test panel. Therefore, a few were chosen for further fractionation experiments. 
 
3.3.2.2. Interesting compounds produced by marine actinobacteria from India 
Additionately to the fact that most of the determined bioactivities could be correlated to known 
compounds or not be reproduced in the fractionation experiment, in some cases, the amount of 
produced bioactive compound was too low or the ionization was very poor to work further on the 
isolation of these substances. Only strain ICN21 was chosen for broader metabolite analysis. 
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3.3.2.2.1. Strain ICN21: producer of staurosporine 
The biological activity against Candida albicans was assigned to a compound with a mass of 467.2079 
[M+H]+m/z, a retention time of 7.5 min and a significant UV absorption (Figure 45). 
 
Figure 45: LC-MS run of the crude extract of ICN21 in 5254-SW medium. UV absorption and mass spectra of the bioactive 
compound with a mass of 467.2079 [M+H]+ m/z. 
 
Using the Dictionary of Natural Products (DNP) the compound was identified to be staurosporine 
(C28H26N4O3) (Figure 46). Staurosporin was described amongst other activities to have inhibitory 
effects against fungi and yeasts (Omura et al. 1977). Additionately, staurosporine was found to be 
produced by the taxonomically closely related strain ICN19. 
 
 
Figure 46: Chemical structure of staurosporine. 
 
 
 
 
 92 
 
 
Figure 47: Media variations and kinetics of ICN21. To detect the production of staurosporin (masses 467.2079 [M+H]+m/z, 
the peak area was determined. A: The media variation and kinetics of the strain ICN21 was done in the screening media for 
actinobacteria 5254 and 5294 with dest. water (dW), sampled sea water of the coast of Neuharlingersiel (SW) and artificial 
sea water (ASW) and was harvested at day 5 (T5) and 7 (T7) after inoculation. B: For amplified media variation of the strain 
ICN21 was cultured in the media: 5010, 5038, 5080, 5254, 5288, 5294, 5304, 5305, 5319, 5321, 5330, 5333 and 5334.  
 
Figure 47 A and B show the media variations and kinetics for the best production of staurosporine. 
For most of the water combinations medium 5254 at day 7 showed the highest production of the 
compound. However, medium 5254 with addition of sampled sea water proved to be the most 
efficient combination. Further media variations with broader media used as common media for the 
production of secondary metabolites showed the medium 5305 to be the best choice for effective 
production of staurosporine by the strain ICN21.   
 
3.4. Part 4: Actinobacteria from deep sea samples from the North Atlantic Ocean: 
Isolation, taxonomic characterization and screening for new bioactive compounds  
The deep sea is one of the most unexplored places in the wold. On an expedition with the research 
vessel “Sonne”, some deep sea sediment samples and sponges were collected from 1092 m depth. It 
was possible to isolate 4 actinobacterial strains from these samples. These strains were 
phylogenetically characterized and screened for the production of biologically active secondary 
metabolites. 
3.4.1. Characterization 
Strains A-, B- and C-Sed H10-3 and ASO4 wet were isolated from deep sea sediments from the North 
Atlantic Ocean. To classify these strains within their phylogeny, 16S rRNA as well as MALDI-TOF and 
RiboPrinter® analyses were done to find the closest relatives of these strains. 
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3.4.1.1. Characterization of strains A-, B- and C-Sed H10-3: Phylogeny, morphology and 
…………..physiology 
Using 16S rRNA sequencing, the strains A-, B- and C-Sed H10-3 were classified as Streptomyces strains. 
This phylogenetic group consists of a plethora of strains which are closely related. The NCBI “Blast” 
search showed a 99 % identity of the 16S rRNA sequence with 35 other Streptomyces type strains 
(appendix). All of these strains are shown in the phylogenetic tree in figure 48. All three strains are 
very closely related to each other (between 99 and 100% homology in the 16S rRNA sequence), with 
strains A- and C-Sed H10-3 being the closest relatives. However, because of the high number of 
related type strains it was decided to stop working on the taxonomic description of the Streptomyces 
strains A-, B- and C Sed H10-3.  
 
 
Figure 48: Phylogenetic tree based on the 16S rRNA sequence of strains A-, B- and C-Sed H10-3 and their closest related 
type strains. All type strains have more than 99% homology in the 16S rRNA sequence to the Sed H10-3 strains and were 
detected via “Blast” tool on NCBI and the tree was calculated using GGDC.   
 
Because of the close relationship between strains A-, B- and C-Sed H10-3 in the 16S rRNA sequence, 
morphological and physiological parameters were examined, to distinguish them from each other. 
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Table 28: Comparison of the morphology (growth, colony colour, aerial mycelium and soluble pigments on ISP plates) of 
the isolated strains:  A-, B- and C-Sed H10-3. 
  A-Sed H10-3 B-Sed H10-3 C-Sed H10-3 
ISP2 
  
  
Growth good good good 
Colony colour colourless brown beige  honey yellow, ochre yellow  
Aerial mycelium sparse silver grey, grey white  sparse 
Soluble pigment none none none 
ISP3 
  
  
Growth good good good 
Colony colour n.d. green beige  honey yellow, ochre yellow  
Aerial mycelium stone grey, pure white  mouse grey,  platinum grey  agate grey, dusty grey  
Soluble pigment ochre yellow  sand yellow  ivory  
ISP4 
  
  
Growth good sparse good 
Colony colour ivory, lemon yellow  brown beige, clay brown  ochre yellow, curry  
Aerial mycelium sparse none dusty grey, light grey  
Soluble pigment none none none 
ISP5 
  
  
Growth good good good 
Colony colour sulfur yellow  lemon yellow  sulfur yellow  
Aerial mycelium none sparse sparse 
Soluble pigment none none none 
ISP6 
  
  
Growth sparse none good 
Colony colour n.d. none beige  
Aerial mycelium none none none 
Soluble pigment none none none 
ISP7 
  
  
Growth sparse good good 
Colony colour colourless curry, khaki grey  curry, khaki grey  
Aerial mycelium none oyster white  oyster white  
Soluble pigment none lemon yellow  sand yellow  
 
All three strains showed very similar growth and colony colours on the different ISP media. The 
colony colour differed in diverse shades of yellow and beige as well as grey areal mycelia, if existent. 
However, the growth and production of areal mycelia differentiated between the strains. Strain A-
Sed H10-3 only formed areal mycelium on ISP3, but only sparse growth on ISP6 and 7, whereas B-Sed 
H10-3 produced areal mycelium on ISP2, 3 and 7 and did not grow on ISP6.  Strain C-Sed H10-3 formed 
areal mycelium on media ISP3, 4, and 7 and grew well on all ISP media. A yellow to ivory soluble 
pigment was detected on ISP3 medium for every strain and on ISP7 medium for strains B- and C-Sed 
H10-3 (Table 28).  
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Table 29: Physiological properties of strains A-, B- and C-Sed H10-3. 
  A-Sed H10-3 B-Sed H10-3 C-Sed H10-3 
Tests  
   
ApiZym: 
   
  Phosphatases alcaline + + + 
  Esterase (C4) + + + 
  Esterase lipase (C8) + + + 
  Lipase (C14)  +/- + + 
  Leucine arylamidase + + + 
  Valine arylamidase + + + 
  Cystine arylamidase +/- +/- - 
  Trypsin - +/- - 
  Chymotrypsin - - - 
  Phosphatase acid + + + 
  Naphtol-AS-BI-
phosphohydrolase 
+ + + 
  α galactosidase +/- - - 
  β galactosidase + +/- + 
  β glucuronidase - - - 
  α glucosidase + +/- + 
  β glucosidase + +/- + 
  N-acetyl-β-glucoseamidase + + + 
  α mannosidase + + + 
  α fucosidase - - - 
Carbon utilization 
   
  Glucose + + + 
  Arabinose + + + 
  Sucrose ++ - - 
  Xylose ++ ++ ++ 
  Inositol - (+) - 
  Mannose ++ ++ + 
  Fructose ++ + + 
  Rhamnose ++ + + 
  Raffinose - - - 
  Cellulose - - - 
 
Using ApiZym® tests the enzymatic activity of the strains were observed. All three strains showed the 
same enzymatic pattern. A negative result was detected for chymotrypsin, β-glucuronidase as well as 
α-fucosidase, whereas a weak negative result was visible for cystine arylamidase, trypsin and α-
galactosidase. All of the other enzymes tested showed a weak positive result for strains A-, B- and C-
Sed H10-3 (Table 29).  
Also the possibility of carbon utilization of the three isolated deep sea strains was very comparably. 
All strains were able to utilize glucose, arabinose, xylose, mannose, fructose and rhamnose. Raffinose 
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and cellulose was not exploited by any strain. However, strain A-Sed H10-3 was able to use sucrose as 
carbon source whereas the other two strains were not able to use this substrate (Table 29).  
 
3.4.1.2. Characterization of strain ASO4 wet: Phylogeny, morphology and physiology 
In contrast to the other three isolates from the deep sea samples, strain ASO4 wet showed a high 
potential to be a new species. Its closest relatives are the strains S. karpasiensis (98, 94%), S. 
glycovorans (98%) and S. abyssalis (98%) with less than 99% identity in the 16S rRNA sequence (Table 
30). So these strains were ordered from the DSMZ for further analyses for the strain characterization 
as well as MALDI-TOF, RiboPrinter® and DNA-DNA hybridization (DDH) analyses. 
Table 30: Closest relatives of the Streptomyces strain ASO4 wet after using the “Blast” tool on NCBI. . Based on the 
homology of the 16S rRNA sequence. 
ASO4 wet 
S. karpasiensis (98,94%) DSM 42068T 
S. glycovorans (98%) DSM 42021T 
S. abyssalis (98%) DSM 42024T 
 
With the help of the MALDI-TOF analysis (Figure 49) the very close relationship between the new 
isolated strain ASO4 wet and the type strain S. karpasiensis was evident (the same separation was 
detected in the phylogenetic tree based on the 16S rRNA sequence). To verify that the new strain 
ASO4 wet constituted as a new species, the strains were analyzed using RiboPrinter® analysis. 
 
 
 
 
 
 
 
 
Figure 49: MALDI-TOF dendrogram of the Streptomyces strain ASO4 wet and its closest related type strains: S. abyssalis 
(DSM 42024T), S. glycovorans (DSM 42021T) and S. karpasiensis (DSM 42068T). S. griseus (DSM 40236T) was used as 
outgroup. 
 
2003004005006007008009001000
Streptomyces karpasiensis DSM 42068T
ASO4 wet
Streptomyces glycovorans DSM 42021T
Streptomyces abyssalis DSM 42024T
Streptomyces griseus DSM 40236T
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The comparison of the fingerprints using the RiboPrinter® software visualized the differences 
between the strains (Figure 50). All four strains showed a diverse band pattern. Especially the 
differences between the type strain S. karpasiensis and the new isolated ASO4 wet indicated the 
latter to be a new species. 
 
Figure 50: RiboPrinter® analysis of the Streptomyces strain ASO4 wet and its closest related type strains: S. abyssalis 
(DSM 42024T), S. glycovorans (DSM 42021T) and S. karpasiensis (DSM 42068T).  
 
The DNA-DNA hybridization analysis of strain ASO4 wet and its closest relatives yielded a value of 
35.8/28.2 % against S. abyssalis, 40.5/44.4% against S. glycovorans and 40.4/54.7% against S. 
karpasiensis (Table 31). Therefore ASO4 wet is a new species, the closest relative of which is S. 
kapasienesis. Furthermore, a GC value of 72.4% was detected 
 
Table 31: DNA-DNA hybridization (DDH) analysis of the Streptomyces strain ASO4 wet and its closest related type strains: 
S. abyssalis (DSM 42024T), S. glycovorans (DSM 42021T) and S. karpasiensis (DSM 42068T). All hybridizations were 
performed twice.    
 DDH value against strain ASO4 wet (%) 
 
S. karpasiensis (DSM 42068T) 40.4 / 54.7 
S. glycovarans (DSM 42021T) 40.5 / 44.4  
S. abyssalis (DSM 42024T) 35.8 / 28.2 
 
To separate strains from each other, additionally to the genome, the morphology and physiology like 
the carbon utilization or the enzymatic activities were a significant marker. 
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Table 32: Comparison of the morphology (growth, colony colour, aerial mycelium and soluble pigments on ISP plates) of 
strains ASO4 wet S. karpasiensis (DSM 42068T), S. glycovorans (DSM 42021T) and S. abyssalis (DSM 42024T). 
  ASO4 wet S. karpasiensis S. glycovorans S. abyssalis 
ISP2 
  
 
  
Growth good good sparse good 
Colony colour light ivory beige n.d. papyrus white/ ruby red 
Aerial mycelium none  none none papyrus white 
Soluble pigment none  none none none 
ISP3 
   
  
Growth good good  good good 
Colony colour light ivory oyster white papyrus white grey white 
Aerial mycelium grey white none none grey white 
Soluble pigment none  none none none 
ISP4 
   
  
Growth good good good good 
Colony colour ivory ivory papyrus white brown beige 
Aerial mycelium none  none none brown beige 
Soluble pigment none  none none none 
ISP5 
   
  
Growth good good  good good 
Colony colour light ivory oyster white papyrus white papyrus white 
Aerial mycelium none  none none brown beige 
Soluble pigment none  none none none 
ISP6 
   
  
Growth sparse sparse good good 
Colony colour sandy yellow beige papyrus white papyrus white 
Aerial mycelium none  none none none 
Soluble pigment none  none none none 
ISP7 
   
  
Growth sparse good good good 
Colony colour nut brown beige dive brown clay brown/ green brown 
Aerial mycelium light grey none none clay brown 
Soluble pigment none  none none none 
 
The morphological data of the isolated deep sea strain ASO4 wet revealed ASO4 wet to be closely 
related to the three strains S. karpasiensis, S. glycovorans and S. abyssalis. The highest conformity 
was detected with its closest relative, S. karpasiensis. Both strains showed good growth on media 
ISP2, 3, 4 and 5 while S. glycovorans did not grow on ISP 2 medium. S. abyssalis grew well on every 
medium. However, ASO4 wet and S. karpasiensis did only grow sparsely on ISP6 medium while the 
other two strains grew well. The colony colour differed between white and beige up to yellow 
nuances on ISP2, 3, 4, 5 and 6 media and a brown colour on ISP7. The main difference between the 
deep sea isolate and the S. karpasiensis type strain was the production of areal mycelia. While ASO4 
wet produced a grey white mycelium on ISP3 and 7, no mycelia production at all was detected for S. 
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karpasiensis. Furthermore, ASO4 wet showed just a sparse growth on ISP7 medium while its closest 
relatives grew well. Soluble pigments were not detected in any of the approaches (Table 32).  
 
Figure 51: Morphological comparison between the strains ASO4 wet, S. karpasiensis (DSM 42068T), S. glycovorans (DSM 
42021T) and S. abyssalis (DSM 42024T) on GYM plates. 
 
On the direct comparison between the four strains (Figure 51), ASO4 wet, S. karpasiensis (DSM 
42068T), S. glycovorans (DSM 42068T) as well as S. abyssalis (DSM 42024T), the close relationship 
between these strains were evident. All strains had a white/beige colour and a rough colony surface. 
However, the strain ASO4 wet was the only strain producing dark brownish pigment on GYM 
medium. 
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Table 33: Physiological properties of the strains ASO4 wet, S. karpasiensis (DSM 42068T), S. glycovorans (DSM 42021T) 
and S. abyssalis (DSM 42024T). 
  ASO4 wet S. karpasiensis  S. glycovorans  S. abyssalis  
Tests  
    
ApiZym: 
    
  Phosphatases alcaline + + + + 
  Esterase (C4) + +/- +/- + 
  Esterase lipase (C8) + +/- + + 
  Lipase (C14)  - - + - 
  Leucine arylamidase + + + + 
  Valine arylamidase + + + + 
  Cystine arylamidase + + + + 
  Trypsin + + + - 
  Chymotrypsin + + + - 
  Phosphatase acid + + + + 
  Naphtol-AS-BI-
phosphohydrolase 
+ + + + 
  α galactosidase - - - - 
  β galactosidase + - + + 
  β glucuronidase - - +/- +/- 
  α glucosidase + + + + 
  β glucosidase - +/- + + 
  N-acetyl-β-glucoseamidase + + + + 
  α mannosidase + + + + 
  α fucosidase - - - - 
Carbon utilization 
    
  Glucose + + + + 
  Arabinose + - ++ + 
  Sucrose + + ++ ++ 
  Xylose ++ ++ ++ ++ 
  Inositol ++ + ++ ++ 
  Mannose (+) + - + 
  Fructose (+) + - + 
  Rhamnose + + - + 
  Raffinose ++ + ++ ++ 
  Cellulose - + - - 
 
The results of the enzymatic activity test via ApiZym helped to distinguish between the new isolate 
and its closest relatives, especially the relation to the type strain S. karpasiensis (DSM 42068T). While 
ASO4 wet, S. glycovorans and S. abyssalis showed a positive reaction on β-galactosidase, S. 
karpasiensis did not show any activity. However, the deep sea isolate and S. karpasiensis did not 
react in the β-glucuronidase test, the other two strains showed an ambiguous reaction. Furthermore, 
ASO4 wet did not react in the β-glucosidase assay while S. glycovorans and S. abyssalis reacted 
positive and S. karpasiensis ambiguous (Table 33).   
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Concerning the use of carbon source the difference between the isolate ASO4 wet and S. 
karpasiensis became more distinct. ASO4 wet could use glucose, arabinose, sucrose, xylose, inositol, 
mannose, fructose and raffinose as carbon source, S. karpasiensis was not able to utilize arabinose. 
However, this strain was the only one which was able to use cellulose as carbon source (Table 33).      
 
3.4.2. Secondary metabolites produced by marine actinobacteria from the deep sea 
The four isolated strains, A-, B-, and C-Sed H10-3 as well as ASO4 wet, were screened using the two 
standard media, 5254 and 5294 medium. However, because of the marine origin of the isolates, the 
strains were additionally screened on the same media charged with artificial sea water. After 
cultivation and isolation of the secondary metabolites, the bioactivity was tested via serial dilution 
assay on the multi resistant test panel.  
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3.4.2.1. Results of bioactivity tests: serial dilution assay with the multi resistant…        
……..…   test panel 
  
Table 34: MIC of the extracts from the isolated actinobacteria from sponge and sediment samples from the deep sea 
against the multi resistant test panel in different media: 4 5254 medium; 5 5254 sea water medium; 6 5294 medium; 7 5294 
sea water medium.  
 
 
After the cultivation of the strains in the different screening media, crude extracts were produced. 
Each crude extract was screened directly on a multi resistant test panel. Unfortunately, neither the 
strains A-, B- or C-Sed H10-3 nor strain ASO4 wet produced any secondary metabolites with significant 
bioactivity (Table 34). 
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A SedH 10-3 4 -  - A - -  - - - - - 
A SedH 10-3 5 - 
 
- - - -  - - - - - 
A SedH 10-3 6 -  - A - -  - - - - - 
A SedH 10-3 7 -  - - - -  - - - - - 
B SedH 10-3 4 -  - - - -  - - - A - 
B SedH 10-3 5 -  - A - -  - - - A - 
B SedH 10-3 6 -  - A - -  - - - - - 
B SedH 10-3 7 -  - A - -  - - - - - 
C SedH 10-3 4 -  A A - -  - - - - - 
C SedH 10-3 5 -  B A - -  - - - - - 
C SedH 10-3 6 -  A A - -  - - - A - 
C SedH 10-3 7 -  B A - -  - - - - - 
A SO4 wet 4 -  A B - -  - - - - - 
A SO4 wet 5 -  - - - -  - - - - - 
A SO4 wet 6 -  B B - -  - - - - - 
A SO4 wet 7 -  - - - -  - - - - - 
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3.5. Part 5: Polyphasic description of Streptomyces strains JS360 and S. davawensis 
Streptomyces davawensis and S. cinnabarinus were described to be very close relatives and both 
producer of the riboflavin (vitamin B2) analogue roseoflavin. Because of this it was not sure whether 
they really do belong to the same species. Additionally, Streptomyces strain JS360 (S. 
cinnabaragriseus) is the producer strain of the biologically active cinnabaramides and was 
misleadingly described as S. cinnabarinus strain. To describe S. cinnabaragriseus as a new and 
separate species and for the validation of S. davawensis being a separate species, all strains were 
analyzed morphologically, physiologically and phylogenetically. 
 
3.5.1. Phylogenetic analysis 
To detect the phylogenetic relationship between the Streptomyces strains JS360 (S. 
cinnabaragriseus), S. davawensis and S. cinnabarinus, 16S rRNA as well as MALDI-TOF analyses were 
done. The 16S rRNA analyses of the three strains were done by Prof. Peter Kämpfer and his team of 
the University of Gießen. They detected the closest relatives with more than 98.5% similarity in the 
16S rRNA sequence (appendix). These 23 Streptomyces type strains were afterwards used for 
construction of a phylogenetic tree based on the MALDI-TOF fingerprints as well as for the 
comparison of the morphological und physiological characteristics.   
Due to the phylogenetic tree based on the MALDI-TOF finger prints it is clearly evident that strains S. 
davawensis (JCM 4913 / DSM 40467T) and S. cinnabarinus (DSM 40467T) are closely related and 
clustered together with 11 further Streptomyces strains in a huge group (green). In contrast, 
Streptomyces strain JS360 is the closest relative of S. griseoruber (DSM 40281T) and together with S. 
corchorusii (DSM 40340T) the three strains build a separate cluster (blue) (Figure 52). 
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Figure 52: MALDI-TOF dendrogram of the Streptomyces strains JS360 (S. cinnabaragriseus), S. davawensis (JCM 4913 / 
DSM 101723), S. cinnabarinus (DSM 40467T) and their closest relatives. All reference strains were detected via 16S rRNA 
analysis.  
 
3.5.2. Morphological and cultural observations 
White, beige grey or cream aerial mycelium were observed on most of the IPS media for the strains 
S. cinnabarinus, S. davawensis and S. cinnabaragriseus (JS360). While ISP6 was the only medium 
where none of the strains produced areal mycelium, S. davawensis also produced no areal mycelium 
on ISP 2 and strain JS360 additionally showed sparse areal mycelium growth on ISP5 and 7. The 
spores of S. davawensis and S. cinnabarinus form fragmented, almost parallel laying spore chains of 
slightly rough spores. In contrast, the surface of the spores of JS360 showed an irregular 
fragmentation which seemed to be desiccated and the spore chains appeared disordered (Figure 53). 
The colour of the substrate mycelium of S. davawensis differed between sad yellow (ISP2), light pink 
(ISP3), red orange (ISP4), black red (ISP5 and 7) and green brown (ISP6). The colours of JS360 (S. 
cinnabaragriseus) were detected to be between honey yellow (ISP2), vermillion (ISP3), red orange 
(ISP4), black red (ISP5, 7) and beige grey (ISP6). However, some differences between the strains S. 
davawensis and S. cinnabaragriseus (JS360) and the strain S. cinnabarinus were observed. The colour 
of the strain S. cinnabarinus on medium ISP2 was brown red whereas the other two strains had a 
yellow colour and on ISP5 S. cinnabarinus showed a very light red colour instead of the red black 
colour of the compared strains. Another significant difference was detected in the production of 
soluble pigments. A reddish pigment was observed in the media ISP2 and 4 produced by S. 
cinnabarinus, on ISP3 from S. cinnabarinus and S. davawensis, an olive brown pigment from all three 
strains on ISP6 and also on ISP7 produced by S. davawensis and S. cinnabaragriseus (JS360) (Table 
35).  
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Figure 53: Scanning electron microscopy displaying the morphology of the Streptomyces strains S. cinnabarinus, S. 
davawensis and JS360. A, B: S. cinnabarinus (DSM 40467T), C, D: S. davawensis (DSM 101723), E, F: JS360 (S. 
cinnabaragriseus). Cultivation was carried out on medium ISP3 at 28 °C for 14 days. (Bar = A, B, C, D, F: 1 μm; E: 2 µm). 
(Taken by Prof. Dr. Rohde, HZI Braunschweig, Germany) 
 
Table 35: Morphology (ISP + carbohydrates) and physiology of S. cinnabarinus (DSM 40467T), S. davawensis (DSM 
101723) and JS360 (S. cinnabaragriseus). 
  S. cinnabarinus S. davawensis JS360 (S. cinnabaragriseus)                                                                                 
ISP2    
Growth good good good 
Colony colour brown red sand yellow honey yellow 
Aerial mycelium cream none beige grey 
Soluble pigment salmon pink none none 
ISP3 
   Growth good good good 
Colony colour salmon pink light pink vermillon 
Aerial mycelium cream signal white beige grey 
Soluble pigment salmon pink beige red none 
ISP4 
   Growth good good good 
Colony colour salmon pink red orange red orange 
Aerial mycelium cream beige grey beige grey 
Soluble pigment salmon pink none none 
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ISP5 
   Growth good good good 
Colony colour salmon pink black red  black red 
Aerial mycelium sparse beige grey beige grey 
Soluble pigment none none none 
ISP6 
   Growth good decreased decreased 
Colony colour olive drab green brown beige grey 
Aerial mycelium none none none 
Soluble pigment olive drab olive brown ocher brown 
ISP7 
   Growth good good good 
Colony colour Salmon pink black red black red 
Aerial mycelium sparse beige grey beige grey 
Soluble pigment none olive brown olive brown 
 
 
3.5.3. Physiology 
The differences in the enzymatic activities were detected by using the ApiZym® test system (Table 
36). All three strains showed a quiet similar enzymatic pattern. However, positive enzymatic 
reactions were detected against α-galactosidase only from Streptomyces strain JS360, against N-
acetyl-β-glucoseamidase only from S. davawensis and α-fucosidase only from S. cinnabarinus 
Glucose, arabinose, sucrose, inositol, mannose, fructose, rhamnose and raffinose were utilized by all 
of the three strains, S. cinnabarinus (DSM 40467T), S. davawensis (DSM 101723T) and Streptomyces 
strain JS360 (S. cinnabaragriseus). In contrast to the both new strains, strain S. cinnabarinus was able 
to utilize cellulose but showed a negative result in the utilization of xylose (Table 36). 
.
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  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
Tests                                                      
ApiZym:                                                     
  Phosphatases alcaline + + + +/- + + + +/- + + + + + + + + + + + + + + + + + + 
  Esterase (C4) + + + - - - + - - - - - - +/- - - + + - + + + - + + - 
  Esterase lipase (C8) + + + - - +/- + - +/- +/- + - - + - +/- + + + + + + - + + + 
  Lipase (C14)  + + + - - - - - - - - + - +/- - - - - - + +/- +/- - + - +/- 
  Leucine arylamidase + + + + + + + + +/- + + + +/- + + + + + + + + + + + + + 
  Valine arylamidase + + + +/- + + + + - + + +/- - + + + - + + + + + - + + + 
  Cystine arylamidase + + + +/- +/- +/- + - + - + - - +/- - + +/- + +/- + +/- +/- - + +/- +/- 
  Trypsin + + (+) +/- - - + - - + + - - + + + - +/- - + +/- - - + - - 
  Chymotrypsin - - - - - - +/- + - - + - - + - + - +/- - + - - - - - - 
  Phosphatase acid + + + + + +/- + + + + + + + + + + + + + + + + + + + + 
  Naphtol-AS-BI-
phosphohydrolase 
+ + + - + - + +/- - +/- + - - - - +/- + + + + + + + + + + 
  α galactosidase - - + - - +/- + + +/- + - +/- - +/- - +/- + + +/- + + + - + + +/- 
  β galactosidase + + + +/- + + + - +/- + + + +/- + + +/- + + + + + + + + + + 
  β glucuronidase - - - - - - - - - - - - - - - - - - - - - - - - - - 
  α glucosidase + + + + - + + - + + + + + + + + + + + + + + + + + + 
  β glucosidase + + + - +/- + + + +/- + + + +/- + + + + +/- +/- + + + + + + + 
  N-acetyl-β-glucoseamidase + - - + - + + - - + + + - + + + + + - + + +/- - + + - 
  α mannosidase + + + + +/- + + - - + - + - + - +/- + + - + + + - + + + 
  α fucosidase - + - - - - - - - - - +/- - +/- - +/- + + - - - + + - - - 
                           
                           
                           
Table 36: Physiological properties of S. davawensis, S. cinnabarinus, Streptomyces strain JS360 and their closest relatives: 1 S. davawensis DSM 101723T, 2 S. cinnabarinus DSM 40467T, 3 S. 
cinnabaragriseus DSM 101724T, 4  S. avermitilis DSM 46492T, 5 S. flavovariabilis DSM 41479T, 6 S. novaecaesareae DSM 40358T, 7 S. alboniger DSM 40043 T, 8  S. cellostaticus DSM 40189T, 9 S. 
bobili DSM 40056T, 10  S. galilaeus DSM 40481T, 11 S. griseochromogenes DSM 40499T, 12 S. pseudovenezuelae DSM 40212T, 13 S. phaeoluteigriseus DSM 41896T, 14 S. atriruber DSM 41860T, 15 
S. resistomycificus DSM 40133T, 16  S. yokosukanensis DSM 40224T, 17  S. olivochromogenes DSM 40451T, 18 S. corchorusii DSM 40340T, 19 S. longwoodensis DSM 41677T, 20  S. curacoi DSM 
40107T, 21 S. antibioticus DSM 40234T, 22 S. canus DSM 40017T, 23 S. ciscaucasicus DSM 40275T, 24 S. griseorubiginosus DSM 40469T, 25 S. phaeopurpureus DSM 40125T and 26 S. griseruber DSM 
40281T; all data from this study. 
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Carbon utilization     
 
                                    
 
        
  Glucose + + + + + + + + + + + + + ++ + + + + + + + + + + + + 
  Arabinose + + + + + + + + + + + + + + ++ + + + (+) + - + + + ++ + 
  Sucrose + + + - + + - (+) + + + + - - - - + + - + - + + + + - 
  Xylose + - + - - + - (+) + - - + ++ + + ++ - - (+) + - - - - ++ - 
  Inositol + + + (+) + + + + + + + + ++ + ++ ++ + + - + + - + + ++ - 
  Mannose + + + + + + + + - - + + ++ ++ ++ - + + (+) + (+) + + + + - 
  Fructose + + ++ + + + - + + + + + ++ ++ ++ + + + - + (+) + + + ++ (+) 
  Rhamnose + + + + + + - + + + - + + ++ + ++ + + - - (+) + + + ++ (+) 
  Raffinose + + + (+) + + - + + + + + - + ++ ++ - - - - - - + + ++ - 
  Cellulose - + - - - - + + + + + - - - - - - - - + - - - + - - 
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4. Discussion 
4.1. Marine myxobacteria 
This part of the study was based on the publications of Jiang et al. (2010) and Brinkhoff et al. (2012) 
about the “Marine Myxobacteria Cluster” (MMC). Using molecular approaches, they found a specific 
rRNA sequence in diverse marine samples, which are on the one hand related to the 16S rRNA 
sequences of known terrestrial myxobacteria but on the other hand phylogenetically different at high 
levels and therefore indicate “a phylogeographical separation between myxobacteria in the ocean 
and on land” (Jiang et al. 2010). The specific MMC sequence was isolated in marine sediments almost 
all over the world (Brinkhoff et al. 2012). However, to date, no MMC sequence harbouring 
myxobacteria could be isolated. Except the three “marine myxobacterial” families Haliangium (Fodou 
et al. 2002), Plesiocystis (Iizuka et al. 2003a) and Enhygromyxa (Iizuka et al. 2003b), which need a 
certain NaCl concentration to thrive (halophilic) but clustered within the terrestrial myxobacteria of 
the genus Nannocystis, only halotolerant bacteria which belong to the genera Myxococcus, 
Angiococcus, Corallococcus and Cystobacter were isolated (e.g. Li et al. 2002, Brinkhoff et al. 2012). 
Just as Brinkhoff et al. (2012), who isolated the two Myxococcus strains MX1 and MX2, in this study 
only halotolerant Myxococcus strains (WS 1.1, 2.1, 2.3, 3.3, 3.4, 4.1, 5.1, 9.1, 15.1, 21.3, 28.1 and 
28.3) were isolated. These 12 strains clustered within the terrestrial myxobacteria and did not 
harbour the MMC sequence. However, this sequence was verified in almost every sample from the 
Wadden Sea besides algae and dry sand samples from the coast of Neuharlingersiel. 
Basing on Zhang et al. (2005) myxobacteria which were isolated from marine habitats could be 
separated into three groups: the nonhalotolerant, the halotolerant and the halophilic isolates. The 
nonhalotolerant strains are not able to grow with salt concentrations higher than 1% (Reichenbach & 
Dworkin 1992) and have been isolated because of washed in myxospores from terrestrial 
myxobacteria. Meanwhile halotolerant isolates can grow with and without salt water and tolerate a 
wide range of NaCl concentrations. These strains are phylogenetically very closely related to 
terrestrial myxobacterial strains (Li et al. 2002) and may have evolved from their terrestrial relatives 
by adapting to the conditions of the marine environment. In contrast, the halophilic isolates, such as 
members of the families Haliangium (Foudou et al. 2002), Plesiocystis (Iizuka et al. 2003a) and 
Enhygromyxa (Iizuka et al. 2003b) were classified as a new myxobacterial group because of 
phylogenetical distance as well as the morphologic differences. Using this description, the 12 
Myxococcus isolates from the Wadden Sea belong to the group of halotolerant myxobacteria. Strains 
WS 3.4, and 4.1 formed orange to yellow fruiting bodies and swarms on media containing up to 2.5% 
NaCl and strain WS 5.1 even build fruiting bodies up to 10% NaCl. This wide range of sodium chloride 
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tolerance is very impressive especially compared with the optimum NaCl concentration of the 
described halophilic myxobacteria between 1.0- 3.0 % (Foudou et al. 2002; Iizuka et al. 2003a; Iizuka 
et al. 2003b). However, Zhang et al. (2005) also described a changing growth strategy of the 
halotolerant myxobacteria. With higher salt concentrations, on agar plates the cells stopped to form 
fruiting bodies and the swarming cells changed their colour to light tan, the cells itself shortened into 
spheres of the size of myxospores and in liquid media they showed cell independent growth as well 
as the formation of myxospores directly from vegetative cells. Almost the same scenario was 
detected during the NaCl tolerance test of the Wadden Sea isolates. All strains formed colourless 
fruiting bodies on media containing up to 10% sodium chloride without any swarming and the cells 
seemed weak. Furthermore, similar to the description of Zhang et al. (2005), the WS–strains 
clustered phylogenetically within their cultured terrestrial relatives. However, most of the strains did 
not have the exact same 16S rRNA sequence and build a separate cluster in between. This close 
relationship was also detected during the screening of the production of new bioactive secondary 
metabolites of the 12 isolated Myxococcus strains. All detected biological activities could be 
correlated to known substances produced by terrestrial myxobacteria in in-house database at HZI, 
“Myxobase”. 
In sum, this study reflects the findings of other working groups (e.g. Li et al. 2002, Brinkhoff et al. 
2012) as it was only possible to isolate halotolerant or even halophilic (Foudou et al. 2002; Iizuka et 
al. 2003a; Iizuka et al. 2003b) myxobacteria from marine habitats. Unfortunately none of these 
myxobacteria harbour the MMC sequence. Phylogenetically, they clustered within their terrestrial 
relatives with a high distance to the bacterial MMC clones from the marine samples (Brinkhoff et al. 
2012). To isolate “real” marine myxobacteria all scientists agree that on the one hand a sample is 
needed from the deep oceans and on the other hand new isolation techniques, which mimic the 
natural environment of the samples, have to be established. Furthermore, because of the unknown 
lifecycle and morphology of marine myxobacteria, isolation techniques should not focus on 
characteristic swarms and fruiting bodies but consider other unusual bacterial colonies.  
 
4.2. Description of new (marine) actinobacteria 
“Taxonomic information is essential, as it enables scientists to understand the biodiversity and 
relationships among living organisms from different ecosystems” (Ramasamy et al. 2014; Gevers et 
al. 2005). With the classification of bacteria by basic phenotypic markers like the description of 
morphology, growth requirement or pathogenic potential, Lehmann and Neumann started the age of 
microbial taxonomy in 1896. However, during the last century physiological and biochemical 
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properties (Orla-Jensen 1909; Buchanan 1955), chemotaxonomy (Minnikin et al 1975), numerical 
taxonomy (Brenner et al. 1969), DNA-DNA hybridization (Johnson 1991) and the comparison of the 
16S rRNA sequence with described type strains (Ramasamy et al. 2014; Gürtler & Mayall 2011; 
Coenye & Vandamme 2004; Konstantinidis & Tiedje, 2007) were added to the common description 
approaches. In sum, to date the description of a new prokaryotic strain is a polyphasic combination 
of phenotypic, chemotaxonomic and genotypic analyses (Vandamme et al. 1996, Stackebrandt et al. 
2002, Tindall et al. 2010).  
In this study, the 16S rRNA sequence was used as a first marker for the search of novel marine 
actinobacteria. Basing on Stackebrandt et al. (2002) a new genus or a new species could be described 
if the isolate had 16S rRNA identity values of 95 and 97%, respectively, compared to their closest 
phylogenetic neighbour. In 2006 this value was increased to 98.7% (Stackebrandt & Ebers). However, 
such high values of 16S rRNA sequence identities like in the genus Streptomyces and 
Micromonospora, where different species have 16S rRNA similarities up to 99%, have to be 
correlated with DNA-DNA hybridizations (Rosselló-Móra 2006). Wayne et al. (1987) described 
isolates with less than 70% homology as distinct species. Moreover, in such genotechnological tight 
relationships, the morphological and physiological descriptions have to be focused. 
Most of the Guam strains as well as all ICN strains and the three isolated deep sea strains A-, B- and 
C-Sed H10-3 belong to the genera Streptomyces or Micromonospora. These strains had a 16Sr RNA 
sequence similarity of 99% to numerus type strains. Therefore, this study focused on the polyphasic 
taxonomic description of strains JS360, S. cinnabarinus and S. davawensis as well as the deep sea 
isolate ASO4 wet.   
Micromonospora strain Guam 1582, the producer strain of the bioactive rakicidins A, B and E was 
further analyzed taxonomically using MALDI-TOF and compared to Micromonospora chalcea via 
RiboPrinter®. After 16S rRNA and MALDI-TOF analyses M. chalcea was detected to be the closest 
relative to strain Guam1582. Songsumanus et al. (2013) as well as Xie et al. (2011) described this 
strain as producer strain for rakicidin A and B. Using the RiboPrinter® analysis, which is able to 
compare different bacteria on strains level, strain Guam 1582 was identified as individual strain of 
the genus Micromonospora. 
Furthermore, strains ICN19 and 21 were morphologically and physiologically compared to the type 
strain Streptomyces wuyuanensis. Strains ICN19 and 21 were 100% identical to each other and 99% 
to S. wuyuanensis due to the 16S rRNA sequence. However, during the morphological (growth on 
different agar plates) and physiological (ApiZym test) analyses, all strains showed different 
characteristics. One explanation for this observation was the sparse growth of ICN21 on the different 
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agar plates. Maybe the pre-culture was not in the same growth phase as the other two strains or the 
cells have even been not fit enough to grow well on the different plates. To be sure, the 
morphological analysis should be repeated and further analyses such as DNA-DNA hybridization as 
well as MALDI-TOF and RiboPrinter® analyses have to be done to describe ICN21 and ICN19 as new 
species. 
 
4.2.1. Streptomyces strains S. cinnabaragriseus (JS360) and S. davawensis 
In this study he phylogenetic relationship between the Streptomyces strains JS360, S. davawensis and 
the type strain S. cinnabarinus was analyzed.   
Streptomyces davawensis was isolated in 1974 from a Philippine soil sample during a screening 
program for new antibiotics (Otani et al. 1974; Shinobu 1974). It was found to produce the red 
compound roseoflavin, which is named after its colour and the close structural relationship to the 
riboflavin (vitamin B2) and biological active against Gram-positive bacteria. To date, roseoflavin is the 
only known natural riboflavin analogue which acts against bacteria Pedrolli et al. 2013. Vitamin 
analogues form a new interesting class of antibiotics. During the search for other producing strains, 
the 16S rRNA of S. davawensis was analyzed and S. cinnabarinus was found be a close phylogenetic 
relative and to be able to synthesize roseoflavin (Jankowitsch et al. 2011). After this success, other 
strains described as S. cinnabarinus, were screened for the production of this uncommon substance. 
As a result the metabolite profile of strain JS360, described as a S. cinnabarinus strain (Stadler et al. 
2007), was analyzed. This strain was isolated from a soil sample collected in Japan and detected 
during a high through put screening program in a human 20S proteasome inhibitory assay (Stadler et 
al. 2004; Stadler et al. 2007). It was not able to produce roseoflavin, however, strain JS360 was 
described to be the producer strain of the cinnabaramides A-G (Stadler et al. 2007). These substances 
are proteasome inhibitors and can be used for the treatment of allergies, asthma as well as cancer 
(Kyle et al.2004). Furthermore, due their chemical structures, which are closely related to lactacystin 
and salinosporamide (a promissing compound isolated from the marine actinobacterium Salinispora 
tropica), it has a great potential to be used as anticancer drug (Stadler et al. 2004; Stadler et al. 
2007).  
To finally detect the relationship between strains S. davawensis, S. cinnabarinus and the 
Streptomyces strain JS360, the three strains were polyphasically analyzed during this thesis. The 
phylogenetic analyses and the tree constructed with MALDI-TOF fingerprints revealed the close 
relationship between the strains S. davawensis (JCM 4913 / DSM 40467T) and S. cinnabarinus (DSM 
40467T). Additionately the phylogenetic distance to strain JS360 (S. cinnabaragriseus, DSM 101724T) 
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which was misleadingly described as S. cinnabarinus (Stadler et al. 2007) was clearly evident. Strain 
JS360 was closely related to S. griseoruber (DSM 40281T) and located in a different phylogenetic 
cluster. Furthermore, the shape of the spores and spore chains, which were quite similar only 
between S. cinnabarinus and S. davawensis, support the phylogenetic findings. During the 
morphological and physiological analyses not only the phylogenetic distance between strain JS360 (S. 
cinnabaragriseus) and both compared strains, but also between the closely related strains S. 
cinnabarinus and S. davawensis, became visible. Some significant differences between the colony 
colour and areal mycelium growth on ISP2, 5 and 7 as well as in the production of soluble pigments 
on ISP 2, 3, 4, 6 and 7 were observed. The physiological tests showed that in contrast to the other 
two strains, S. cinnabarinus was able to utilize cellulose but no xylose. However, during the 
enzymatic activity test, all three strains showed a similar enzymatic pattern besides the positive 
reaction against against α-galactosidase from S. cinnabaragriseus (JS360), against N-acetyl-β-
glucoseamidase from S. davawensis and α-fucosidase from S. cinnabarinus.  
In sum, based on the phylogenetic, morphological and physiological analyses conducted during this 
thesis, including the DNA-DNA hybridization results of the working group of Peter Kämpfer from the 
university of Gießen (data not shown), strain S. davawensis (DSM 101723T) could be validly described 
as separate individual species and the strain JS360 as the new Streptomyces species S. 
cinnabaragriseus (DSM 101724T). 
 
4.2.2. Streptomyces strain ASO4 wet 
During the course of this study three Streptomyces strains from deep sea sediment samples were 
isolated from 1092 m depth (A-, B- and C-Sed H10-3) and one from a deep sea sponge (ASO4 wet) 
from the North Atlantic Ocean. Because of the close relationship between the strains of the genus 
Streptomyces (99% similarity within the 16S rRNA sequence between different species) this study 
was focused on strain ASO4 wet. With a 16S rRNA similarity of 98% to strains S. glycovorans (DSM 
42021T) and S. abyssalis (DSM 42024T) as well as 98.94% to S. karpasiensis (DSM 42068T), the strain 
seemed to be a promising new species.  
Due to the morphological and physiological analyses ASO4 wet was revealed to be closely related to 
the type strain S. karpasiensis. S. karpasiensis was isolated from a soil sample collected from the 
Karpaz National Park in Magusa, northern Cyprus (Veyisoglu et al. 2014). In the direct comparison 
between the four strains on GYM medium the colonies of these two strains only differed in the 
production of melanin. Furthermore, except the mycelia production on all ISP media as well as a 
sparse growth on ISP7 medium of S. karpasiensis, both strains were detected to produce the same 
 114 
 
colony colours. However, significant differences were noticed during the physiological tests, like the 
positive reaction of ASO4 wet on β-galactosidase and the ability to use arabinose as carbon source, 
while S. karpasiensis could utilize cellulose.   
Using DNA-DNA hybridization with a value of 40.4 and 54.7 % against S. karpasiensis, respectively, 
and the comparison of the fingerprints, visualized via RiboPrinter®, it became clear that ASO4 wet 
could be described as a new distinct species of the genus Streptomyces. 
During cultivation, strain ASO4 wet did not produce any interesting bioactive compounds. However, 
this strain was isolated from a marine sponge and after Blunt et al. (2011; 2012; 2013) most sponge 
associated bacteria are described to be produces of natural products. Therefore, maybe the 
cultivation conditions have to be adapted to the natural marine habitat of this strain, like a decrease 
of the cultivation temperature, cultivation approaches in the dark, co-cultivation with other bacteria 
isolated from this sponge or even an increase of the atmospheric pressure.  
 
4.3. Bioactive substances isolated from marine actinobacteria 
In general, it is very difficult to isolate new bioactive compounds from actinobacteria because over 
50% of the antibiotics in clinical use today were produced from members of the genus 
Actinomycetales. Up to the year 2002, a sum of 20,000 antibiotics have been discovered of which 
45% were produced by actinobacteria (Berdy 2005). Therefore, without a complete and updated 
database it is not possible to identify possibly new compounds as known ones. As a result much work 
was invested to detected bioactive compounds which were later on identified as rakicidins A, B and 
E, aloesaponarin II, 5-hxdroxyaloesaponarin II as well as staurosporine. However, in some cases the 
known compound could be correlated to a new activity or new microbial source. 
 
4.3.1. Rakicidin A, B and E- known compounds, new bioactivity 
In this study, rakicidins A, B and E were isolated from the marine Micromonospora strain Guam 1582. 
In general,  Micromonospora sp. are known to be important producers of various antibiotic 
secondary metabolites such as gentamicin, kanamycin, microsporin or megalomycin (Genilloud et al. 
2012) to name just a few. Songsumanus et al. (2013) as well as Xie et al. (2011) described 
Micromonospora chalcea as producer strain for rakicidin A and B and in other papers (e.g. McBrien et 
al. 1995) the producer strain was only described as Micromonospora sp. 
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Rakicidins A and B are well known substances which are described to inhibit tumour cell lines (Xie et 
al. 2011; Takeuchi et al. 2011; Yamazaki et al. 2007), whereas for rakicidin E no bioactivity has been 
described, yet (Oku et al 2014). With an IC50 value of 40 ng/mL and 200 ng/mL McBrien et al. (1995) 
described the cytotoxicity of rakicidins A and B against the murine cell line M109 (MADISON lung 
carcinoma 109), respectively. Because of its significant ability to induce hypoxia-selective cytotoxicity 
in solid cells and to induce cell death in TKI-resistant CML stem cells (Takeuchi et al. 2011; Yamazaki 
et al. 2007), rakicidin A is a highly interesting compound and other members of the rakicidin family 
are of ”particular interest for both, synthetic and medicinal studies” (Poulsen, 2011; Clement et al. 
2015; Sang et al. 2014; Tsakos et al. 2016; Sang et al. 2016). Except rakicidin A, B and E, which were 
part of this study, the rakicidin family included two further compounds, rakicidin C and D. While 
rakicidin C did not show any bioactivity (Hu et al. 2000), rakicidin D was described to inhibit the 
invasion of murine carcinoma colon 26-L5 cells with an IC50 of 3.3 μg/mL (Igarashi et al. 2010). 
However, these two compounds were produced by Streptomyces sp. strains. Furthermore, the 
rakicidin family belongs to a rare structural group with the unusual amino acid, 4-amino-2, 4-
pentadienoate which is only found to be produced by actinobacteria (Igarashi et al. 2010). To date, 
there are only two further classes of cyclic peptides reported to contain this unusual amino acid: the 
BE-43547 complexes (Nishioka et al. 1998) as well as the vinylamycin-microtermolide class (Igarashi 
et al. 1999; Carr et al. 2012; Oku et al. 2014). The compound vinylamicin is described as an antibiotic 
against Gram-positive bacteria including MRSA (Igarashi et al. 1999) whereas the microtermolides A 
and B show neither antibiotic nor antifungal activities (Carr et al. 2012). Contrary to the findings of 
Mc Brien et al. (1995) who stated that rakicidin A and B did not show any bioactive effect on bacteria 
or fungi, in this study it was shown that in liquid culture, also rakicidin A, B and E were selectively 
active against Gram–positive bacteria including the methicillin resistant Staphylococcus aureus N315 
(MRSA) and the vancomycin resistant Enterococcus faecium DSM 17050 (VREF). Only a bioactivity 
against the Gram-positive bacterium Kocuria rhizophila was detected by Songsumanus et al. (2013) 
during the screening of a raw extract, before. These antibiotic activities, especially against the multi 
resistant MRSA and VREF strains show new aspects of the medical impact of the rakicidin family. 
However, because of a two to 16 times higher bioactivity value against the murine cell line than 
against the tested multi resistant bacteria, further studies will probably focus on the cytotoxicity 
instead of the antibiotic effects of rakicidin A, B and E. Especially the very interesting activities of 
rakicidin A against cancer cell lines (Takeuchi et al. 2011; Yamazaki et al. 2007), and the studies 
towards the total synthesis, stereochemistry and structure activity of this compound during the last 
years (Poulsen 2011; Sang et al. 2014; Oku et al. 2014; Oku et al. 2015; Sang et al. 2016; Tsakos et al. 
2016) showed the high potency of this compound for medical research.  
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4.3.2. Aloesaponarin II, 5-hydroxyaloesaponarin II – known compounds – new bioactivity – … 
….new source: marine actinobacteria 
During the screening of the strain Guam 928 selective growth inhibitions of the Gram-positive test 
organisms Staphylococcus aureus Newman and Enterococcus faecium (DSM 20477) including the 
MRSA and VREF strain were detected. Further analyses showed that strain Guam 928 was the 
producer of two interesting compounds which were finally identified as aloesaponarin II and its 
derivative 5-hydroxyaloesaponarin II (3,5,8-trihydroxyaloesaponarin). However, only 5-
hydroxyaloesaponarin II could be correlated to the bioactivity against the Gram-positive test 
organisms. To date this compound was only described to be produced as blue pigment which was 
isolated together with aloesaponarin II from an actinorhodin-negative mutant of Streptomyces 
coelicolor A3 (2) (Bystrykh et al. 1997). Aloesaponarin II was originally isolated from the higher plant 
Aloe saponaria Haw. I (Yagi et al. 1974). Afterwards, it was found to be produced by a Streptomyces 
mutant of S. coelicolor which normally did not produce aloesaponarin II (Bartel at al. 1990; Bystrykh 
et al 1997) as well as by terrestrial and marine Streptomyces sp. strains (Fotso et al. 2003; Cui et al. 
2006, Cui et al. 2008).  
Finally, the first isolation of 5-hydroxyaloesaponarin II from a bacterial wild type strain was 
described, in this case the marine Micromonospora strain Guam 928. Additionally the specific 
bioactivity against Gram-positive bacteria including an MRSA and VREF strain was revealed.  
 
4.3.3. Staurosporine – known compounds – new source: marine actinobacteria 
In this study, staurosporine was isolated from the marine Streptomyces strain ICN21 from 
rhizosphere sediment of a mangrove plant (Rhizophora mucronata) from the coast of Tamil Nadu, 
India. During the screening process a high bioactivity against the fungal test strains C. albicans (DSM 
1665) and M. hiemalis (DSM 2656) was detected. The following LC-MS analysis of the crude extract 
identified the active compound as the alkaloid staurosporine.  
Staurosporine (AM-2282) was originally isolated from the soil bacterium Streptomyces staurosporeus 
(former known as Streptomyces sp. AM-2282) during a search for new alkaloids produced by 
members from the genus Actinomycetales (Omura et al. 1977). Omura et al. also described 
antimicrobial activities against fungi and yeast. To date this compound is known to have a strong 
inhibitory effect against HeLa S3 cells (Tamaoki et al. 1986), platelet aggregation (induced by collagen 
and ATP) (Oka et al. 1986) and several protein kinases (Meggio et al. 1995) as well as antibacterial 
and immunosuppressive activities (Gani et al. 2010; Park et al. 2013). Because of the non-selectivity 
of this compound and the resulting cross-reactivities with other kinases, staurosporine cannot be 
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used as therapeutic agent (Karaman et al. 2008). However, to use this compound for further medical 
approaches, many scientists worked on the isolation of staurosporine analogues from different 
microbial sources or tried to create new derivatives by chemical synthesis to specify the compounds 
for a particular protein kinase (Park et al. 2013). Finally, most of these analogues were detected as 
cytotoxic on cellular level or as inhibitor of different protein kinases, but also immunomodulatory as 
well as neurite outgrowth inhibition activities were found (Park et al. 2013). 
 
5. Conclusion 
In this study the strains JS360 (“Streptomyces cinnabaragriseus”) and Streptomyces davawensis were 
described as separate individual species, 12 Myxococcus sp. strains from Wadden Sea sediments as 
well as four Streptomyces strains from deep sea sediments and sponges from 1092 m depth (North 
Atlantic Ocean) were isolated, of which strain ASO4 wet could be described as new species. 
Additionately, strains ICN19 and ICN21, isolated from rhizosphere sediments from mangroves in 
India, seemed to belong to the same, hopefully novel species and also most of the actinobacterial 
strains which were isolated by DGC from sponges in Guam have partly a high potential to be 
described as new. However, due to the describtion of novel species being very time and money 
consuming this study focused on the describtion of either very interesting compound producers or 
strains from extraordinary habitats.  
Though the question, whether it is profitable to work on marine actinobacteria and myxobacteria for 
the discovery of new bioactive substances is hard to answer, this study shows that it is at least 
feasible. 24 actinobacterial and 12 myxobacterial strains were screened for the production of novel 
secondary metabolites without any success. All strains were isolated from uncommon marine 
environments like rhizosphere sediments of a mangrove plant (coast of Tamil Nadu, India), and 
marine sediments as well as sponges from Guam, the deep sea (1092 m, North Atlantic Ocean) and 
the Wadden Sea (Germany). Furthermore, several enrichment approaches were tested for the 
isolation of marine bacteria by trying to simulate the natural marine environment. However, in this 
study only halotolerant and halophilic but no real marine microorganisms could be found. All strains 
used or isolated were very closely related to known terrestrial myxobacteria and actinobacteria. Even 
the new deep sea strain ASO4 wet belongs to the genus Streptomyces which is mainly known to be a 
terrestrial actinobacteria. To find new compounds in the future new bacterial families or genera 
which are indigenous in the marine habitats have to be isolated. Good examples for the theory “new 
strain = new metabolite” in the marine habitats was found for both, the myxobacteria as well as for 
the actinobacteria. As described before, the members of the obligate marine genera Haliangium and 
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Ehygromyxa produced the antifungal agent haliangin and the antibiotic salimabromide, respectively. 
Meanwhile, the marine actinobacterial genera Salinispora and Marinospora produced the very 
interesting proteasome inhibitor salinosporamide A and marinomycin A which has a cytotoxic as well 
as an antibacterial effect against MRSA and VREF. All of these compounds were described to feature 
novel scaffolds and modes of action. However, even a closely related structure and mode of action to 
salinosporamide A was detected for the cinnabaramides. These compounds are produced by the 
terrestrial Streptomyces strain. 
Finally, to discover novel bioactive compounds, new marine myxobacteria and actinobacteria have to 
be isolated. Therefore, the focus should be on new and obligate marine genera from undiscovered 
marine habitats. Furthermore, new isolation techniques have to be established which mimic the 
natural environment or techniques like the DGC should be established in diverse approaches. 
Moreover, screening approaches for the isolation of secondary metabolites should be adapted to 
natural environments of the strains like co-cultivation, increasing or decreasing of the cultivation 
temperature and pressure, as well as the addition of different components from the marine 
environment in the cultivation media. However, many molecular biological studies (including the 
MMC sequence) as well as this thesis showed, that the marine habitat has a great potential for the 
isolation of marine myxobacteria and actinobacteria.  
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7. Appendix 
 
Detection of MMC sequence in sediment samples (Agarose gels after MMC-PCR) 
 
Agarose gel of the MMC detection PCR for the Janssand samples 1: sediment sample 1; 2: sediment sample 2; 3: rockworm 
excrutions.  
 
 
Agarose gel of the MMC detection for the sediment core samples from Neuharlingersiel: Schick 1: mud from 1cm depth; 
Schick 4: mud from 4 cm depth; Schlick 8: mud from 8cm depth; Schlick 12: mud from 12cm depth; nS1: sediment sample 
near the beach from 1cm depth; nS4: sediment sample near the beach from 4cm depth; nS8: sediment sample near the 
beach from 8cm depth; nS12: sediment sample near the beach from 12cm depth; nW1: sediment sample near the water 
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from 1cm depth; nW4: sediment sample near the water from 4cm depth; nW8: sediment sample near the water from 8cm 
depth; nW12: sediment sample near the water from 12cm depth.  
 
Closest relatives of the isolated actinobacterial strains based on the 16S rRNA detected via “Blast” 
search on NCBI.  
Closest relatives (type strains) of the Micromonospora strains Guam 928, 1509, 1510, 1582 and 1583 after using the “Blast” 
tool on NCBI based on the 16S rRNA sequence. 
Guam 928 (99%) Guam 1510 (99%) Guam 1582 (99%) 
M. aurantiaca  DSM 43813T M. citrea DSM 43903T M. echinospora DSM 43816T 
M. halophytica DSM 43171T M. aurantiaca DSM 43813T M. citrea DSM 43903T 
M. chalcea DSM 43026T 
M. sagamiensis 
subsp. flava DSM 44887T M. aurantiaca DSM 43813T 
M. schwarzwaldiensis DSM 45708T M. endolithica DSM 44398T 
M. sagamiensis 
subsp. flava DSM 44887T 
M. echinosora DSM 43816T M. rosaria DSM 803T M. endolithica DSM 44398T 
M. citrea DSM 43903T M. echinospora DSM 43816T M. rosaria DSM 803T 
M.rosaria DSM 803T M. echinofusca DSM 43913T M. sagamiensis DSM 43912T 
Guam 1509 (99%) M. chersina DSM 44151T M. echinofusca DSM 43913T 
M. echinospora DSM 43816T M. echinaurantiaca DSM 43904T M. chalcea DSM 43026T 
M. citrea DSM 43903T M. inyonensis DSM 46123T M. inyonensis DSM 46123T 
M. aurantiaca DSM 43813T M nigra DSM 43818T M. chersina DSM 44151T 
M. sagamiensis 
subsp. flava DSM 44887T M. fulviviridis DSM 43906T M. pallida DSM 43817T 
M. endolithica DSM 44398T M. viridifaciens DSM 43909T M. halophytica DSM 43171T 
M. rosaria DSM 803T M. pallida DSM 43817T     
M. sagamiensis  DSM 43912T 
  
Guam 1583 (99%) 
M. echinofusca DSM 43913T 
  
M. aurantiaca DSM 43813T 
M. chalcea DSM 43026T 
  
M. sagamiensis 
subsp. flava DSM 44887T 
M. inyonensis DSM 46123T 
  
M. endolithica DSM 44398T 
M. chersina DSM 44151T 
  
M. rosaria DSM 803T 
M. pallida DSM 43817T 
  
M. echinospora DSM 43816T 
    
  
M. echinofusca DSM 43913T 
  
 
  
 
M. sagamiensis DSM 43912T 
  
 
  
 
M. chersina DSM 44151T 
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Closest relatives (type strains) of the Streptomyces strains Guam 1322, 1285 and after using the “Blast” tool on NCBI based 
on the 16S rRNA sequence. 
Guam 1322 (99%) Guam 1285 (99%) 
S. tendae DSM 40101T S. tendae DSM 40101T 
S.violaceorubidus DSM 41478T S.violaceorubidus DSM 41478T 
S. djakartensis DSM 40743T S. djakartensis DSM 40743T 
S. collinus DSM 40129T S. collinus DSM 40129T 
S. griseoflavus DSM 40456T S. griseoflavus DSM 40456T 
S. malachitofuscus DSM 40332T S. malachitofuscus DSM 40332T 
S. albogriseolus DSM 40003T S. paradoxus DSM 43350T 
S. tritolerans DSM 41899T S. albogriseolus DSM 40003T 
S. paradoxus DSM 43350T S. viridochromogenes DSM 40110T 
S. viridochromogenes DSM 40110T S. rubrogriseus DSM 41477T 
S. rubrogriseus DSM 41477T S. lienomycini DSM 41475T 
S. lienomycini DSM 41475T S. griseorubens DSM 40160T 
S. marokkonensis DSM 41918T S. marokkonensis DSM 41918T 
S. griseorubens DSM 40160T S. lienomycini DSM 41475T 
S. chattanoogensis DSM 40002T S. parvulus DSM 40048T 
S. parvulus DSM 40048T S. tuirus DSM 40505T 
S. tuirus DSM 40505T S. chattanoogensis DSM 40002T 
S. tricolor DSM 41704T S. flaveolus DSM 40061T 
S. anthocyanicus DSM 41422T S. geysiriensis  DSM 40742T 
S. violaceoruber DSM 40049T S. tricolor DSM 41704T 
S. coelescence DSM 40421T S. anthocyanicus DSM 41422T 
S. flaveolus DSM 40061T S. violaceoruber DSM 40049T 
S. geysiriensis  DSM 40742T S. althioticus DSM 40092T 
S. althioticus DSM 40092T S. mutabilis DSM 40169T 
S. ambofaciens DSM 40053T S. ambofaciens DSM 40053T 
S. chartreusis DSM 40085T S. rochei DSM 40231T 
S. mutabilis DSM 40169T S. enissocaesilis DSM 41454T 
S. variabilis DSM 40053T S. glaucescens DSM 40155T 
S. labedae DSM 41446T S. luteogriseus DSM 40483T 
S. erythrogriseus DSM 40116T S. violaceolatus DSM 40438T 
S. violaceolatus DSM 40438T S. vinaceusdrappus DSM 40470T 
S. griseoinicanatus DSM 40274T S. plicatus DSM 40319T 
S. humiferus DSM 43030T S. matensis  DSM 40188T 
S. rochei DSM 40231T S. ambofaciens DSM 40053T 
S. enissocaesilis DSM 41454T S. humiferus DSM 43030T 
S. glaucescens DSM 40155T S. violaceolatus DSM 40438T 
S. luteogriseus DSM 40483T S. tuirus DSM 40505T 
S. vinaceusdrappus DSM 40470T S. almquistii DSM 40447T 
S. plicatus DSM 40319T S. variabilis DSM 40053T 
S. matensis  DSM 40188T S. labedae DSM 41446T 
S. almquistii DSM 40447T S. lomondensis DSM 41428T 
S. lomondensis DSM 41428T S. erythrogriseus DSM 40116T 
S. misionensis DSM 40306T S. griseoincarnatus DSM 40274T 
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S. violaceochromogenes DSM 40181T S. chartreusis DSM 40085T 
S. viridis DSM 40381T S. viridis DSM 40381T 
S. malachitospinus DSM 41828T S. malachitospinus DSM 41828T 
S. iakyrus DSM 40482T S. iakyrus DSM 40482T 
S. purpurascens  DSM 40310T S. purpurascens DSM 40310T 
S. flavoviridis DSM 40153T S. flavoviridis DSM 40153T 
S. pilosus DSM 40097T S. pilosus DSM 40097T 
S. eurythermus DSM 40014T S. misionensis DSM 40306T 
S. levis DSM 41458T S. arenae DSM 40293T 
S. nogalater DSM 40546T S. violaceus DSM 40082T 
S. violaceus DSM 40082T S. roseoviolaceus DSM 40277T 
S. roseoviolaceus DSM 40277T S. eurythermus DSM 40014T 
S. phaeoluteichromatogenes DSM 41898T S. levis DSM 41458T 
S. olivaceus DSM 40072T S. olivaceus DSM 40072T 
S. pactum DSM 40530T S. bellus DSM 40185T 
S. coerulescens DSM 40146T S. azureus DSM 40106T 
S. bellus DSM 40185T S. pactum DSM 40530T 
S. azureus DSM 40106T S. althioticus DSM 40092T 
S. arenae DSM 40293T S. coerulescens DSM 40146T 
    S. nogalater DSM 40546T 
 
Closest relatives (type strains) of the Streptomyces strains A-, B- and C SedH 10-3 after using the “Blast” tool on NCBI based 
on the 16S rRNA sequence. 
ASedH 10-3 (99%) BSedH 10-3 (99%) CSedH 10-3 (99%) 
S. anulatus DSM 40361T S. anulatus DSM 40361T S. anulatus DSM 40361T 
S. caviscabis ATCC 51928T S. caviscabis ATCC 51928T S. rubiginosohelvolus DSM 40176T 
S. fulvissimus DSM 40593T S. fulvissimus DSM 40593T S.pluricoloresces DSM 40019T 
S. rubiginosohelvolus DSM 40176T S. rubiginosohelvolus DSM 40176T S. globisporus DSM 40199T 
S. microflavus DSM 40331T S. microflavus DSM 40331T S. caviscabies ATCC 51928T 
S. cyaneofuscatus DSM 40148T S. cyaneofuscatus DSM 40148T S. fulvissimus DSM 40593T 
S. griseus DSM 40236T S. griseus DSM 40236T S. microflavus DSM 40331T 
S. mediolani DSM 41647T S. mediolani DSM 41647T S. cyaneofuscatus DSM 40148T 
S. parvus DSM 40348T S. parvus DSM 40348T S. griseus DSM 40236T 
S. argenteolus DSM 40226T S. argenteolus DSM 40226T S. argenteolus DSM 40226T 
S. badius DSM 40139T S. badius DSM 40139T S. mediolani DSM 41647T 
S. sindenensis DSM 40255T S. sindenensis DSM 40255T S. badius DSM 40139T 
S. fulvorobeus DSM 41455T S. fulvorobeus DSM 41455T S. fulvorobeus DSM 41455T 
S. globisporus DSM 40199T S. globisporus DSM 40199T S. cinereorectus DSM 41469T 
S. baarnensis DSM 40232T S. baarnensis DSM 40232T S. microflavus DSM 40331T 
S. cinereorectus DSM 41469T S. cinereorectus DSM 41469T S. baarnensis DSM 40232T 
S. pluricolorescens DSM 40019T S. pluricolorescens DSM 40019T S. parvus DSM 40348T 
S. griseolus DSM 40067T S. griseolus DSM 40067T S. flavovirens DSM 40062T 
S. halstedii DSM 40068T S. halstedii DSM 40068T S. griseolus DSM 40067T 
S. flavovirens DSM 40062T S. flavovirens DSM 40062T S. puniceus DSM 40083T 
S. tanashiensis DSM 40195T S. tanashiensis DSM 40195T S. halstedii DSM 40068T 
S. pulveraceus DSM 41657T S. pulveraceus DSM 41657T S. cyaneus DSM 40108T 
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S. bacillaris DSM 40598T S. bacillaris DSM 40598T S. tanashiensis DSM 40195T 
S. finayi DSM 40218T S. finayi DSM 40218T S. pulveraceus DSM 41657T 
S. atroolivaceus DSM 40137T S. atroolivaceus DSM 40137T S. finlayi DSM 40218T 
S. clavifer DSM 40843T S. clavifer DSM 40843T S. atroolivaceus DSM 40137T 
S. nitrosporeus DSM 40023T S. nitrosporeus DSM 40023T S. nitrosporeus DSM 40023T 
S. mutomycini DSM 41691T S. mutomycini DSM 41691T S. clavifer DSM 40843T 
S. albolongus DSM 40570T S. albolongus DSM 40570T S. bacillaris DSM 40598T 
S. cavourensis DSM 40300T S. cavourensis DSM 40300T S. mutomycini DSM 41691T 
S. atratus DSM 41673T S. atratus DSM 41673T S. sanglieri DSM 41791T 
S. gelaticus DSM 40065T S. gelaticus DSM 40065T S. atratus DSM 41673T 
S. spiroverticillatus DSM 40036T S. spiroverticillatus DSM 40036T S. gelaticus DSM 40065T 
        S. spiroverticillatus DSM 40036T 
          
 
Closest relatives (type strains) of the Streptomyces S. davawensis, S. cinnabarinus and Streptomyces strain JS360 (S. 
cinnabaragriseus) after phylogenetic analysis of the 16S rRNA serquence of the Prof. Dr. Peter Kämpfer and his team 
(University of Gießen). 
Strain name Strain no. 
Streptomyces davawensis JCM 4913 = DSM 101723T 
Streptomyces cinnabarinus DSM 40467T 
Streptomyces cinnabaragriseus JS360 = DSM 101724T 
Streptomyces avermitilis DSM 46492T 
Streptomyces flavovariabilis DSM 41479T 
Streptomyces novaecaesareae DSM 40358T  
Streptomyces alboniger DSM 40043T 
Streptomyces cellostaticus DSM 40189T 
Streptomyces bobili DSM 40056T 
Streptomyces galilaeus DSM 40481T 
Streptomyces griseochromogenes  DSM 40499T 
Streptomyces pseudovenezuelae DSM 40212T 
Streptomyces phaeoluteigriseus DSM 41896T 
Streptomyces atriruber DSM 41860T 
Streptomyces resistomycificus DSM 40133T 
Streptomyces yokosukanensis DSM 40224T 
Streptomyces olivochromogenes DSM 40451T 
Streptomyces corchorusii DSM 40340T 
Streptomyces longwoodensis DSM 41677T 
Streptomyces curacoi DSM 40107T 
Streptomyces antibioticus DSM 40234T 
Streptomyces canus DSM 40017T 
Streptomyces ciscaucasicus DSM 40275T 
Streptomyces griseorubiginosus DSM 40469T 
Streptomyces phaeopurpureus DSM 40125T 
Streptomyces griseruber DSM 40281T  
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MALDI TOF dendrogrammes of Guam strains 
 
MALDI-TOF dendrogram of the Micomonospora strain Guam 1509 and its closest relatives (type strains). 
 
        MALDI-TOF dendrogram of the Micromonospora strain Guam 1510 and its closest relatives (type strains). 
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 MALDI-TOF dendrogram of the Micromonospora strain Guam 1583 and its closest relatives (type strains). 
 
 
 
MIC of extracts from isolated Actinobacteria from Guam and India on the standard test panel. 
 
MIC of the extracts from the isolated actinobacteria from sponges and marine sediment from Guam against the standard 
test panel in different media: 4 5254 medium; 5 5254 sea water medium; 6 5294 medium; 7 5294 sea water medium. 
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Guam 9284 - - -  - E - -  A - - - 
Guam 9285 - - -  H H E B  A - - B 
Guam 9286 - - -  - F - -  - - - - 
Guam 9287 - - -  F E D -  - - - - 
Guam 12574 - - -  A A - -  - - - - 
Guam 12575 - - -  C B A B  A - A - 
Guam 12576              
Guam 12577              
Guam 12854 - - -  H H H B  F A C A 
Guam 12855 - - -  H H H B  E A C A 
Guam 12856              
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Guam 12857              
Guam 13224 - - -  H H H B  D - - - 
Guam 13225 - - -  H H H B  D - B B 
Guam 13226              
Guam 13227              
Guam 15094 - - -  A B B -  A - - - 
Guam 15095 - - -  B B - -  - - - - 
Guam 15096 - - A  C D C -  A - - - 
Guam 15097 - - -  B C B -  - - - - 
Guam 15104 - - -  B D A B  A - - - 
Guam 15105 - - -  C C A B  - - - - 
Guam 15106              
Guam 15107              
Guam 15664 - - -  C G B -  - - - - 
Guam 15665 - - -  - G - -  - - - - 
Guam 15666 - - -  F G E -  - - - - 
Guam 15667 - - -  C B - -  A - - A 
Guam 15824 - - -  F - - -  - - - - 
Guam 15825 - A -  G H D -  - - - - 
Guam 15826 - - A  D E B -  A A - D 
Guam 15827 - - A  G G D -  - - - - 
Guam 15834 - - A  E D A -  - - - - 
Guam 15835 - - A  G G E -  - - - - 
Guam 15836 - - A  D D B -  A - - C 
Guam 15837 - - A  F F D -  - - - - 
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MIC of the extracts from the isolated actinobacteria from rhizosphere sediment from mangroves from India against the 
standard test panel in different media: 4 5254 medium; 5 5254 sea water medium; 6 5294 medium; 7 5294 sea water 
medium.  
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ICN44 - - -  G H G -  B - - B 
ICN45 - - -  G H G -  C - - D 
ICN46              
ICN47              
ICN164 - - A  - B - -  - - - - 
ICN165 - - B  F G E A  - - - A 
ICN166 - - A  A A A -  - - - - 
ICN167 - - -  - - - -  - - - - 
ICN184 - - B  H H H B  D - A B 
ICN185 - - A  F H F -  C - - - 
ICN186 C C D  H H H G  H B G H 
ICN187 - - -  F F F -  B - - A 
ICN194 C H H  H H H H  D - - F 
ICN195 C F F  H H D F  - - - C 
ICN196 F F G  H H H H  F - A H 
ICN197 D E E  H G D E  - - - C 
ICN214 C/F* H H  A C B B  - - - C 
ICN215 B/E* F F  B D A B  - - - C 
ICN216 F H H  B C - A  - - - E 
ICN217 D F F  A C - -  A - - - 
ICN264 - - A  C E D A  A - - - 
ICN265 - - -  - - - -  - - - - 
ICN266 - - -  C A C -  A - - - 
ICN267 F H H  A B - B  A - - E 
ICN284 - - A  D E C -  - - - - 
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ICN285 E E D  C E - B  - - - - 
ICN286 D D D  H H H A  B - - - 
ICN287 B/C* B B  D E C -  - - - - 
 
Sequences of bacterial isolates 
Guam 928 
ATGCAGTCGAGCGGAAGGCCCTTCGGGGTACTCGAGCGGCGAACGGGTGAGTAACACGTGAGCAACCTGCCC
TAGGCTTTGGGATAACCCCGGGAAACCGGGGCTAATACCGAATAGGACCTCCGATCGCATGGTTGGGGGTGG
AAAGTTTTTCGGCCTGGGATGGGCTCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACG
ACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGC
AGCAGTGGGGAATATTGCACAATGGGCGGAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCG
GGTTGTAAACCTCTTTCAGCAGGGACGAAGCGTAAGTGACGGTACCTGCAGAAGAAGCGCCGGCCAACTACG
TGCCAGCAGCCGCGGTAAGACGTAGGGCGCGAGCGTTGTCCGGATTTATTGGGCGTAAAGAGCTCGTAGGCG
GCTTGTCGCGTCGACCGTGAAAACCTGGGGCTCAACCCCAGGCCTGCGGTCGATACGGGCAGGCTAGAGTTC
GGTAGGGGAGACTGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAG
GCGGGTCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGT
AGTCCACGCTGTAAACGTTGGGCGCTAGGTGTGGGGGGCCTCTCCGGTTCCCTGTGCCGCAGCTAACGCATTA
AGCGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGC
GGAGCATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGGCCGCAAAACTGTCAGA
GATGGCAGGTCCTTCGGGGGCGGTCACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGT
TAAGTCCCGCAACGAGCGCAACCCTCGTTCGATGTTGCCAGCGCGTTATGGCGGGGACTCATCGAAGACTGCC
GGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACGCATGCT
ACAATGGCCGGTACAATGGGCTGCGATACCGTGAGGTGGAGCGAATCCCAAAAAGCCGGTCTCAGTTCGGAT
CGGGGTCTGCAACTCGACCCCGTGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATAC
GTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGCAACACCCGAAGCCGGTGGCCCAACCCT
TGTGGAGGGAGCCGTCGAAGGTGGGGCTGGCGAT 
 
Guam 1257 
TTCATGACTTGACGGGCGGTGTGTACAAGACCCGGGAACGTATTCACCGCAGCGTTGCTGATCTGCGATTACT
AGCGACTCCGACTTCATGAGGTCGAGTTGCAGACCTCAATCCGAACTGGGACCGGCTTTTTGGGATTCGCTCC
ACCTCGCGGTATCGCAGCCCATTGTACCGGCCATTGTAGCATGCGTGAAGCCCAAGACATAAGGGGCATGATG
ATTTGACGTCATCCCCACCTTCCTCCGAGTTGACCCCGGCAGTATCCCATGAGTTCCCACCATAACGTGCTGGCA
ACATAGAACGAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGC
ACCACCTGTTCACCAGTGTCCAAAGAGTTGACCATTTCTGGCCCGTTCTGGCGTATGTCAAGCCTTGGTAAGGT
TCTTCGCGTTGCATCGAATTAATCCGCATGCTCCGCCGCTTGTGCGGGTCCCCGTCAATTCCTTTGAGTTTTAGC
CTTGCGGCCGTACTCCCCAGGCGGGGAACTTAATGCGTTAGCTACGTCACGGAATCCGTGGAAAGGACCCCAC
AACTAGTTCCCAACGTTTACGGGGTGGACTACCAGGGTATCTAAGCCTGTTTGCTCCCCACCCTTTCGCTCCTCA
GCGTCAGTAACGGCCCAGAGATCTGCCTTCGCCATCGGTGTTCCTCCTGATATCTGCGCATTCCACCGCTACAC
CAGGAATTCCAATCTCCCCTACCGCACTCTAGTCTGCCCGTACCCACTGCAAGCCCGAGGTTGAGCCTCGGAAT
TTCACAGCAGACGCGACAGACCGCCTACGAGCTCTTTACGCCCAATAATTCCGGATAACGCTTGCGCCCTACGT
ATTACCGCGGCTGCTGGCACGTAGTTAGCCGGCGCTTTTTCTGCAGGTACCGTCACCCGAAGGCTTCTTCCCTA
CCAAAAGAGGTTTACAACCCGAAGGCCGTCATCCCTCACGCGGCGTTGCTGCATCAGGCTTGCGCCCATTGTG
CAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGGTCACCCTCTCA
GGCCGGCTACCCGTCGACGCCTTGGTGAGCCATTACCTCACCAACAAGCTGATAGGCCGCGAGCCCATCCCAA
ACCGAAAAATCTTTCCAACCCCCACCATGCGATGAGAGCTCATATCCAGTATTAGACGCCGTTTCCAGCGCTTA
TCCCAGAGTCCAGGGCAGGTTGCTCACGTGTTACTCACCCGTTCGCCACTGATCCACCAAGCAAGCTTGGCTTC
ACCGTTCGACTTGCATGTGTTAAGCACGCCGCCAGCGTTCATCCTGAGCC 
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Guam 1285 
TGCAGTCGACGATGAACCACTTCGGTGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCT
GCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATACTGACCCTCACGGGCATCTGTGAGGTTCGA
AAGCTCCGGCGGTGCAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGAGGTAATGGCTCACCAAGGCGACG
ACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGC
AGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCG
GGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACG
TGCCAGCAGCCGCGGTAATACGTAGGGCGCGAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCG
GCTTGTCACGTCGGTTGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTC
GGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAG
GCGGATCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGT
AGTCCACGCCGTAAACGGTGGGCACTAGGTGTGGGCAACATTCCACGTTGTCCGTGCCGCAGCTAACGCATTA
AGTGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGC
GGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATTAGA
GATAGTGCCCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGT
TAAGTCCCGCAACGAGCGCAACCCTTGTCCCGTGTTGCCAGCAGGCCCTTGTGGTGCTGGGGACTCACGGGAG
ACCGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCAC
ACGTGCTACAATGGCCGGTACAATGAGCTGCGATACCGCGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAG
TTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGT
GAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCC
AACCCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGA 
 
Guam 1322 
CCACTTCGGTGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTCTGGGACAAGC
CCTGGAAACGGGGTCTAATACCGGATACTGACCCTCACGGGCATCTGTGAGGTTCGAAAGCTCCGGCGGTGC
AGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGAGGTAATGGCTCACCAAGGCGACGACGGGTAGCCGGCCT
GAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATAT
TGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTT
CAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGG
TAATACGTAGGGCGCGAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTT
GTGAAAGCCCGGGGCTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGG
AATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCG
ATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACG
GTGGGCACTAGGTGTGGGCAACATTCCACGTTGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGA
GTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATT
CGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATTAGAGATAGTGCCCCCCTTGTGG
TCGGTGTACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGC
AACCCTTGTCCCGTGTTGCCAGCAGGCCCTTGTGGTGCTGGGGACTCACGGGAGACCGCCGGGGTCAACTCG
GAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGT
ACAATGAGCTGCGATACCGCGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAA
CTCGACCCCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTT
GTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGA
GCTGTCGAAGGTGGGACTGGCGATTGGACGAAG 
 
Guam 1509 
TGCAGTCGAGCGGAAGGCCCTTCGGGGTACTCGAGCGGCGAACGGGTGAGTAACACGTGAGCAACCTGCCCC
AGGCTTTGGGATAACCCCGGGAAACCGGGGCTAATACCGAATATGACCTCCGATCGCATGGTTGGTGGTGGA
AAGTTTTTCGGCTTGGGATGGGCTCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACGAC
 145 
 
GGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAG
CAGTGGGGAATATTGCACAATGGGCGGAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGG
TTGTAAACCTCTTTCAGCAGGGACGAAGCGTAAGTGACGGTACCTGCAGAAGAAGCGCCGGCCAACTACGTG
CCAGCAGCCGCGGTAAGACGTAGGGCGCGAGCGTTGTCCGGATTTATTGGGCGTAAAGAGCTCGTAGGCGGC
TTGTCGCGTCGACTGTGAAAACCCGCAGCTCAACTGCGGGCCTGCAGTCGATACGGGCAGGCTAGAGTTCGGT
AGGGGAGACTGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCG
GGTCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTC
CACGCTGTAAACGTTGGGCGCTAGGTGTGGGGGGCCTCTCCGGTTCCCTGTGCCGCAGCTAACGCATTAAGCG
CCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAG
CATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGGCCGCAAAACTGTCAGAGATGG
CAGGTCCTTCGGGGGCGGTCACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGT
CCCGCAACGAGCGCAACCCTCGTTCGATGTTGCCAGCGCGTTATGGCGGGGACTCATCGAAGACTGCCGGGG
TCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACGCATGCTACAA
TGGCCGGTACAATGGGCTGCGATACCGTGAGGTGGAGCGAATCCCAAAAAGCCGGTCTCAGTTCGGATCGGG
GTCTGCAACTCGACCCCGTGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCC
CGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGCAACACCCGAAGCCGGTGGCCCAACCCTTGTGG
AGGGAGCCGTCGAAGGTGGGGCTGGCGA 
 
Guam 1510 
TCGACGGCTCCCTCCACAAGGGTTGGGCCACCGGCTTCGGGTGTTGCCGACTTTCGTGACGTGACGGGCGGTG
TGTACAAGGCCCGGGAACGTATTCACCGCAGCGTTGCTGATCTGCGATTACTAGCGACTCCGACTTCACGGGG
TCGAGTTGCAGACCCCGATCCGAACTGAGACCGGCTTTTTGGGATTCGCTCCACCTCACGGTATCGCAGCCCAT
TGTACCGGCCATTGTAGCATGCGTGAAGCCCTGGACATAAGGGGCATGATGACTTGACGTCATCCCCACCTTC
CTCCGAGTTGACCCCGGCAGTCTTCGATGAGTCCCCGCCATAACGCGCTGGCAACATCGAACGAGGGTTGCGC
TCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGTGACCGCCCCCG
AAGGACCTGCCATCTCTGACAGTTTTGCGGCCATGTCAAACCCAGGTAAGGTTCTTCGCGTTGCATCGAATTAA
TCCGCATGCTCCGCCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTTAGCCTTGCGGCCGTACTCCCCAGG
CGGGGCGCTTAATGCGTTAGCTGCGGCACAGGGAACCGGAGAGGCCCCCCACACCTAGCGCCCAACGTTTAC
AGCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTATCGGCCCAGA
GACCCGCCTTCGCCACCGGTGTTCCTCCTGATATCTGCGCATTTCACCGCTACACCAGGAATTCCAGTCTCCCCT
ACCGAACTCTAGCCTGCCCGTATCGACTGCAGGCCCGCAGTTGAGCTGCGGGTTTTCACAGTCGACGCGACAA
GCCGCCTACGAGCTCTTTACGCCCAATAAATCCGGACAACGCTCGCGCCCTACGTCTTACCGCGGCTGCTGGCA
CGTAGTTGGCCGGCGCTTCTTCTGCAGGTACCGTCACTTACGCTTCGTCCCTGCTGAAAGAGGTTTACAACCCG
AAGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTCCGCCCATTGTGCAATATTCCCCACTGCTGCCTC
CCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGGTCGCCCTCTCAGGCCGGCTACCCGTCGTCGCC
TTGGTAGGCCATCACCCCACCAACAAGCTGATAGGCCGCGAGCCCATCCCAAGCCGAAAAACTTTCCACCACC
AACCATGCGATCGGAGGTCATATTCGGTATTAGCCCCGGTTTCCCGGGGTTATCCCAAAGCCTGGGGCAGGTT
GCTCACGTGTTACTCACCCGTTCGCCGCTCGAGTACCCCGAAGGGCCTTTCCGCTCGACTTGCATGTGTTAAGC
ACGCCGCCAGCGTTCGTCCTGAGCC 
 
Guam 1566  
TGGCTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGGTAAGGCCCTTCGGGGTACACGA
GTGGCGAACGGGTGAGTAACACGTGGGTGATCTGCCCTGCACTTCGGGATAAGCCCGGGAAACTGGGTCTAA
TACCGGATAGGACTGCGCGGTGCATGCCGTGTGGTGGAAAGATTTATCGGTGCAGGATGGGCCCGCGGCCTA
TCAGCTTGTTGGTGGGGTAATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCAC
ACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGC
CTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGACGAAGCGTG
AGTGACGGTACCTGCAGAAGAAGCACCGGCCAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGC
 146 
 
GTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGCGGTTTGTCGCGTCGTCTGTGAAAACCAGCAGCTCAA
CTGTTGGCTTGCAGGCGATACGGGCAGACTTGAGTATTTCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGA
AATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGGTCTCTGGGAAATAACTGACGCTGAGGAGCG
AAAGCGTGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGCGCTAGGTGTGGGT
TTCCTTCCACGGGATCCGTGCCGTAGCTAACGCATTAAGCGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAA
ACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACGCGAAGAACC
TTACCTGGGTTTGACATACACCGGAAAGCCGTGGAGACACGGCCCCCCTTGTGGTCGGTGTACAGGTGGTGCA
TGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCTGTGTTGCC
AGCGGATTATGCCGGGGACTCGCAGGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGT
CATCATGCCCCTTATGTCCAGGGCTTCACACATGCTACAATGGCCGGTACAGAGGGCTGCGATACCGTGAGGT
GGAGCGAATCCCTTAAAGCCGGTCTCAGTTCGGATCGGGGTCTGCAACTCGACCCCGTGAAGTCGGAGTCGCT
AGTAATCGCAGATCAGCAACGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCATGAA
AGTCGGTAACACCCGAAGCCGGTGGNCTAACCCTTGTGGAGGGAGCCGTC 
 
Guam 1582 
TGCAAGTCGAGCGGAAGGCCCTTCGGGGTACTCGAGCGGCGAACGGGTGAGTAACACGTGAGCAACCTGCCC
CAGGCTTTGGGATAACCCCGGGAAACCGGGGCTAATACCGAATATGACCTCCGATCGCATGGTTGGTGGTGG
AAAGTTTTTCGGCTTGGGATGGGCTCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACG
ACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGC
AGCAGTGGGGAATATTGCACAATGGGCGGAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCG
GGTTGTAAACCTCTTTCAGCAGGGACGAAGCGTAAGTGACGGTACCTGCAGAAGAAGCGCCGGCCAACTACG
TGCCAGCAGCCGCGGTAAGACGTAGGGCGCGAGCGTTGTCCGGATTTATTGGGCGTAAAGAGCTCGTAGGCG
GCTTGTCGCGTCGACTGTGAAAACCCGCAGCTCAACTGCGGGCCTGCAGTCGATACGGGCAGGCTAGAGTTC
GGTAGGGGAGACTGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAG
GCGGGTCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGT
AGTCCACGCTGTAAACGTTGGGCGCTAGGTGTGGGGGGCCTCTCCGGTTCCCTGTGCCGCAGCTAACGCATTA
AGCGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGC
GGAGCATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGTTTGACATGGCCGCAAAACTGTCAGA
GATGGCAGGTCCTTCGGGGGCGGTCACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGT
TAAGTCCCGCAACGAGCGCAACCCTCGTTCGATGTTGCCAGCGCGTTATGGCGGGGACTCATCGAAGACTGCC
GGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGTCCAGGGCTTCACGCATGCT
ACAATGGCCGGTACAATGGGCTGCGATACCGTGAGGTGGAGCGAATCCCAAAAAGCCGGTCTCAGTTCGGAT
CGGGGTCTGCAACTCGACCCCGTGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCAACGCTGCGGTGAATAC
GTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGCAACACCCGAAGCCGGTGGCCCAACCCT
TGTGGAGGGAGCCGTCGAAGGTGGGGCTGGCG 
 
Guam 1583 
GACGGCTCCCTCCACAAGGGTTGGGCCACCGGCTTCGGGTGTTGCCGACTTTCGTGACGTGACGGGCGGTGT
GTACAAGGCCCGGGAACGTATTCACCGCAGCGTTGCTGATCTGCGATTACTAGCGACTCCGACTTCACGGGGT
CGAGTTGCAGACCCCGATCCGAACTGAGACCGGCTTTTTGGGATTCGCTCCACCTCACGGTATCGCAGCCCATT
GTACCGGCCATTGTAGCATGCGTGAAGCCCTGGACATAAGGGGCATGATGACTTGACGTCATCCCCACCTTCC
TCCGAGTTGACCCCGGCAGTCTTCGATGAGTCCCCGCCATAACGCGCTGGCAACATCGAACGAGGGTTGCGCT
CGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGTGACCGCCCCCGA
AGGACCTGCCATCTCTGACAGTTTTGCGGCCATGTCAAACCCAGGTAAGGTTCTTCGCGTTGCATCGAATTAAT
CCGCATGCTCCGCCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTTAGCCTTGCGGCCGTACTCCCCAGGC
GGGGCGCTTAATGCGTTAGCTGCGGCACAGGGAACCGGAGAGGCCCCCCACACCTAGCGCCCAACGTTTACA
GCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTATCGGCCCAGAG
ACCCGCCTTCGCCACCGGTGTTCCTCCTGATATCTGCGCATTTCACCGCTACACCAGGAATTCCAGTCTCCCCTA
CCGAACTCTAGCCTGCCCGTATCGACTGCAGGCCCGCAGTTGAGCTGCGGGTTTTCACAGTCGACGCGACAAG
 147 
 
CCGCCTACGAGCTCTTTACGCCCAATAAATCCGGACAACGCTCGCGCCCTACGTCTTACCGCGGCTGCTGGCAC
GTAGTTGGCCGGCGCTTCTTCTGCAGGTACCGTCACTTACGCTTCGTCCCTGCTGAAAGAGGTTTACAACCCGA
AGGCCGTCATCCCTCACGCGGCGTCGCTGCATCAGGCTTCCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCC
GTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGGTCGCCCTCTCAGGCCGGCTACCCGTCGTCGCCTT
GGTAGGCCATCACCCCACCAACAAGCTGATAGGCCGCGAGCCCATCCCAAGCCGAAAAACTTTCCACCACCAA
CCATGCGATCGGAGGTCATATTCGGTATTAGCCCCGGTTTCCCGGGGTTATCCCAAAGCCTGGGGCAGGTTGC
TCACGTGTTACTCACCCGTTCGCCGCTCGAGTACCCCGAAGGGCCTTTCCGCTCGACTTGCATGTGTTAAGCAC
GCCGCCAGCGTTCGTCCTGAGCCA 
 
ASO4 wet 
TCCTGGCTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCTCTTCGGGGGTG
GATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTTCGGGACAAGCCCTGGAAACGGGG
TCTAATACCGGATACTACTTCCTTGGGCATCCTTGGGGGTGGAAAGCTTCGGCGGTGCAGGATGAGCCCGCGG
CCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGC
CACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGGA
AGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGC
GAAAGTGACGGTACCTGCAGAAGAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCG
AGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCCTGTCACGTCGGATGTGAAAGCCCGGGGC
TTAACCCTGGGTCTGCATTCGATACGGGCAGGCTGGAGTTCGGTAGGGGAGATCGGAATTCCTGGTGTAGCG
GTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACTGACGCTGAGG
AGCGAAAGCATGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGTTGGGCACTAGGTGT
GGGCGACATTCCACGTTGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGAGTACGGCCGCAAGG
CTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATTCGACGCAACGCGAA
GAACCTTACCAAGGCTTGACATACACCAGAAAGCTGTGGAGACACAGCCCCCCTTGTGGTTGGTGTACAGGTG
GTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCTCGT
GTTGCCAGCAGGCCCTTGTGGTGCTGGGGACTCACGGGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGG
ACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGTTGCG
ATGCCGTGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAA
GTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCG
TCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCC 
 
A-Sed H10-3 
GCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAACACTCTGTCCCGCATGGGACGGGG
TTAAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTAATGGCCTACCAAGGC
GACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGG
AGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCC
TTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAAC
TACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATGGGGCGTAAAGAGCTCGTA
GGCGGCTTGTCACGTCGGATGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATTCGATACGGGCTAGCTAGA
GTGTGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGC
GAAGGCGGATCTCTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCC
TGGTAGTCCACGCCGTAAACGTTGGGAACTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGC
ATTAAGTTCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGC
AGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCA
GAGATGGTGCCCCCCTTGTGGTCGGTATACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGG
GTTAAGTCCCGCAACGAGCGCAACCCTTGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAG
GAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTG
CACACGTGCTACAATGGCCGGTACAATGAGCTGCGATGCCGCGAGGCGGAGCGAATCTCAAAAAGCCGGTCT
CAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGC
 148 
 
GGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGG
CCCAACCCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGA 
 
B-Sed H10-3 
GCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATAC
CGGATAACACTCTGTCCCGCATGGGACGGGGTTAAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCA
GCTTGTTGGTGGGGTAATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACT
GGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTG
ATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGT
GACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTT
GTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGATGTGAAAGCCCGGGGCTTAACC
CCGGGTCTGCATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAA
TGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGACGCTGAGGAGCGAA
AGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGTTGGGAACTAGGTGTTGGCGA
CATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAAC
TCAAAGGAATTGACGGGGGCCCGCACAAGCAGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTT
ACCAAGGCTTGACATATACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTGGTCGGTATACAGGTGGTGCATG
GCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTCTGTGTTGCCA
GCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACG
TCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCTGCGATGCCGC
GAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGA
GTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTC
ACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGG
CGA 
 
C-Sed H10-3 
TGCAGTCGACGATGAAGCCCTTCGGGGTGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCT
TCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAACACTCTGTCCCGCATGGGACGGGGTTAAA
AGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTAATGGCCTACCAAGGCGACGA
CGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCA
GCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGG
GTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGT
GCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGG
CTTGTCACGTCGGATGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATTCGATACGGGCTAGCTAGAGTGTGG
TAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGC
GGATCTCTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGT
CCACGCCGTAAACGTTGGGAACTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGT
TCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGCGGA
GCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCAGAGATG
GTGCCCCCCTTGTGGTCGGTATACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAG
TCCCGCAACGAGCGCAACCCTTGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACT
GCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACG
TGCTACAATGGCCGGTACAATGAGCTGCGATGCCGCGAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTC
GGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAA
TACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAAC
CCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGA 
 
 
 
 149 
 
ICN16 
GACACGGCCCAGACTCNTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCG
ACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTAC
CTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCGAGCGTTGTCCGGAA
TTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTTGTGAAAGCCCGGGGCTTAACCCCGGGTCTG
CAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGAT
ATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGG
AGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGCACTAGGTGTGGGCGACATTCCACG
TCGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGA
ATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGC
TTGACATACACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGTCGT
CAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCCGTGTTGCCAGCAGGCCC
TTGTGGTGCTGGGGACTCACGGGAGACCGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCAT
CATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCTGCGATACCGCGAGGTGGA
GCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTCGCTAGT
AATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGT
CGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGATTGGG
ACGAAGTCGTAACA 
 
ICN18 
TTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTCTGGGACAAGCCCTGGAAACGGGGTC
TAATACCGGATACTGACCCGCTTGGGCATCCAAGCGGTTCGAAAGCTCCGGCGGTGCAGGATGAGCCCGCGG
CCTATCAGCTTGTTGGTGAGGTAATGGCTCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGC
CACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAA
AGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGC
GAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGC
GAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTTGTGAAAGCCCGGGG
CTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATTCCTGGTGTAGC
GGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACTGACGCTGAG
GAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGCACTAGGT
GTGGGCGACATTCCACGTCGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGAGTACGGCCGCAA
GGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATTCGACGCAACGCG
AAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTGGTCGGTGTACAGG
TGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCC
GTGTTGCCAGCAGGCCCTTGTGGTGCTGGGGACTCACGGGAGACCGCCGGGGTCAACTCGGAGGAAGGTGG
GGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCTG
CGATACCGCGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATG
AAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCC
CGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGAGCTGTCGAAGGT
GGGACTGGCGATTGGGACGAAGTCGTAACAAGNAAACCCG 
 
ICN19 
ACGATGAACCTCCTTCGGGAGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTC
TGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATACGACCACTGAGGGCATCCTCGGTGGTGGAAAGCTC
CGGCGGTGCAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACGACGGGT
AGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGT
GGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGT
AAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAG
CAGCCGCGGTAATACGTAGGGCGCGAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGT
 150 
 
CGCGTCGGTTGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGG
GGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGAT
CTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCAC
GCCGTAAACGTTGGGCACTAGGTGTGGGCGACATTCCACGTCGTCCGTGCCGCAGCTAACGCATTAAGTGCCC
CGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCAT
GTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATCAGAGATGGTGC
CCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCC
GCAACGAGCGCAACCCCTGTCCTGTGTTGCCAGCGGGTCATGCCGGGGACTCACAGGAGACCGCCGGGGTCA
ACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGG
CCGGTACAATGAGCTGCGATACCGCGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTC
TGCAACTCGACCCCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGG
GCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCTTGGGAGG
GAGCCGTCGAAGGTGGGACTGGCGATTGGG 
 
ICN21 
GGAGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTCTGGGACAAGCCCTGGA
AACGGGGTCTAATACCGGATACGACCACTGAGGGCATCCTCGGTGGTGGAAAGCTCCGGCGGTGCAGGATGA
GCCCGCGGCCTATCAGCTTGTTGGTGGGGTGATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGG
GCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACA
ATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAG
GGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATAC
GTAGGGCGCGAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCGCGTCGGTTGTGAA
AGCCCGGGGCTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATTCC
TGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACT
GACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGTTGG
GCACTAGGTGTGGGCGACATTCCACGTCGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGAGTAC
GGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATTCGAC
GCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTGGTCG
GTGTACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAAC
CCCTGTCCTGTGTTGCCAGCGGGTCATGCCGGGGACTCACAGGAGACCGCCGGGGTCAACTCGGAGGAAGGT
GGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGC
TGCGATACCGCGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCA
TGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCG
CCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACC 
 
ICN26 
GCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCASCAGGGAAGAAGCGAAAGTGACGG
TACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCGAGCGTTGTCCG
GAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTTGTGAAAGCCCGGGGCTTAACCCCGGG
TCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGC
AGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGT
GGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGCACTAGGTGTGGGCGACATTC
CACGTCGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAA
GGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAA
GGCTTGACATACACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGT
CGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCCGTGTTGCCAGCAGG
CCCTTGTGGTGCTGGGGACTCACGGGAGACCGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGT
CATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCTGCGATACCGCGAGGT
GGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTCGCT
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AGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAA
AGTCGGTAACACCCGAAGCCGGTGGC 
 
ICN27 
TTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTCTGGGACAAGCCCTGGAAACGGGGTC
TAATACCGGATACTGACCACTGGGGGCATCTTCAGTGGTCGAAAGCTCCGGCGGTGCAGGATGAGCCCGCGG
CCTATCAGCTTGTTGGTGAGGTAGTGGCTCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGC
CACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAA
AGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGC
GAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGC
GAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTTGTGAAAGCCCGGGG
CTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATTCCTGGTGTAGC
GGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACTGACGCTGAG
GAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGCACTAGGT
GTGGGCAACATTCCACGTTGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGAGTACGGCCGCAAG
GCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATTCGACGCAACGCGA
AGAACCTTACCAAGGCTTGACATACACCGGAAACGTCTGGAGACAGGCGCCCCCTTGTGGTCGGTGTACAGGT
GGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCCG
TGTTGCCAGCAAGCCCCTTCGGGGGTGTTGGGGACTCACGGGAGACCGCCGGGGTCAACTCGGAGGAAGGT
GGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGC
TGCGATACCGCGAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCA
TGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCG
CCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGAGCTGTC 
 
 
Streptomyces davawensis 
AGAGTTTGATCCTGGCTCAGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCCTTC
GGGGTGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAA
ACGGGGTCTAATACCGGATATCACTCCCACTCGCATGGGTGGGGGTCGAAAGCTCCGGCGGTGAAGGATGAG
CCCGCGGCCTATCAGCTTGTTGGTGAGGTAATGGCTCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGC
GACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATG
GGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGA
AGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAG
GGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGGTGTGAAAGCT
CGGGGCTTAACCCCGAGTCTGCATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTGGT
GTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGACGC
TGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGAACT
AGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGCCTGGGGAGTACGGCCG
CAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGCGGAGCATGTGGCTTAATTCGACGCAAC
GCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATCAGAGATGGTGCCCCCCTTGTGGTCGGTGTAC
AGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGT
TCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACCGCCGGGGTCAACTCGGAGGAAGG
TGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGATACAATGAG
CTGCGATACCGCAAGGTGGAGCGAATCTCAAAAAGTCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCC
ATGAAGTTGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACC
GCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGAGCTGTCGAA
GGTGGGACTGGCGATTGGGACGAAGTCGTAACAAGGTAGCCGTACCGGAAGGTGCGGCTGGATCACCT 
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Streptomyces cinnabarinus 
CGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCCTTCGGGGTGGATTAGTGGCGAACG
GGTGAGTAACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATATC
ACTCTCGCAGGCATCTGTGAGGGTCGAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTATCAGCTTGTTG
GTGAGGTAATGGCTCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGA
GACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCG
ACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTAC
CTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAA
TTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGGTGTGAAAGCTCGGGGCTTAACCCCGAGTCTG
CATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGAT
ATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGACGCTGAGGAGCGAAAGCGTGGGG
AGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGAACTAGGTGTTGGCGACATTCCACG
TCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGA
ATTGACGGGGGCCCGCACAAGCAGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGC
TTGACATACACCGGAAACGTCCAGAGATGGGCGCCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGTCGT
CAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTCTGTGTTGCCAGCATGCCCT
TCGGGGTGATGGGGACTCACAGGAGACCGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCAT
CATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGATACAATGAGCTGCGATACCGCAAGGTGGA
GCGAATCTCAAAAAGTCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTTGGAGTTGCTAGT
AATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGT
CGGTAACACCCGAAGCCGGTGGCCCAACCCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGATTGGG
ACGAAGTCGTAACAAGGTAGCCGTACCGGAAGG 
 
JS360 – S. cinnabaragriseus 
GCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGA
ATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCT
CTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCG
CGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTC
GGGTGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGAT
CGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGG
GCCATTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTA
AACGGTGGGAACTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGCCTG
GGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGCGGAGCATGTGGCT
TAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAAGCATTA 
 
 
WS 1.1 
CTCAGAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGC
GGCGCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAATA
CCGGATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAGAT
GAGTCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAG
GACGATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCA
ATGGGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTTGGATTGTAAAGCACTTTCGACCG
GGAAGAAAACCCGTTGGCTAACATCCAACGGCTTGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGC
CAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGCG
TGACAAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCGG
AGAGGGTGGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGGGGAGGAACACCGGTGGCGAAGGCG
GCCACCTGGACGGTAACTGACG 
 153 
 
WS 2.1 
TAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCGGCGCACGGGTGCGTAACACGTGGAT
AATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAATACCGGATAAGCCCACGGTTTCTTCGGAG
ACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAGATGAGTCCGCGGCCCATCAGCTAGTTGGC
GGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGGACGATCAGCCACACTGGAACTGAGA
CACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAATGGGCGAAAGCCTGACGCAGCAACG
CCGCGTGTGTGATGAAGGTCTTCGGATTGTAAAGCACTTTCGACCGGGACGAAAACCCGTAGCCCAACACGCT
ACGGCT 
 
WS 2.3 
TGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCGGCGCACGGGTGC
GTAACACGTGGATAATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAATACCGGATAAGCCCAC
GGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAGATGAGTCCGCGGCCCA
TCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGGACGATCAGCCACA
CTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAATGGGCGAAAGCCT
GACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTCGGATTGTAAAGCACTTTCGACCGGGACGAAAACCCGT
AGCCCAACACGCTACGGCTtGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCCAGCAGCCGCGGTA
ATACA 
 
WS 3.3 
GGCTCAGAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGA
GCGGCGCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAA
TACCGGATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAG
ATGAGTCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAG
AGGACGATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCG
CAATGGGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTCGGATTGTAAAGCACTTTCGACC
GGGACGAAAACCCGTAGCCCAACACGCTACGGCTtGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTG
CCAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGC
GTGACAAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCG
GAGAGGGTGGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGGGGAGGAACACCGGTGGCGAAGGC
GGCCACCTGGACGGTAACTGACGCTGAGAC 
 
WS 3.4 
ATAGGGGCAACCCTTAGTAGAGCGGCGCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCTCGGGATA
ACCAKACGAAAGATTGGCTAATACCGGATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCT
GTATACAAGCTATCACAACCAGATGAGTCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGC
AACGACGGGTAGCTGGTCTGAGAGGACGATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGA
GGCAGCAGTGGGGAATTTTGCGCAATGGGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTT
CGGATTGTAAAGCACTTTCGACCGGGACGAAAACCCGTAGCCCAACACGCTACGGCTTGACGGTACCGGGAG
AAGAAGCACCGGCTAACTCTGTGCCAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTG
GGCGTAAAGCGCGTGTAGGCGGCGTGACAAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCC
CGAAACTGTCGTGCTTGAGTGCCGGAGAGGGTGGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGG
GGAGGAACACCGGTGGCGAAGGCGGCCACCTGGACGGTAACTGACGCTGAGACGCGAAAGCGTGGGGAGC
AAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAGAACTAGGTGTCGTGGGAGTTGACCCCC 
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WS 4.1 
GCTCAGAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAG
CGGCGCACGGGTGCGTAACACGTGGATAATCTGCCTGAGTGCTCGGGATAACCAGTCGAAAGATTGGCTAAT
ACCGGATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACATTCAGA
TGAGTCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGA
GGACGATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGC
AATGGGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTTGGATTGTAAAGCACTTTCGACC
GGGAAGAAAACCCGTTGGCTAACATCCAACGGCTtGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTG
CCAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGC
GTGACAAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGANGTGCC
GGAGAGGGTGGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGGGGAGGAACACCGGTGGCGAAGG
CGGCCACCTGGACGGTAACTGACGCTGAGACG 
 
WS 5.1 
CGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCGGCGCAC
GGGTGCGTAACACGTGGATAATCTGCCTGAGTGCTCGGGATAACCAGTCGAAAGATTGGCTAATACCGGATA
AGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACATTCAGATGAGTCCG
CGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGGACGATC
AGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAATGGGCG
AAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTTGGATTGTAAAGCACTTTCGACCGGGAAGAA
AACCCGTTGGCTAACATCCAACGGCTTGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCCAGCAGC
CGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGCGTGACAAG
TCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCGGAGAGGGT
GGCGGAATTC 
 
WS 9.1 
TCAGAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCG
GCGCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAATAC
CGGATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAGATG
AGTCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGG
ACGATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAA
TGGGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTCGGATTGTAAAGCACTTTCGACCGG
GACGAAAACCCGTAGCCYtAACACGCTACGGCTtGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCC
AGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGCGT
GACAAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCGGA
GAGGGTGGC 
 
WS 15.1 
GAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCGGC
GCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAATACCG
GATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAGATGAG
TCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGGAC
GATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAATG
GGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTCGGATTGTAAAGCACTTTCGACCGGGA
CGAAAACCCGTAGCCCAACACGCTACGGCTTGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCCAG
CA 
 
 
 
 155 
 
WS 21.3 
GAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCGGC
GCACGGGTGCGTAACACGTGGATAATCTGCCTGAGTGCTCGGGATAACCAGTCGAAAGATTGGCTAATACCG
GATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACATTCAGATGAG
TCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGGAC
GATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAATG
GGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTTGGATTGTAAAGCACTTTCGACCGGGA
AGAAAACCCGTTGGCTAACATCCAACGGCTTGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCCAG
CAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGCGTGA
CAAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCGGAGA
GGGTGGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGGGGAGGAACACCGGTGGCGAAGGCGGCC
ACCTGGACGGTAACTGACG 
 
WS 28.1 
AGAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCGG
CGCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAATACC
GGATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAGATGA
GTCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGGA
CGATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAAT
GGGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTTGGATTGTAAAGCACTTTCGACCGGG
AAGAAAACCCGTTGGCTAACATCCAACGGCTTGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCCA
GCAGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGCGTG
ACAAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCGGAG
AGGGTGGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGGGGAGGAACACCGGTGGCGAAGGCGGC
CACCTGGACGGTAACTGACGCTGAGACGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCA
CGCCGTAAACGATGAGAACTAGGTGTCGTGGGAGTTGACCCCCGCGGTGCCGTAG 
 
WS 28.3 
GAACGAACGCTGGCGGCGTGCCTAACACATGCAAGTCGAGCGCGAATAGGGGCAACCCTTAGTAGAGCGGC
GCACGGGTGCGTAACACGTGGATAATCTGCCTGGATGCTCGGGATAACCAGTCGAAAGATTGGCTAATACCG
GATAAGCCCACGGTTTCTTCGGAGACTGAGGGAAAAGGTGGCCTCTGTATACAAGCTATCACAACCAGATGAG
TCCGCGGCCCATCAGCTAGTTGGCGGGGTAATGGCCCACCAAGGCAACGACGGGTAGCTGGTCTGAGAGGAC
GATCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGCGCAATG
GGCGAAAGCCTGACGCAGCAACGCCGCGTGTGTGATGAAGGTCTTCGGATTGTAAAGCACTTTCGACCGGGA
CGAAAACCCGTAGCCCAACACGCTACGGCTtGACGGTACCGGGAGAAGAAGCACCGGCTAACTCTGTGCCAGC
AGCCGCGGTAATACAGAGGGTGCAAGCGTTGTTCGGAATTATTGGGCGTAAAGCGCGTGTAGGCGGCGTGAC
AAGTCGGGTGTGAAAGCCCTCAGCTCAACTGAGGAAGTGCGCCCGAAACTGTCGTGCTTGAGTGCCGGAGAG
GGTGGCGGAATTCCCCAAGTAGAGGTGAAATTCGTAGATATGGGGAGGAACACCGGTGGCGAAGGCGGCCA
CCTGGACGGTAACTGACGCTGAGACGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACG
CCGTAAACGATGAGAACTAGGTGTCGTGGGAGTTGACCCCC 
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